<b>Materials & methods:</b> Data of 784 Greek patients receiving psychiatric care who were genotyped for CYP2D6, CYP2C19, CYP1A2, CYP3A5 and CYP2C9 isoenzymes were inferred to gene-drug pairs according to the US FDA, Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group annotations and published literature	217	268	DATABASE	Clinical Pharmacogenetics Implementation Consortium
<b>Materials & methods:</b> Data of 784 Greek patients receiving psychiatric care who were genotyped for CYP2D6, CYP2C19, CYP1A2, CYP3A5 and CYP2C9 isoenzymes were inferred to gene-drug pairs according to the US FDA, Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group annotations and published literature	273	309	DATABASE	Dutch Pharmacogenetics Working Group
Studies of the genetics of gene expression (also described as expression quantitative locus (eQTL) mapping or genetical genomics) represent a novel approach for identification of functional genetic variants that influence gene expression	93	97	TECHNIQUE	eQTL
In logistic regression model, the overall incidence of adverse events was 1	3	22	ANALYTICAL_METHOD	logistic regression
Food and Drug Administration (FDA) and the European Medicine Agency (EMA), and well-recognized research consortia, like the Clinical Pharmacogenetics Implementation Consortium (CPIC), that propose therapeutic recommendations after the thorough evaluation of the existing scientific evidence base	124	175	DATABASE	Clinical Pharmacogenetics Implementation Consortium
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	69	85	ANALYTICAL_METHOD	machine learning
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	89	116	ANALYTICAL_METHOD	natural language processing
To this end, we measured cellular susceptibility to cisplatin in 176 HapMap lymphoblastoid cell lines derived from Yoruba individuals from Ibadan, Nigeria	69	75	DATABASE	HapMap
As shown by in silico molecular docking and biochemical approaches, vinblastine, vincristine and vinorelbine bound with high affinity to α/β-tubulin and inhibited tubulin polymerization, whereas the effects of vindoline and catharanthine were weak	22	39	ANALYTICAL_METHOD	molecular docking
Expression quantitative trait locus (eQTL) analysis is rapidly moving from a cutting-edge concept in genomics to a mature area of investigation, with important connections to genome-wide association studies for human disease, pharmacogenomics and toxicogenomics	37	41	TECHNIQUE	eQTL
Despite the importance of the topic, many investigators must develop their own code or use tools not specifically suited for eQTL analysis	125	129	TECHNIQUE	eQTL
Convenient computational tools are becoming available, but they are not widely publicized, and investigators who are interested in discovery or eQTL, or in using them to interpret genome-wide association study results may have difficulty navigating the available resources	144	148	TECHNIQUE	eQTL
The purpose of this review is to help investigators find appropriate programs for eQTL analysis and interpretation	82	86	TECHNIQUE	eQTL
This review elaborates the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation-aided drug design	83	106	ANALYTICAL_METHOD	artificial intelligence
0% of the individuals carried at least one high risk genotype-predicted phenotype in pharmacogenes with PharmGKB level of evidence 1A for drug interaction	104	112	DATABASE	PharmGKB
0% of the cohort used at least one PharmGKB evidence level 1A drug, and 18	35	43	DATABASE	PharmGKB
9% of individuals who used PharmGKB evidence level 1A drugs had a genotype-predicted phenotype of high-risk gene-drug interaction	27	35	DATABASE	PharmGKB
<b>Conclusion:</b> This study described the applicability of next-generation sequencing (NGS) techniques for translating PGx variants into clinically relevant phenotypes on a large scale in the Brazilian population and explores the feasibility of systematic adoption of PGx testing in Brazil	89	92	TECHNIQUE	NGS
DNA technologies like the human genome microarray are now partially integrated into clinical practice and are used for developing new "personalized medicines" and "pharmacogenetics" for improving the efficiency and safety of cancer medications	39	49	TECHNIQUE	microarray
PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels, were determined	26	77	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Clinical Pharmacogenetics Implementation Consortium (CPIC) is a platform that advances the pharmacogenomics (PGx) practice by developing evidence-based guidelines	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The groove-surface and key binding residues involved in PGN-Dap and Lys-type interaction intended by the molecular docking, and were also accompanied by significant BE values directed their importance in pharmacogenomics, and warrants further in vivo studies for drug targeting and immune signaling pathways exploration	105	122	ANALYTICAL_METHOD	molecular docking
However, techniques, such as next-generation sequencing (NGS), are being implemented to detect a wide spectrum of new alterations that also include point mutations	57	60	TECHNIQUE	NGS
Such an approach was pioneered in the late 1970s, but its broad clinical acceptance and implementation have been hampered by the lack of widespread computer technology, including user-friendly software tools	64	72	CHALLENGE	clinical
<b></b>Breast cancer is the fifth cause of cancer death among women worldwide and represents a global health concern due to the lack of effective therapeutic regimens that could be applied to all disease groups	136	145	CHALLENGE	effective
Genotyping was conducted by the QuantStudio 12K Flex Real-Time PCR System using a custom open array chip with metabolism, transport, and transcription factor polymorphisms of interest to cisplatin disposition and toxicity	63	66	TECHNIQUE	PCR
HCPs identified that lack of financial reimbursements (62%) and lack of infrastructure (38%) were the main reasons likely to prevent/slow the implementation of PGx screening program into routine clinical care	195	203	CHALLENGE	clinical
Filtering the variants according to Pharmacogenomics Knowledge Base (PharmGKB) annotations identified 27 diplotypes and 26 variants with an evident clinical relevance	69	77	DATABASE	PharmGKB
Recommendations for nurses interested in promoting the use of pharmacogenomics include learning as much as possible about testing and implications, networking with other providers, identifying a knowledgeable pharmacist, assessing for a family history of problems with medication side effects or lack of efficacy, and keeping records of relevant medical and medication information to share with providers	304	312	CHALLENGE	efficacy
Seven candidate polymorphisms (rs3842 and rs1045642 in ABCB1, rs212091 and rs3743527 in ABCC1, rs3745274 in CYP2B6, rs628031 in SLC22A1 and rs1517618 in SLCO3A1) were evaluated if they were associated with virological failure through logistic regression analysis	234	253	ANALYTICAL_METHOD	logistic regression
Using logistic regression analysis, a significant association was detected between rs1045642 (3435C>T, ABCB1) and rs212091 (198217T>C; 3'-UTR, ABCC1) with virological failure of first-line antiretroviral regimens containing protease inhibitors, when controlled by clinical factors, such as sex, age and race	6	25	ANALYTICAL_METHOD	logistic regression
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	92	99	DATABASE	ClinVar
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	78	86	DATABASE	PharmGKB
Genotyping of <i>CYP2D6*4</i> (<i>1846G > A</i>, <i>rs3892097</i>) was performed using real-time polymerase chain reaction with allele-specific hybridization	97	122	TECHNIQUE	polymerase chain reaction
Twenty polymorphisms replicated associations with identical or related phenotypes reported in the Catalog of Published Genome-Wide Association Studies, including several not previously reported in HIV-positive cohorts	119	150	TECHNIQUE	Genome-Wide Association Studies
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Up-to-date information can be found at PharmGKB (http://www	39	47	DATABASE	PharmGKB
Genotyping was performed using real-time polymerase chain reaction-based methods	41	66	TECHNIQUE	polymerase chain reaction
The <i>ABCB1</i> T-129C, G1199A, C1236T, G2677T/A and C3435T SNPs in the 168 patients with psoriasis were genotyped by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) and TaqMan SNP genotyping assays	129	154	TECHNIQUE	polymerase chain reaction
The possible associations of selected drugs with AD genes were predicted by pharmacogenomics analysis and confirmed through data mining	124	135	ANALYTICAL_METHOD	data mining
The binding interaction patterns and conformations of screened drugs within active region of AChE were confirmed through molecular docking profiles	121	138	ANALYTICAL_METHOD	molecular docking
The main reason behind this fact is the lack of confirmation in clinical studies for the assumed, and in animals confirmed, therapeutic results	64	72	CHALLENGE	clinical
A major bottleneck for CYP2C9 pharmacogenomics in clinical field applications is the lack of knowledge regarding the numerous genetic polymorphisms and their molecular functionalities	50	58	CHALLENGE	clinical
Genotyping for <i>CYP2C19</i>*2 and *17 was conducted using the real-time polymerase chain reaction method	74	99	TECHNIQUE	polymerase chain reaction
<b>Conclusions:</b> This study did identify associations between <i>CHRM2</i> variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors	112	131	ANALYTICAL_METHOD	logistic regression
We compare the accuracy of stable warfarin dose prediction using linear and nonlinear machine learning models in a large cohort enriched for US Latinos and Latin Americans (ULLA)	86	102	ANALYTICAL_METHOD	machine learning
The three top scoring SNPs (rs12248560, rs878567, rs17710780) were subsequently combined into an unweighted GRS, which was included in linear and logistic regression models using the CES-D score, occurrence of a major depressive episode (MDE) during follow-up and regular antidepressant treatment during the 6 months preceding follow-up assessment as outcomes	146	165	ANALYTICAL_METHOD	logistic regression
We investigated 44 SNPs previously associated with antidepressant response by ranking them with regard to their association to the Center for Epidemiologic Studies Short Depression Scale (CES-D) score using random forest	207	220	ANALYTICAL_METHOD	random forest
In summary, we present validated TaqMan assay methodology for efficient detection of HLA haplotypes <i>HLA-B*15:02</i> and <i>HLA-A*31:01</i>	33	45	TECHNIQUE	TaqMan assay
We used Cox regression models to compare the incidence of clinical outcomes between carriers and noncarriers of the SNVs or haplotypes	8	11	ANALYTICAL_METHOD	Cox
Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that might be related to inappropriate drug exposure	91	99	CHALLENGE	efficacy
Using a case-control study design, the association of each SNP locus with the outcome of asthma exacerbations (defined as asthma-related emergency department visits or hospitalizations concurrent with oral corticosteroid use), was evaluated for each population by logistic regression analysis, adjusting for age, gender and the first four principal components	264	283	ANALYTICAL_METHOD	logistic regression
As shown by hierarchical cluster analysis and chi-squared test, the distribution of cell lines in the dendrogram according to their gene expression profiles predicted sensitivity or resistance to cantharidin (P=6	12	32	ANALYTICAL_METHOD	hierarchical cluster
25 kcal/mol) in molecular docking analyses	16	33	ANALYTICAL_METHOD	molecular docking
By using COMPARE analysis of microarray-based transcriptome-wide mRNA expressions, 21 genes were found to significantly correlate with response of 60 tumor cell lines to cantharidin	29	39	TECHNIQUE	microarray
In the first 4 months of routine next generation sequencing, we have identified 10 novel alleles that have been discovered through laboratory testing for all facets of HLA typing, i	33	59	TECHNIQUE	next generation sequencing
The advent of NGS HLA typing in routine clinical practice, and the concomitant routine typing of exons outside the norm, opens the window for rapid discovery of new HLA alleles and a potential for overwhelming the current HLA nomenclature naming conventions	14	17	TECHNIQUE	NGS
The device combines a blood lysis chamber, a cross-flow filter, a T-junction mixer, and a microreactor for quantitative polymerase chain reaction (qPCR)	120	145	TECHNIQUE	polymerase chain reaction
<b>Methods:</b> While not a true review article, this work was written using various search engines and terms and previous and newly published Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for statins to provide a historical perspective in addition to the current status of statin-related pharmacogenetics and future perspectives	143	194	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The results showed that only 68 very important pharmacogenes currently exist, while 867 drug label annotations, 201 curated functional pathways, and 746 annotated drugs have been catalogued on the largest pharmacogenomics database (PharmGKB)	232	240	DATABASE	PharmGKB
At the pathway level, the Gene Ontology (GO) terms GO: 0005694 (chromosome) and GO: 0044427 (chromosomal part) were associated with improvement (corrected P=0	26	39	DATABASE	Gene Ontology
Overall, 89% of patients discontinued treatment, with over half of these (51%) due to lack of efficacy	94	102	CHALLENGE	efficacy
Significantly longer drug survival was seen for patients who discontinued treatment due to lack of efficacy versus drug safety (<i>p</i> = 0	99	107	CHALLENGE	efficacy
Notably, none of the prioritized genes are represented among the 59 genes compiled by the ACMG, and 78% had a pathogenic or likely pathogenic variant in ClinVar	153	160	DATABASE	ClinVar
Inhaled corticosteroids and β2-agonists have been the mainstay asthma therapies for 30 years, but they are not effective in all patients, while high costs and side-effects also drive the need for better targeted treatment of asthma	144	154	CHALLENGE	high costs
Recent progress in Next Generation Sequencing (NGS) technologies has for the first time allowed to comprehensively map the genetic landscape of human pharmacogenes	47	50	TECHNIQUE	NGS
Furthermore, NGS technologies face challenges in the interrogation of genes residing in complex genomic regions, such as CYP2D6 and HLA genes	13	16	TECHNIQUE	NGS
We here provide an update of the implementation of pharmacogenomic variations in the clinical setting and present emerging strategies that facilitate the translation of NGS data into clinically useful information	169	172	TECHNIQUE	NGS
The relation of SOCS1-1478 CA/del polymorphism to PCOS status and insulin resistance was analysed via logistic regression analysis	102	121	ANALYTICAL_METHOD	logistic regression
Data on physical examination, anthropometric measurements and blood biochemistry analysis were recorded for each subject along with analysis for SOCS1-1478 CA/del polymorphism by polymerase chain reaction-restriction fragment length polymorphism	179	204	TECHNIQUE	polymerase chain reaction
<b>Abbreviations:</b> PASI: Psoriasis Area and Severity Index; SNP: Single-Nucleotide Polymorphism Rs: Reference SNP; PASI75: 75% reduction in Psoriasis Area and Severity Index; PASI90: 90% reduction in Psoriasis Area and Severity Index; PASI100: 100% reduction in Psoriasis Area and Severity Index; NGS: Next-Generation Sequencing; OR: Odds Ratio; CAP: Canonical Analysis of Principal coordinates; BMI: Body Mass Index; LD: Linkage Disequilibrium	300	303	TECHNIQUE	NGS
Nevertheless, there is a lack of evidence for this and more validation studies need to be conducted to apply this information to clinical practice	129	137	CHALLENGE	clinical
Existing warfarin dose prediction algorithms based on pharmacogenetics and clinical parameters have not been used clinically due to the absence of external validation, lack of assessment for clinical utility, and high risk of bias	75	83	CHALLENGE	clinical
In this study, we analyzed the whole-genome sequencing data from The 1000 Genomes Project (Phase 3) and the pharmacogenetic information from Drug Bank, PharmGKB, PharmaADME, and Biotransformation	152	160	DATABASE	PharmGKB
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy	4	40	DATABASE	Dutch Pharmacogenetics Working Group
In vitro cytochrome P450 isoenzyme assays were performed in human liver microsomes using LC-MS/MS method to assess the metabolites of CYPs substrates	89	94	TECHNIQUE	LC-MS
Real-time polymerase chain reaction was used to evaluate single-nucleotide polymorphisms of the ABCB1 gene (rs1045642 and rs4148738) and CES1 gene (rs2244613)	10	35	TECHNIQUE	polymerase chain reaction
Our logistic regression analyses indicated the probability that 76% patients carrying combination of four SNPs will not show favorable response to AAP therapy	4	23	ANALYTICAL_METHOD	logistic regression
Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries	216	227	ANALYTICAL_METHOD	data mining
The structure of the haplotypes and linkage disequilibrium (LD) of the methylenetetrahydrofolate reductase gene (MTHFR) in 9 population groups from Northern Eurasia and populations of the international HapMap project was investigated in the present study	202	208	DATABASE	HapMap
PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs	0	8	DATABASE	PharmGKB
PharmGKB contains information about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations on drug-related phenotypes	0	8	DATABASE	PharmGKB
PharmGKB provides very detailed clinical associations between genetic variants and drug response, including genotype-specific drug dosing guidelines, and this procedure will armGKB	0	8	DATABASE	PharmGKB
We first mapped drugs extracted from PharmGKB drug-disease relationships to those in the National Drug File Reference Terminology (NDF-RT) and to Structured Product Labels (SPLs)	37	45	DATABASE	PharmGKB
Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations	143	151	DATABASE	PharmGKB
In the second part of the study, consensus real-time polymerase chain reaction (RT-PCR) (Takara Bio Inc	53	78	TECHNIQUE	polymerase chain reaction
In the second part of the study, consensus real-time polymerase chain reaction (RT-PCR) (Takara Bio Inc	80	86	TECHNIQUE	RT-PCR
9%) were positive by consensus RT-PCR	31	37	TECHNIQUE	RT-PCR
All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test	70	76	TECHNIQUE	RT-PCR
5%) by RT-PCR and in five (12	7	13	TECHNIQUE	RT-PCR
In addition, a significant degree of concordance was detected between HC2 and concensus RT-PCR methods (Cohen's kappa: 0	88	94	TECHNIQUE	RT-PCR
The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling	284	287	TECHNIQUE	NGS
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	219	227	CHALLENGE	efficacy
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	377	385	CHALLENGE	clinical
The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction	225	250	TECHNIQUE	polymerase chain reaction
To address its large interindividual variability and narrow therapeutic window, the Clinical Pharmacogenetics Implementation Consortium has recommended using pharmacogenetic dosing algorithms, such as the ones developed by the International Warfarin Pharmacogenetics Consortium (IWPC) and by Gage et al, to dose warfarin when genotype information is available	84	135	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry assay	99	123	TECHNIQUE	tandem mass spectrometry
PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented	0	3	TECHNIQUE	PCR
Current pharmacogenomics guidelines formulated by different countries, such as the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety, and the French National Network (Réseau) of Pharmacogenetics, play important roles in clinical practices	83	134	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Current pharmacogenomics guidelines formulated by different countries, such as the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety, and the French National Network (Réseau) of Pharmacogenetics, play important roles in clinical practices	140	176	DATABASE	Dutch Pharmacogenetics Working Group
A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology	58	64	DATABASE	HapMap
Genes were studied by sequencing and quantitative polymerase chain reaction (PCR)	77	80	TECHNIQUE	PCR
Genes were studied by sequencing and quantitative polymerase chain reaction (PCR)	50	75	TECHNIQUE	polymerase chain reaction
Loxapine and its metabolites were measured in biological samples by liquid chromatography coupled to tandem mass spectrometry	101	125	TECHNIQUE	tandem mass spectrometry
Despite this, there is currently a lack of a formal assessment of provider needs and established best practice design principles to guide the ongoing development of PGx result notes	85	96	CHALLENGE	established
Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS)	12	38	TECHNIQUE	next generation sequencing
Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS)	40	43	TECHNIQUE	NGS
Here, we used Oxford Nanopore Technologies' adaptive sampling to enrich a panel of 1,036 genes with well-documented PGx relevance extracted from the Pharmacogenomics Knowledge Base (PharmGKB)	182	190	DATABASE	PharmGKB
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	59	69	TECHNIQUE	microarray
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	71	96	TECHNIQUE	polymerase chain reaction
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	101	122	TECHNIQUE	short-read sequencing
To address current challenges, this minireview provides an update regarding genotyping (SNP analysis/arrays/NGS), structural variant detection (star-alleles/CNVs/hybrid alleles), genotype-to-phenotype translations, cost-effectiveness, and actionability of results (FDA/CPIC/PharmGKB) regarding clinical importance of pre-emptive pharmacogenomic testing for prescription of antidepressants and antipsychotics	274	282	DATABASE	PharmGKB
To address current challenges, this minireview provides an update regarding genotyping (SNP analysis/arrays/NGS), structural variant detection (star-alleles/CNVs/hybrid alleles), genotype-to-phenotype translations, cost-effectiveness, and actionability of results (FDA/CPIC/PharmGKB) regarding clinical importance of pre-emptive pharmacogenomic testing for prescription of antidepressants and antipsychotics	108	111	TECHNIQUE	NGS
Genetic association studies have detected single-nucleotide polymorphisms (SNPs) that link to drug responses; however, to understand mechanisms underlying how genetic traits alter drug responses, a biological interface is needed	0	19	ANALYTICAL_METHOD	Genetic association
While most existing studies investigate the omics data separately, data integration is needed on the horizon of precision medicine by using machine learning	140	156	ANALYTICAL_METHOD	machine learning
Using the obtained genomic DNA followed by PCR amplification and sequencing, the frequency of nine SNPs as well as alleles associated with slow (47	43	46	TECHNIQUE	PCR
In 2018, the Clinical Pharmacogenetics Implementation Consortium included NUDT15 rs116855232 to also guide thiopurines dosing	13	64	DATABASE	Clinical Pharmacogenetics Implementation Consortium
International genome collaborations, such as HapMap and the Welcome Trust Case-Control Consortium single nucleotide polymorphism (SNP) mapping project have identified common genetic variations in diseases of major public health importance	45	51	DATABASE	HapMap
This is likely due, in large part, to a lack of robust evidence demonstrating clinical utility and to its polygenic response modulated by other exogenous or epigenetics factors	48	54	CHALLENGE	robust
This is likely due, in large part, to a lack of robust evidence demonstrating clinical utility and to its polygenic response modulated by other exogenous or epigenetics factors	78	86	CHALLENGE	clinical
Here, we present a new method for polymerase chain reaction (PCR) melting curve analysis using one fluorescent probe to discriminate the UGT1A1*1 [(TA)<sub>6</sub> ] and *28 [(TA)<sub>7</sub> ] genotypes	34	59	TECHNIQUE	polymerase chain reaction
The reasons for this include the lack of in vitro models that correlate with clinical results and poor preclinical toxicity screening assays	77	85	CHALLENGE	clinical
Genomics is at the forefront of research to understand interindividual variability, and there are many genotype-drug response associations in diabetes with inconsistent findings	156	177	CHALLENGE	inconsistent findings
It entails obtaining a genetic sample, often via buccal swab or peripheral blood sample, and genetic analysis achieved through either polymerase chain reaction +/- Sanger sequencing, microassays, restriction length fragment polymorphism analysis, or genetic library preparation and next generation sequencing	282	308	TECHNIQUE	next generation sequencing
It entails obtaining a genetic sample, often via buccal swab or peripheral blood sample, and genetic analysis achieved through either polymerase chain reaction +/- Sanger sequencing, microassays, restriction length fragment polymorphism analysis, or genetic library preparation and next generation sequencing	134	159	TECHNIQUE	polymerase chain reaction
We compared our data with those of other populations using the HapMap data set, and observed that the frequency distribution of Zhuang population in Yunnan closely resembles that of JPT	63	69	DATABASE	HapMap
The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a "genomic era" of cancer research and treatment	47	50	TECHNIQUE	NGS
NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistance mechanisms, quantification of mutational burden, germline mutations which settled the foundation of a new approach in cancer care	0	3	TECHNIQUE	NGS
In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM approach and the emerging role of the research field of pharmacogenomics	81	84	TECHNIQUE	NGS
The Clinical Pharmacogenetics Implementation Consortium (CPIC) is a publicly funded international consortium of experts who curate published PGx data and create peer-reviewed guidelines on how to translate PGx results into actionable prescribing decisions	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Then the challenge of taking pharmacogenomic tests (compared to drugs) into clinical practice is explained by focusing on regulatory oversight, the methodological/scientific issues concerning diagnostic tests, and cost-effectiveness issues	122	142	CHALLENGE	regulatory oversight
Based on these findings, data from patients treated with cannabis and genotyped for several candidate polymorphic genes (single-nucleotide polymorphism: SNP) were collected, integrated, and analyzed through a machine learning (ML) model to demonstrate that the reduction in pain intensity is closely related to gene polymorphisms	209	225	ANALYTICAL_METHOD	machine learning
Despite some previous examples of successful application to the field of pharmacogenomics, the utility of machine learning (ML) techniques for warfarin dose predictions in Caribbean Hispanic patients has yet to be fully evaluated	106	122	ANALYTICAL_METHOD	machine learning
The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB; www	58	66	DATABASE	PharmGKB
Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB)	218	226	DATABASE	PharmGKB
This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information	21	37	ANALYTICAL_METHOD	machine learning
This chapter describes a process of developing evidence based drug dosing and pharmacotherapeutic guidelines per genotype by the Dutch Pharmacogenetics Working Group	129	165	DATABASE	Dutch Pharmacogenetics Working Group
Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups	50	53	TECHNIQUE	PCR
The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations to individualize treatment with tramadol and codeine	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The family medication history can serve as an impetus for pharmacogenomic testing to explain lack of medication efficacy or an adverse drug reaction and pre-emptive testing can drive recognition and documentation of medication response in family members	112	120	CHALLENGE	efficacy
This guideline updates and expands the 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and codeine therapy and includes a summation of the evidence describing the impact of CYP2D6, OPRM1, and COMT on opioid analgesia and adverse events	44	95	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The selected <i>ADRB1</i> and <i>CYP2D6</i> gene polymorphisms were detected by high-resolution melting polymerase chain reaction (HRM-PCR) analysis	131	134	TECHNIQUE	HRM
The selected <i>ADRB1</i> and <i>CYP2D6</i> gene polymorphisms were detected by high-resolution melting polymerase chain reaction (HRM-PCR) analysis	104	129	TECHNIQUE	polymerase chain reaction
Implementation challenges include the limited evidence base available to guide clinical use and the lack of data from diverse populations	79	87	CHALLENGE	clinical
The aim of the study was to assess exome data for preemptive pharmacogenetic screening for 203 clinically relevant pharmacogenetic variant positions from the Pharmacogenomics Knowledgebase and Clinical Pharmacogenetics Implementation Consortium and identify copy-number variants (CNVs) in CYP2D6	193	244	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We explored the feasibility of obtaining accurate HLA type using pre-existing NGS data not generated for HLA purposes	78	81	TECHNIQUE	NGS
83 exomes and 500 targeted NGS pharmacogenomic panels were analyzed using Omixon HLA Explore, OptiType, and/or HLA-Genotyper software	27	30	TECHNIQUE	NGS
Therefore, highly efficient and accurate next generation sequencing (NGS) platforms for the sequencing of PK-related genes are needed	41	67	TECHNIQUE	next generation sequencing
Therefore, highly efficient and accurate next generation sequencing (NGS) platforms for the sequencing of PK-related genes are needed	69	72	TECHNIQUE	NGS
In this review, we describe the current NGS platforms for the sequencing of PK-related genes	40	43	TECHNIQUE	NGS
The NGS platforms, including the PKseq panel, will be useful not only for the identification of all the variants of PK-related genes associated with adverse drug reactions and drug efficacy, but also for clinical sequencing to achieve pharmacogenomics-based stratified medicine	4	7	TECHNIQUE	NGS
We have developed PKseq, a targeted sequencing panel based on multiplex PCR, which targets the coding regions of 37 drug transporters, 30 cytochrome P450 isoforms, 10 UDP-glucuronosyltransferases, 5 flavin-containing monooxygenases, 4 glutathione S-transferases, 4 sulfotransferases, and 10 other genes	72	75	TECHNIQUE	PCR
The high homology of sequences among PK-related genes is suspected to lead to potential read misalignment and genotyping errors when short-read sequencing was performed	133	154	TECHNIQUE	short-read sequencing
The SmartAmp method enables us to detect genetic polymorphisms or mutations in target genes within 30-40 min without DNA isolation and PCR amplification	135	138	TECHNIQUE	PCR
Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important	31	34	TECHNIQUE	PCR
Ethambutol plasma concentrations, determined by liquid chromatography-tandem mass spectrometry, in 63 patients receiving ethambutol as part of rifampin-based fixed-dose combination therapy for tuberculosis were analyzed using nonlinear mixed-effects modeling	70	94	TECHNIQUE	tandem mass spectrometry
In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www	13	64	DATABASE	Clinical Pharmacogenetics Implementation Consortium
org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB, http://www	64	72	DATABASE	PharmGKB
Lack of studies on cost-effectiveness, absence of clinical guidelines based on pharmacogenetic biomarkers for several commonly used antipsychotics, the cost of genetic testing and the delay in results delivery hamper the implementation of pharmacogenetic interventions in clinical settings	50	58	CHALLENGE	clinical
Whole exome sequencing revealed biallelic mutations in SLC28A1 encoding the pyrimidine nucleoside transporter CNT1 in the index and his brother	0	22	TECHNIQUE	Whole exome sequencing
Lack of pharmacogenomics knowledge among healthcare professionals is the most frequently cited barrier to adopting and implementing pharmacogenomics in clinical settings	152	160	CHALLENGE	clinical
, metabolizer status) frequencies published by the Clinical Pharmacogenetics Implementation Consortium and census data from the Canada and the US	51	102	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Moreover, students may fail to learn that the relation between race and health is easily biased by factors such as socioeconomic status, racism, ancestry, and environment and that this limits the generalizability of race-based recommendations	196	212	CHALLENGE	generalizability
Genome-Wide Association Studies (GWAS), whole genome sequencing, and high-throughput omics techniques have generated vast amounts of genotypic and molecular phenotypic data	0	31	TECHNIQUE	Genome-Wide Association Studies
Results: Using unsupervised hierarchical clustering and a combination of candidate genotypes and clinical variables, we identified several distinct clusters of patients at high risk (36-38%) and low risk (10-17%) of respiratory depression; the relative risk of respiratory depression for high versus low risk clusters was 2	15	51	ANALYTICAL_METHOD	unsupervised hierarchical clustering
To better understand the contribution of germline genetic variation to paclitaxel-induced peripheral neuropathy, we undertook an integrative approach that combines genome-wide association study (GWAS) data generated from HapMap lymphoblastoid cell lines (LCL) and Asian patients	221	227	DATABASE	HapMap
Graft and patient survival were reduced among variant carriers; however, inconsistent findings with the primary analysis suggest these associations were not due to genotype	73	94	CHALLENGE	inconsistent findings
Therefore, molecular docking experiments validated the binding interaction patterns and structural behaviors of screened flavonoid compounds within the active region of the Ewing sarcoma protein (EWS)	11	28	ANALYTICAL_METHOD	molecular docking
Clinical annotations are one of the most popular resources available on the Pharmacogenomics Knowledgebase (PharmGKB)	108	116	DATABASE	PharmGKB
Evidence from the pharmacogenomic literature is curated into PharmGKB as variant annotations, which can be used to create new clinical annotations or added to existing clinical annotations	61	69	DATABASE	PharmGKB
As more evidence is curated into PharmGKB, the task of maintaining consistency when assessing all the available evidence and assigning an LOE becomes increasingly difficult	33	41	DATABASE	PharmGKB
In combination with increased standardization of how clinical annotations are written, use of this scoring system helps to ensure that PharmGKB clinical annotations continue to be a robust source of pharmacogenomic information	135	143	DATABASE	PharmGKB
Clinical implementation has proven challenging, with barriers including a lack of replicable prospective evidence for clinical utility required for altering medical care	0	8	CHALLENGE	clinical
In most cases with three copies of <i>CYP2D6</i>, the duplicated allele can be determined using a combination of targeted genotyping using real-time PCR with CNV detection without need for reflex sequencing	149	152	TECHNIQUE	PCR
In ambiguous cases and those with >3 copies, LR-PCR and Sanger sequencing may still be necessary for determination of the duplicated allele	48	51	TECHNIQUE	PCR
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	142	158	ANALYTICAL_METHOD	machine learning
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	182	215	ANALYTICAL_METHOD	non-negative matrix factorization
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	223	244	ANALYTICAL_METHOD	partial least squares
Genetic association studies have been reported for pharmacokinetic genes such as the CYP450 isoenzymes or MDR1, and pharmacodynamic genes such as the serotonin transporter (SLC6A4) or the serotonin 2A receptor (HTR2A)	0	19	ANALYTICAL_METHOD	Genetic association
Of the drugs recorded, there were 38 for which high levels of evidence for clinical actionability with PGx was available from the US FDA and/or the Clinical Pharmacogenetics Implementation Consortium (CPIC)	148	199	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This is attributed to the generation of large volumes of high-throughput multimodal data, and the lack of standardized workflows that are robust, scalable, and flexible to perform large-scale analyses	138	144	CHALLENGE	robust
This is attributed to the generation of large volumes of high-throughput multimodal data, and the lack of standardized workflows that are robust, scalable, and flexible to perform large-scale analyses	180	191	CHALLENGE	large-scale
Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression	88	107	ANALYTICAL_METHOD	logistic regression
The Clinical Pharmacogenetics Implementation Consortium (CPIC) plays an important role in this context, and it aims at specifically guiding the translation of clinically relevant and evidence-based pharmacogenomics research	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Patients' plasma samples for TDM analysis were collected at steady state and analyzed by an LC-MS/MS method for minimum plasma concentration (C<sub>min</sub>) evaluation	92	97	TECHNIQUE	LC-MS
Pathway analysis revealed significant enrichment of Gene Ontology terms such as extracellular matrix remodeling, cell adhesion, and chemotaxis	52	65	DATABASE	Gene Ontology
We used RNA-Seq analysis to examine the global profile of gene expression in a rat serotonergic cell line (RN46A) after exposure to these two mood stabilizer drugs	8	15	TECHNIQUE	RNA-Seq
Factors which contribute to these difficulties include imprecise understanding of etiology, syndromal nature of many disorders and overlap in diagnostic criteria between conditions, medical and psychiatric comorbidity and high rates of noncompliance to treatment either due to lack of efficacy or adverse effects	285	293	CHALLENGE	efficacy
This has been challenging to validate due to the lack of measured metabolite concentrations in tamoxifen clinical trials	105	113	CHALLENGE	clinical
Associations between genetic variants and EDP were assessed using logistic regression models and associated variants (<i>p</i> <0	66	85	ANALYTICAL_METHOD	logistic regression
Shortcomings of this hormone therapy are the long duration of treatment, sometimes longer than 2 years, and the inconvenience of injections every second or third day	45	58	CHALLENGE	long duration
Based on the concept of precision pharmacy, we adpoted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children and elderly patients	152	168	ANALYTICAL_METHOD	machine learning
At present, there is inconsistent and rather low use of pharmacogenetic testing in the clinical setting because of a lack of robust evidence or of resources	125	131	CHALLENGE	robust
At present, there is inconsistent and rather low use of pharmacogenetic testing in the clinical setting because of a lack of robust evidence or of resources	87	95	CHALLENGE	clinical
Recent advances including the Human Genome Project, the International HapMap project, advances in throughput technology and reduction in cost of genetic testing, and the inclusion of genotype-related dosing recommendations into package inserts all point to the integration of pharmacogenetics into clinical practice	70	76	DATABASE	HapMap
The best machine learning (ML) model for AR based on clinical and genetic factors was characterized by AUC = 0	9	25	ANALYTICAL_METHOD	machine learning
In this study, HLA-A, -B and -DRB1 allele and haplotype frequencies were determined in 8333 volunteer bone marrow donors of Zhejiang Han population using the polymerase chain reaction sequence-based typing	158	183	TECHNIQUE	polymerase chain reaction
The combined effect of clinical and genetic factors was assessed using The Least Absolute Shrinkage and Selection Operator penalized regression in the Cox proportional hazards model	151	154	ANALYTICAL_METHOD	Cox
According to the genotype-metabolic phenotypes of CYP2C19, CYP2D6, CYP2C9 enzymes patients were classified according to the guidelines by Clinical Pharmacogenetics Implementation Consortium (CPIC): normal metabolizers (NMs), intermediate metabolizers (IMs), rapid metabolizers (RMs), ultrarapid metabolizers (UMs), and poor metabolizers (PMs)	138	189	DATABASE	Clinical Pharmacogenetics Implementation Consortium
However, clinical evidence for pharmacogenetics-guided warfarin dosing is limited to intermediary outcomes, and consequently, there is a lack of information on the cost-effectiveness of anticoagulation treatment options	9	17	CHALLENGE	clinical
In the present study, 100 cardiac patients with percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) who were undergoing treatment with clopidogrel were selected and the patients were analyzed for CYP2C19*2 allelic variants using an allele-specific primer extension polymerase chain reaction method	287	312	TECHNIQUE	polymerase chain reaction
This research study explored the potential adoption of clinical decision support system mobile apps by clinicians through investigating the initial usability of the PGx prototype application in an effort to address the lack of such tools used in practice	55	63	CHALLENGE	clinical
One important argument against the widespread adoption of pharmacogenetics as a clinical tool is the lack of evidence showing its impact on medical decision making and on risk benefit ratio for the patients	80	88	CHALLENGE	clinical
After isolation of genomic DNA, genotyping was done by polymerase chain reaction-restriction fragment length polymorphism method and the lung cancer risk was evaluated as odds ratio that was adjusted for age, sex, and smoking status	55	80	TECHNIQUE	polymerase chain reaction
The clinical need for novel approaches to improve drug therapy derives from the high rate of adverse reactions to drugs and their lack of efficacy in many individuals that may be predicted by pharmacogenetic testing	138	146	CHALLENGE	efficacy
The clinical need for novel approaches to improve drug therapy derives from the high rate of adverse reactions to drugs and their lack of efficacy in many individuals that may be predicted by pharmacogenetic testing	4	12	CHALLENGE	clinical
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	522	529	DATABASE	BioGrid
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	266	279	DATABASE	Gene Ontology
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	281	283	DATABASE	GO
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	361	365	DATABASE	KEGG
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	52	56	DATABASE	LOKI
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	608	612	DATABASE	MINT
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	234	238	DATABASE	NCBI
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	313	317	DATABASE	Pfam
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	565	573	DATABASE	PharmGKB
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	662	681	DATABASE	UCSC Genome Browser
Furthermore, the potential combination of genomic biomarker identification and machine learning is a promising approach for tailoring antihypertensive therapy to individual patients, thereby mitigating the risk of developing adverse events	79	95	ANALYTICAL_METHOD	machine learning
By developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy, the Dutch Pharmacogenetics Working Group (DPWG) aims to advance the implementation of pharmacogenetics (PGx)	90	126	DATABASE	Dutch Pharmacogenetics Working Group
This lack of diverse representation in PGx studies will impede equitable clinical implementation through potentially inappropriate application of gene-based dosing algorithms, whereas representing a missed opportunity for identification of population specific single nucleotide variants and alleles	73	81	CHALLENGE	clinical
However, an overwhelming lack of genetic diversity in current PGx studies is evident	41	50	CHALLENGE	diversity
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has put forward recommendations for the <i>CYP2D6</i> phenotype, but the list of studied drug-gene pairs continues to grow	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
, the NIH Genetic Testing Registry) demonstrate the availability of these sequencing-based tests, we do not currently understand the extent to which these tests are used	10	34	DATABASE	Genetic Testing Registry
To accomplish this, we performed a scoping review to examine what RWD sources have been used in studies of PM utilization between January 2015 and August 2021 to characterize the use of genome sequencing (GS), exome sequencing (ES), tumor sequencing (TS), next-generation sequencing-based panels (NGS), gene expression profiling (GEP), and pharmacogenomics (PGx) panels	297	300	TECHNIQUE	NGS
To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB	116	124	DATABASE	PharmGKB
In line with these functional data, immunohistochemical analyses showed that 75%-90% of GCs expressing the immediate early gene cFos are CaMKIIα<sup>+</sup> in naive animals and in mice that have been exposed to a novel odor and go/no-go operant conditioning, or that have been subjected to long-term associative memory and spontaneous habituation/dishabituation odor discrimination tasks	229	231	DATABASE	GO
To gain insight into the molecular mechanisms which determine the response of T-ALL cells towards ISL, DOX and MTX, we applied array-based matrix comparative genomic hybridisation and microarray-based mRNA expression profiling and compared the genomic and transcriptomic profiles of the cell lines with their 50% inhibition (IC(50)) values for these three drugs	184	194	TECHNIQUE	microarray
, Clinical Pharmacogenetics Implementation Consortium (CPIC) clinical guidelines, and routine therapeutic drug monitoring (TDM)	2	53	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next-generation sequencing (NGS) significantly enhances precision medicine (PM) by offering personalized approaches to diagnosis, treatment, and prevention of unmet medical needs	28	31	TECHNIQUE	NGS
This scoping review focused on Asian countries starting with non-cancer studies, including rare and undiagnosed diseases (RUDs), non-communicable diseases (NCDs), infectious diseases (IDs), and pharmacogenomics, with a focus on NGS	228	231	TECHNIQUE	NGS
In Asia, developments of NGS have made remarkable progress in PM	25	28	TECHNIQUE	NGS
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	345	396	DATABASE	Clinical Pharmacogenetics Implementation Consortium
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	401	437	DATABASE	Dutch Pharmacogenetics Working Group
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	10	18	DATABASE	PharmGKB
We compared the diagnostic performance of 4 MSI molecular tests based on fragment length assay in capillary electrophoresis (OncoMate™ MSI assay, Promega) and in microcapillary electrophoresis (TapeStation 4200, Agilent); with high-resolution melting (HRM) analysis approaches (Idylla™ MSI Test, Biocartis; EasyPGX® ready MSI, Diatech Pharmacogenetics) on a series of 56 ECs, which was well characterized for MMR status with immunohistochemical approach (IHC, nonmolecular reference test)	252	255	TECHNIQUE	HRM
In this study, we introduce a novel polymerase chain reaction (PCR) melting curve analysis method for discriminating DPYD c	36	61	TECHNIQUE	polymerase chain reaction
While the power of single clinical predictors would remain inadequate if analyzed only with traditional statistical approaches, these predictors are now increasingly used to impute machine learning models that can have adequate accuracy even in the presence of relatively small sample size	181	197	ANALYTICAL_METHOD	machine learning
In this narrative review, we summarized the most important findings in precision medicine in psychiatry based on studies that constructed machine learning models using clinical, neuroimaging and/or biological data	138	154	ANALYTICAL_METHOD	machine learning
It synthesizes the recommendations of two learned societies, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), to produce a recommendation table adapted to a wide panel of antidepressants	65	116	DATABASE	Clinical Pharmacogenetics Implementation Consortium
It synthesizes the recommendations of two learned societies, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), to produce a recommendation table adapted to a wide panel of antidepressants	132	168	DATABASE	Dutch Pharmacogenetics Working Group
These data were integrated with microarray genome-wide expression data to identify pairs of miRNA/mRNA inversely and significantly correlated	32	42	TECHNIQUE	microarray
In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium	22	48	TECHNIQUE	next generation sequencing
Although our results show that only 26% (63/242) of class 1A/1B PharmGKB variants were identified, we estimate that 99	64	72	DATABASE	PharmGKB
Coding and regulatory regions of 509 genes, selected from PharmGKB and Phenopedia, were sequenced using massive parallel sequencing in blood DNA from 105 breast cancer patients in the testing phase	58	66	DATABASE	PharmGKB
05 were further prioritized for validation phase based on a newly developed decision tree	76	89	ANALYTICAL_METHOD	decision tree
In the current study, the mRNA and microRNA (miRNA) expression profiles derived from next generation sequencing data for APAP-treated (5 and 10 mM) HepaRG cells and controls were analyzed systematically	85	111	TECHNIQUE	next generation sequencing
Plasma concentrations of cyclophosphamide/4-hydroxycyclophosphamide were determined using liquid chromatography-tandem mass spectrometry and pharmacokinetic parameters calculated	112	136	TECHNIQUE	tandem mass spectrometry
Genetic association studies were included if they assessed > 10 germline genetic variants in > 5 genes in relevant drug pathways or if they used a genotyping array or other large-scale genetic analysis	0	19	ANALYTICAL_METHOD	Genetic association
The US Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), and Dutch Pharmacogenetics Working Group (DPWG) provided guidelines in the translation of clinically relevant and evidence-based SCARs pharmacogenomics research into clinical practice	43	94	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The US Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), and Dutch Pharmacogenetics Working Group (DPWG) provided guidelines in the translation of clinically relevant and evidence-based SCARs pharmacogenomics research into clinical practice	107	143	DATABASE	Dutch Pharmacogenetics Working Group
The chapter further reviews the similarities and the differences between the guidelines of the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium which both support healthcare professionals in understanding PGx test results and help guiding pharmacotherapy by providing evidence-based dosing recommendations	140	191	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The chapter further reviews the similarities and the differences between the guidelines of the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium which both support healthcare professionals in understanding PGx test results and help guiding pharmacotherapy by providing evidence-based dosing recommendations	95	131	DATABASE	Dutch Pharmacogenetics Working Group
The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases	79	87	CHALLENGE	clinical
Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ	14	33	ANALYTICAL_METHOD	logistic regression
Our previous whole-exome sequencing study found SIRT1 intronic region single-nucleotide polymorphism (SNP) rs7896005 to be associated with MRONJ in cancer patients treated with intravenous (iv) bisphosphonates (BPs)	13	35	TECHNIQUE	whole-exome sequencing
Time-to-event analysis using Cox regression was conducted to model ischemic stroke events based on CYP2C19 loss-of-function allele and adjusted with the most predictive covariates from univariate analysis	29	32	ANALYTICAL_METHOD	Cox
A number of bottlenecks have hampered progress, including a lack of large-scale replication studies, inconsistencies in defining valid treatment outcomes across experiments, a failure to routinely incorporate adverse drug reactions and serum metabolite monitoring in study designs, and inadequate investment in the longitudinal data collections required to demonstrate clinical utility	369	377	CHALLENGE	clinical
A number of bottlenecks have hampered progress, including a lack of large-scale replication studies, inconsistencies in defining valid treatment outcomes across experiments, a failure to routinely incorporate adverse drug reactions and serum metabolite monitoring in study designs, and inadequate investment in the longitudinal data collections required to demonstrate clinical utility	68	79	CHALLENGE	large-scale
Based on the combined TPMT/NUDT15 metabolic phenotypes, the Clinical Pharmacogenetics Implementation Consortium recommendations for thiopurine dose adjustment applies to 40	60	111	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We utilized PyPGx to identify star alleles (haplotype patterns) and compared allele frequencies across populations using the Pharmacogenomics Knowledgebase PharmGKB	156	164	DATABASE	PharmGKB
Proofreading PCR (PR-PCR) was developed for mutation detection in 1998 but is rarely applied due to its low efficiency in allele discrimination	13	16	TECHNIQUE	PCR
Here we developed a modified PR-PCR method using a ddNTP-blocked primer and a mixture of DNA polymerases with and without the 3'-5' proofreading function	32	35	TECHNIQUE	PCR
The modified PR-PCR method is quite capable of detecting various mutation types, including point mutations and insertions/deletions (indels), and allows discrimination amplification when the mismatch is located within the last eight nucleotides from the 3'-end of the ddNTP-blocked primer	16	19	TECHNIQUE	PCR
The modified PR-PCR has a sensitivity of 1-5 × 102 copies and a selectivity of 5 × 10-5 mutant among 107 copies of wild-type DNA	16	19	TECHNIQUE	PCR
These results suggest that the modified PR-PCR technique is effective in detection of various mutations or polymorphisms as a simple, sensitive and promising approach	43	46	TECHNIQUE	PCR
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	159	162	TECHNIQUE	PCR
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	98	123	TECHNIQUE	polymerase chain reaction
Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5	34	53	ANALYTICAL_METHOD	cart classification
0 decision tree) combined with different resampling methods were used for model building with five or three variables	2	15	ANALYTICAL_METHOD	decision tree
0 decision tree combined with the synthetic minority oversampling technique (SMOTE) using five variables had the highest area under the receiver operating characteristic curve (AUC 0	2	15	ANALYTICAL_METHOD	decision tree
Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression	215	234	ANALYTICAL_METHOD	logistic regression
This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning	177	193	ANALYTICAL_METHOD	machine learning
Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5	5	21	ANALYTICAL_METHOD	machine learning
When developed machine learning models were evaluated in the validation dataset, the C5	15	31	ANALYTICAL_METHOD	machine learning
The results support potential clinical application of machine learning for patient risk classification	54	70	ANALYTICAL_METHOD	machine learning
Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5	113	126	ANALYTICAL_METHOD	random forest
Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5	58	74	ANALYTICAL_METHOD	regression trees
Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5	89	111	ANALYTICAL_METHOD	support vector machine
Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the "post-genomic era"	150	153	TECHNIQUE	NGS
The present paper introduces array and NGS methods as two important innovation driving methods and provides examples for their application in large-scale scientific projects	39	42	TECHNIQUE	NGS
Here, we aimed to predict neutropenia and fever related to high-dose MTX using artificial intelligence	79	102	ANALYTICAL_METHOD	artificial intelligence
Five machine learning algorithms combined with four resampling techniques were used to build optimal predictive model	5	21	ANALYTICAL_METHOD	machine learning
By machine learning, we have developed and validated comprehensive models to predict the risk of neutropenia and fever	3	19	ANALYTICAL_METHOD	machine learning
The combination of random forest with adaptive synthetic appeared to be the best model for neutropenia (sensitivity = 0	19	32	ANALYTICAL_METHOD	random forest
However, due to the lack of well-designed, prospective, large-sample cohort validation and low positive predictive values, there may still be some way to go before the current results can be truly translated into clinical practice for precise prediction and prevention of DILI risk	213	221	CHALLENGE	clinical
Of course, economic evaluations on targeted therapies cannot help overcome the lack of clinical evidence for most of them	87	95	CHALLENGE	clinical
In this guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants	108	116	DATABASE	PharmGKB
The modalities for prescribing a psychotropic (dose and choice of molecule) are currently unsatisfactory, which can lead to a lack of efficacy of the treatment associated with prolonged exposure of the patient to the symptoms of his or her illness and the side effects of the molecule	134	142	CHALLENGE	efficacy
LC-MS/MS analysis was performed to measure the catalytic activities of the P450 2C9 variants, using diclofenac as a substrate	0	5	TECHNIQUE	LC-MS
<b>Materials &</b> <b>methods :</b> Based on the drug-gene interactions involved in the Clinical Pharmacogenetics Implementation Consortium guidelines, whole-genome sequencing data from the Chinese Academy of Sciences Precision Medicine Initiative project and the medication data of pediatric patients from a children's hospital, the prevalence of the Chinese population with actionable pharmacogenomic variants was calculated, the prescribing pattern for pediatric patients was analyzed	88	139	DATABASE	Clinical Pharmacogenetics Implementation Consortium
0% of the drugs involved in the Clinical Pharmacogenetics Implementation Consortium guidelines were used by Chinese pediatric patients, 8	32	83	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	156	207	DATABASE	Clinical Pharmacogenetics Implementation Consortium
DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method	117	120	TECHNIQUE	PCR
DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method	114	120	TECHNIQUE	RT-PCR
With the completion of the human genome and HapMap projects, together with the rapid advances in genotyping technologies, we have unprecedented capabilities in identifying genetic predisposing factors for these relatively rare, but serious, reactions	44	50	DATABASE	HapMap
In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	264	315	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	246	254	DATABASE	PharmGKB
However, rare variants of <i>CYP2D6</i> present a unique challenge for academia, industry, and regulatory agencies alike due to the lack of feasibility of characterizing their clinical relevance in clinical trials, particularly in variants that exhibit population-specific frequencies in racial and ethnic groups that are poorly represented in clinical trials	176	184	CHALLENGE	clinical
Under suitable assumptions and by exploiting the independence between inherited genetic susceptibility and treatment assignment, the case-only design yields efficient estimates for subgroup treatment effects and gene-treatment interaction in a Cox model	244	247	ANALYTICAL_METHOD	Cox
We show that these designs can identify all parameters in a Cox model and that the efficient case-only estimator can be incorporated in a two-step plug-in procedure	60	63	ANALYTICAL_METHOD	Cox
Herein, we will examine the recent innovations in assays, devices and software, along with next generation sequencing in genomics diagnostics which are in use or are being developed for personalized medicine	91	117	TECHNIQUE	next generation sequencing
The study identified pathogenic or likely pathogenic genetic variants-classified according to the American College of Medical Genetics and Genomics variant classification guidelines-and actionable pharmacogenomic variants, as defined by the Clinical Pharmacogenetics Implementation Consortium	241	292	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Clinical Pharmacogenetics Implementation Consortium guidelines defined clinical actionability	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The purpose of this study was to determine the frequency of clinically actionable treatment-relevant germline pharmacogenomic variants in patients with cancer and assess the real-world clinical utility of universal screening using whole-exome sequencing in this population	231	253	TECHNIQUE	whole-exome sequencing
Cancer patients underwent research-grade germline whole-exome sequencing as a component of sequencing for somatic variants	50	72	TECHNIQUE	whole-exome sequencing
Identifying germline pharmacogenomic variants was feasible using whole-exome sequencing	65	87	TECHNIQUE	whole-exome sequencing
Universal pharmacogenomic screening can be performed using whole-exome sequencing data originally obtained for quality control purposes and could be considered for patients who are candidates for irinotecan, 5-fluorouracil, capecitabine, and mercaptopurine	59	81	TECHNIQUE	whole-exome sequencing
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed on selected core targets with the help of the Metascape platform	0	13	DATABASE	Gene Ontology
To investigate the mechanism of action of the classical formula Ling-Gui-Zhu-Gan (LGZG) decoction in treating type 2 diabetes mellitus based on network pharmacology and molecular docking	169	186	ANALYTICAL_METHOD	molecular docking
Finally, the AutoDock platform was used to perform molecular docking and display the results by Pymol software	51	68	ANALYTICAL_METHOD	molecular docking
Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	191	242	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	258	294	DATABASE	Dutch Pharmacogenetics Working Group
The completion of the Human Genome Project and the associated HapMap Project, together with advances in technologies for investigating genetic variation, have greatly advanced the potential to develop such tests; however, many challenges remain	62	68	DATABASE	HapMap
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	77	88	ANALYTICAL_METHOD	Elastic Net
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	90	95	ANALYTICAL_METHOD	LASSO
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	48	64	ANALYTICAL_METHOD	machine learning
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	101	106	ANALYTICAL_METHOD	Ridge
With the developments in storage capacity, artificial intelligence, and learning algorithms, we are now able to learn and interpret complex systems such as the human genome in a very short time	43	66	ANALYTICAL_METHOD	artificial intelligence
Array comparative genomic hybridization (aCGH), whole-exome sequencing (WES), and pharmacogenetics approaches, respectively, have identified relevant copy number alterations (CNAs), single nucleotide variants (SNVs), and polymorphisms (SNPs) that were then combined into an integrated analysis	41	45	TECHNIQUE	aCGH
Array comparative genomic hybridization (aCGH), whole-exome sequencing (WES), and pharmacogenetics approaches, respectively, have identified relevant copy number alterations (CNAs), single nucleotide variants (SNVs), and polymorphisms (SNPs) that were then combined into an integrated analysis	48	70	TECHNIQUE	whole-exome sequencing
While the term artificial intelligence and the concept of deep learning are not new, recent advances in high-performance computing, the availability of large annotated data sets required for training, and novel frameworks for implementing deep neural networks have led to an unprecedented acceleration of the field of molecular (network) biology and pharmacogenomics	15	38	ANALYTICAL_METHOD	artificial intelligence
We also: (1) discuss some aspects of future development of deep learning in drug discovery/chemistry; (2) provide references to published information; (3) provide recently advocated recommendations on using artificial intelligence and deep learning in -omics research and drug discovery	207	230	ANALYTICAL_METHOD	artificial intelligence
The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary	233	250	ANALYTICAL_METHOD	feature selection
The need to align biological data to innovative machine learning has stimulated developments in both data integration (fusion) and knowledge representation, in the form of heterogeneous, multiplex, and biological networks or graphs	48	64	ANALYTICAL_METHOD	machine learning
The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary	182	198	ANALYTICAL_METHOD	machine learning
Recently, a new generation of generic dsDNA binding dyes (LCGreenTM) contributed to the development of fast and low-cost method for SNP detection and/or genotyping based on high resolution melting (HRM) analysis	198	201	TECHNIQUE	HRM
The aim of our study was to develop HRM assay for IL23R gene (rs7517847) and to perform association study in Slovenian inflammatory bowel diseases (IBD) patients	36	39	TECHNIQUE	HRM
With combination of results from »Tm calling« and »gene scanning« methods, we achieved 98,6% concordance between PCR-RFLP and PCR-HRM results, based on the analysis of 640 samples	130	133	TECHNIQUE	HRM
Moffitt Cancer Center's Personalized Medicine Clinical Service (PMCS) reviews somatic next-generation sequencing (NGS) assay results, provides interpretations, and identifies potential therapeutic options	114	117	TECHNIQUE	NGS
Major PGx resources, such as the Clinical Pharmacogenetics Implementation Consortium, provide valuable recommendations for the development of CDS for specific gene-drug pairs but do not specify whether the administration route of a drug is clinically relevant	33	84	DATABASE	Clinical Pharmacogenetics Implementation Consortium
SIGNIFICANCE STATEMENT: Efavirenz likely alters the pharmacokinetics of coadministered drugs, potentially causing lack of efficacy or increased adverse effects, as well as the disposition of endogenous compounds relevant in homeostasis through upregulation of UGT1A1 and multidrug resistance-associated protein 2	122	130	CHALLENGE	efficacy
Two leading approaches for identifying these relationships in medical literature are: human expert led manual curation efforts, and modern data mining based automated approaches	139	150	ANALYTICAL_METHOD	data mining
Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) analyses of target genes were performed by R-clusterProfiler	0	13	DATABASE	Gene Ontology
Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) analyses of target genes were performed by R-clusterProfiler	62	66	DATABASE	KEGG
GO and KEGG analyses revealed significant enrichment of relevant target genes in various biological processes, cellular functions(e	7	11	DATABASE	KEGG
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	171	179	DATABASE	PharmGKB
To explore the mechanism of Hedyotis Diffusae Herba-Smilacis Glabrae Rhizoma(HDH-SGR) in treating lung adenocarcinoma based on big data bioinformatics combined with network pharmacology analysis and molecular docking technology	199	216	ANALYTICAL_METHOD	molecular docking
Based on the results of molecular docking validation, diosgenin, quercetin, naringenin, taxifolin, 2-methoxy-3-methyl-9,10-anthraquinone, stigmasterol, and β-sitosterol were able to bind tightly to the core targets	24	41	ANALYTICAL_METHOD	molecular docking
We suggest the use of the geometric mean of ACTB, B2M and GAPDH for normalization of qPCR data of target genes in pharmacogenomics studies in asthma patients before and after anti-asthmatic therapy, however if gene expression is measured only before anti-asthmatic treatment, we recommend the use of the geometric mean of POLR2A and B2M	85	89	TECHNIQUE	qPCR
RNA-seq offers more utilities than microarray in determining the transcriptomic characteristics of cancer	35	45	TECHNIQUE	microarray
The rat BodyMap study provided a comprehensive rat transcriptomic body map by performing RNA-Seq on 320 samples from 11 organs in either sex of juvenile, adolescent, adult and aged Fischer 344 rats	89	96	TECHNIQUE	RNA-Seq
Genetic association analysis was performed with PLINK using the relative bioavailability as the phenotype	0	19	ANALYTICAL_METHOD	Genetic association
With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples	24	50	TECHNIQUE	next generation sequencing
Regulatory guidance information was collected from the PharmGKB online knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	93	144	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Regulatory guidance information was collected from the PharmGKB online knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	55	63	DATABASE	PharmGKB
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on https://www	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months	9	28	ANALYTICAL_METHOD	logistic regression
In multiple logistic regression analysis, the presence of the CYP2C19 loss of function (LOF) alleles *2, *3, and *8 in the medically managed patients was associated with lower odds of primary endpoint compared with wild-type homozygotes (odds ratio [OR] 0	12	31	ANALYTICAL_METHOD	logistic regression
A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death demonstrated a significant trend in multiple logistic regression analysis of CYP2C19 variants, with lower odds of secondary endpoint in patients carrying at least 1 LOF allele (*2, *3, *8) than in wild-type homozygotes (OR 0	127	146	ANALYTICAL_METHOD	logistic regression
Moreover, an additional barrier for clinical implementation of precision medicine is the lack of correlation between genotype and phenotype, considering that most of the current methods include only genotyping	36	44	CHALLENGE	clinical
There is, however, a lack of agreement in actual practice about at what point in the oncology clinical drug development process pharmacogenomic studies should be incorporated	94	102	CHALLENGE	clinical
Whole exome sequencing of the FH family with four patients and six unaffected members identified a heterozygous splicing mutation (c	0	22	TECHNIQUE	Whole exome sequencing
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	193	199	DATABASE	HapMap
PharmGKB is a knowledge base that captures the relationships between drugs, diseases/phenotypes and genes involved in pharmacokinetics (PK) and pharmacodynamics (PD)	0	8	DATABASE	PharmGKB
PharmGKB's website is designed to effectively disseminate knowledge to meet the needs of our users	0	8	DATABASE	PharmGKB
PharmGKB currently has literature annotations documenting the relationship of over 500 drugs, 450 diseases and 600 variant genes	0	8	DATABASE	PharmGKB
In order to meet the needs of whole genome studies, PharmGKB has added new functionalities, including browsing the variant display by chromosome and cytogenetic locations, allowing the user to view variants not located within a gene	52	60	DATABASE	PharmGKB
PharmGKB has also added functionality to accept, store, display and query high throughput SNP array data	0	8	DATABASE	PharmGKB
PharmGKB is available at www	0	8	DATABASE	PharmGKB
Recent advances in text and data mining have been applied to a broad spectrum of key biomedical questions in genomics, pharmacogenomics and other fields	28	39	ANALYTICAL_METHOD	data mining
We present an overview of the fundamental methods for text and data mining, as well as recent advances and emerging applications toward precision medicine	63	74	ANALYTICAL_METHOD	data mining
PANCDR outperformed other machine learning models in predicting external test data	26	42	ANALYTICAL_METHOD	machine learning
In this study, a Precision Medicine Prediction using an Adversarial Network for Cancer Drug Response (PANCDR) model is proposed	102	108	ANALYTICAL_METHOD	PANCDR
PANCDR consists of two sub-models, an adversarial model and a CDR prediction model	0	6	ANALYTICAL_METHOD	PANCDR
PANCDR outperformed other machine learning models in predicting external test data	0	6	ANALYTICAL_METHOD	PANCDR
Extraordinary advances in high throughput next generation sequencing (NGS) technology and bioinformatics are the main thrust that transforms the current state of healthcare into the era of precision medicine where clinical practice takes individual variability into account	42	68	TECHNIQUE	next generation sequencing
Extraordinary advances in high throughput next generation sequencing (NGS) technology and bioinformatics are the main thrust that transforms the current state of healthcare into the era of precision medicine where clinical practice takes individual variability into account	70	73	TECHNIQUE	NGS
We believe that with decreasing costs of NGS, increasing ability to interpret the genomic data, a greater number of actionable and available treatments, implementation of precision medicine at the public health level is not a matter of if but when	41	44	TECHNIQUE	NGS
The use of high-throughput genomic analysis allows identification of additional candidate genetic factors associated with pharmacogenetic phenotypes, such as TPMT enzymatic activity: PACSIN2 polymorphisms have been identified by a genome-wide analysis, combining evaluation of polymorphisms and gene expression, as a significant determinant of TPMT activity in the HapMap CEU cell lines and the effects of PACSIN2 on TPMT activity and mercaptopurine induced adverse effects were confirmed in children with ALL	365	371	DATABASE	HapMap
Thus, we selected the ridge model of panobinostat for further application of explainable artificial intelligence (XAI)	89	112	ANALYTICAL_METHOD	artificial intelligence
As recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings	94	104	TECHNIQUE	microarray
Next-generation sequencing (NGS) is present in all fields of life science, which has greatly promoted the development of basic research while being gradually applied in clinical diagnosis	28	31	TECHNIQUE	NGS
The major risk factors for developing drug-induced nutrient deficiencies are lack of awareness by the prescribing physician and long duration of drug therapy	128	141	CHALLENGE	long duration
Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR) = 1	9	28	ANALYTICAL_METHOD	logistic regression
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	25	28	ANALYTICAL_METHOD	Cox
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	55	74	ANALYTICAL_METHOD	logistic regression
Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing or by PCR restriction fragment length polymorphism	119	122	TECHNIQUE	PCR
Overall, the personalized prescription of antipsychotic drugs in schizophrenia remains limited by a lack of data in the literature, justifying the development of clinical studies in this field	162	170	CHALLENGE	clinical
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has recommended dose adjustments based on the results of TPMT and NUDT15 genotyping	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways	85	94	CHALLENGE	effective
However, its implementation in the clinical practice of psychiatry/neurology still has barriers, mainly due to a lack of evidence	35	43	CHALLENGE	clinical
A considerable amount of efforts have been devoted by the regulatory agents like the food and drug administration (FDA) as well as the expert-based networks such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) to overcome the existing barriers	169	220	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Clinical Pharmacogenetics Implementation Consortium (CPIC) categorizes the guanine (G) allele of this SNP as non-functional	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Although polymerase chain reaction (PCR) followed by Sanger sequencing (SS; PCR-SS) is a prevalent method for <i>DPYD</i> genotyping, it may encounter limitations	36	39	TECHNIQUE	PCR
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	123	126	TECHNIQUE	PCR
This preventive measure is essential to avoid sequence frameshifts or primer misalignments arising from SNP occurrences in the genome, which can compromise PCR-SS and lead to genotyping failures	156	159	TECHNIQUE	PCR
Although polymerase chain reaction (PCR) followed by Sanger sequencing (SS; PCR-SS) is a prevalent method for <i>DPYD</i> genotyping, it may encounter limitations	9	34	TECHNIQUE	polymerase chain reaction
We developed machine learning models to predict the ICS response in patients with asthma	13	29	ANALYTICAL_METHOD	machine learning
Real-time PCR FRET assays for the CYP3A4 A-392G, CYP3A5 A6986G, ABCB1 C1236T, G2677T/A and C3435T polymorphisms were used and the melting curves of both DNA isolation methods were compared	10	13	TECHNIQUE	PCR
PharmaKU can help to overcome several hurdles posed by previous pharmacogenomics tools, including input in hg38 format only, while hg19/GRCh37 is now the most popular reference genome assembly among clinicians and geneticists, as well as the lack of clinical recommendations and other pertinent dosage-related information	250	258	CHALLENGE	clinical
A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system	93	101	DATABASE	PharmGKB
Eleven variants in the thymidylate synthetase (<i>TYMS</i>), methylenetetrahydrofolate reductase (<i>MTHFR</i>)<i>,</i> dihydrofolate reductase (<i>DHFR</i>), <i>SLC19A1</i> and <i>SLCO1B</i> genes were analyzed in 148 patients, using PCR- and sequencing-based methodology	235	238	TECHNIQUE	PCR
Genotyping was performed using the DMET Plus microarray platform	35	55	TECHNIQUE	DMET Plus microarray
To embrace the complexity of drug response, machine learning methods could help to identify gene-gene interactions and develop pharmacogenetic predictors of drug response	44	60	ANALYTICAL_METHOD	machine learning
Though, projects like the HapMap increase credibility and use of SNPs, still there are some concern like the required sample (patient) sizes, the number of SNPs required for mapping, number of association studies, the cost of SNP genotyping, and the interpretation and explanation of results are some of the challenges that surround this field	26	32	DATABASE	HapMap
This is due in part to a separate and more complex regulatory process for diagnostics coupled with a lack of clear regulatory guidance	109	114	CHALLENGE	clear
More importantly, payers have placed restrictions on reimbursement of personalized medicines and their companion diagnostics, given the lack of evidence on the clinical utility of many tests	160	168	CHALLENGE	clinical
We identified several methods and combinations of techniques registered in the Genetic Testing Registry (GTR), which can be used to guide therapy with drugs for which pharmacogenomic-related information is provided in the European public assessment reports	79	103	DATABASE	Genetic Testing Registry
However, partly due to lack of education, pharmacogenomic testing has not been fully implemented in clinical practice	100	108	CHALLENGE	clinical
On the informatics side, methods based on data integration, data mining, and knowledge representation can provide decision support for both researchers and clinicians	60	71	ANALYTICAL_METHOD	data mining
The singleplex nature of the 5'nuclease real-time PCR ensures that the primers anneal with equal affinity to both the sequence of the <i>CYP2D6</i> and the reference gene	50	53	TECHNIQUE	PCR
Of all the genetic variants, copy number variations are particular difficult to detect by polymerase chain reaction	90	115	TECHNIQUE	polymerase chain reaction
521T>C) SNP was performed with allele-specific polymerase chain reaction, whilst polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping the SLCO1B1 rs2306283 (c	47	72	TECHNIQUE	polymerase chain reaction
The International HapMap Project provides a key resource of genotypic data on human lymphoblastoid cell lines derived from four major world populations of European, African, Chinese and Japanese ancestry for researchers to associate with various phenotypic data to find genes affecting health, disease and response to drugs	18	24	DATABASE	HapMap
Recent progress in dissecting genetic contribution to natural variation in gene expression within and among human populations and variation in drug response are two examples in which researchers have utilized the HapMap resource	213	219	DATABASE	HapMap
The HapMap Project provides new insights into the human genome and has applicability to pharmacogenomics studies leading to personalized medicine	4	10	DATABASE	HapMap
More and more hospital laboratories are acquiring new high-throughput sequencing devices ("next-generation sequencers", NGS), allowing them to analyze tens or hundreds of genes, or even the entire exome	120	123	TECHNIQUE	NGS
NGS is now sufficiently sensitive to analyze circulating fetal DNA in maternal blood (cell-free fetal DNA, cffDNA), enabling applications such as non invasive diagnosis of fetal sex (and X-linked diseases), fetal rhesus among rhesus-negative women, trisomy and, in the near future, Mendelian mutations	0	3	TECHNIQUE	NGS
In the field of constitutional oncogenetics, NGS can also be used for simultaneous analysis of genes involved in " hereditary " cancers (21 breast cancer genes, 6 colon cancer genes, etc	45	48	TECHNIQUE	NGS
More generally, NGS can identify all genomic abnormalities (deletions, translocations, mutations) in a given malignant tissue (hemopathy or solid tumor), and has the potential to distinguish between important mutations (those that drive tumor progression) from " bystander " or accessory mutations, and also to identify "druggable" mutations amenable to targeted therapies (e	16	19	TECHNIQUE	NGS
To promote implementation, the Dutch Pharmacogenetics Working Group (DPWG) develops evidence-based guidelines on how to optimize pharmacotherapy based on PGx test results	31	67	DATABASE	Dutch Pharmacogenetics Working Group
Genotyping was performed by real-time polymerase chain reaction (PCR) using the TaqMan<sub>®</sub> Drug Metabolism Genotyping Assay for <i>UGT2B7 c	38	63	TECHNIQUE	polymerase chain reaction
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	269	275	DATABASE	HapMap
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	109	117	DATABASE	PharmGKB
This paper presents a brief overview of the many available public resources for cheminformatics (DrugBank, PharmGKB and other drugrelated databases) and SNPs (dbSNP, HapMap, SNP500Cancer, SNP-RFLPing 2 and other SNP tools) and points out the importance of integrating cheminformatic and SNP resources for the future of pharmacogenomics	166	172	DATABASE	HapMap
This paper presents a brief overview of the many available public resources for cheminformatics (DrugBank, PharmGKB and other drugrelated databases) and SNPs (dbSNP, HapMap, SNP500Cancer, SNP-RFLPing 2 and other SNP tools) and points out the importance of integrating cheminformatic and SNP resources for the future of pharmacogenomics	107	115	DATABASE	PharmGKB
Plasma levels of atorvastatin and its metabolites were measured sequentially using liquid chromatography-tandem mass spectrometry from 0 to 24 h after atorvastatin administration	105	129	TECHNIQUE	tandem mass spectrometry
In the following, we examine current molecular methods for probing factors behind reproductive pregnancy loss including reverse transcription polymerase chain reaction and next generation sequencing (NGS)	172	198	TECHNIQUE	next generation sequencing
In the following, we examine current molecular methods for probing factors behind reproductive pregnancy loss including reverse transcription polymerase chain reaction and next generation sequencing (NGS)	200	203	TECHNIQUE	NGS
In the following, we examine current molecular methods for probing factors behind reproductive pregnancy loss including reverse transcription polymerase chain reaction and next generation sequencing (NGS)	142	167	TECHNIQUE	polymerase chain reaction
We argue that (1) a genomic learning healthcare system must allow for continuous collection and assessment of rare variants, (2) emerging machine learning methods will enable algorithms to predict the clinical impact of rare variants on protein function, and (3) ethical considerations must inform the construction and deployment of all rare-variation triage strategies, particularly with respect to health disparities arising from unbalanced ancestry representation	138	154	ANALYTICAL_METHOD	machine learning
Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes	47	55	CHALLENGE	clinical
Authors discuss the perspectives of practical utilization of pharmacogenetics (identification of single candidate genes using PCR) or pharmacogenomics (using genome wide association studies) in choice of optimal treatment of osteoporosis	126	129	TECHNIQUE	PCR
Nevertheless, identification of new genes and verification their association with bone density and/or quality using both PCR and genome wide association studies remain to be a great challenge targeting optimal prevention and treatment of osteoporosis	121	124	TECHNIQUE	PCR
In recent years, clinical pharmacogenetics has accumulated knowledge in pediatric pharmacotherapy, and guidelines from professional organizations, such as the Clinical Pharmacogenetics Implementation Consortium, can be consulted to determine the efficacy of specific drugs and the risk of adverse effects	159	210	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Pharmacogenomics is at the forefront of research to understand interindividual drug response variability, but although many genotype-drug response associations have been identified, translation of pharmacogenomic associations into clinical practice has been hampered by inconsistent findings and inadequate predictive values	270	291	CHALLENGE	inconsistent findings
One of the goals of the Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health’s Pharmacogenomics Research Network (http://www	24	75	DATABASE	Clinical Pharmacogenetics Implementation Consortium
org) and the Pharmacogenomics Knowledge Base (PharmGKB, http://www	46	54	DATABASE	PharmGKB
The slow rate at which pharmacogenetic tests are being adopted in clinical practice is partly due to the lack of specific guidelines on how to adjust medications on the basis of the genetic test results	66	74	CHALLENGE	clinical
Real Time PCR (Melting Curve Analysis) followed DNA extraction from buccal swabs and statistical analysis of the results was performed	10	13	TECHNIQUE	PCR
The historic lack of clear-cut biological prognostic factors has led to over- or under-treatment of some patients	21	26	CHALLENGE	clear
However, only a few, if any, studies have discussed a mapping of expression quantitative trait loci (eQTL) in a gene-based framework	101	105	TECHNIQUE	eQTL
Neither study has discussed ancestry-informative eQTL nor investigated their roles in pharmacogenetics by integrating single nucleotide polymorphism (SNP)-based eQTL (s-eQTL) and gene-based eQTL (g-eQTL)	49	53	TECHNIQUE	eQTL
Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics	16	39	TECHNIQUE	mass spectrometry-based
Advance in next generation sequencing and platform brings new opportunities in validating the genetic candidates in certain reactions, and could be used to develop the preemptive tests to predict the outcome of the variation in a personal response to a drug	11	37	TECHNIQUE	next generation sequencing
The blood serum concentration of estradiol was investigated in accordance to method of solid phase enzyme immunoassay, the genotyping procedure was performed in accordance to indices of polymerase chain reaction with analysis of the restrictional fragments length	186	211	TECHNIQUE	polymerase chain reaction
Currently, there are few organizations/associations responsible for releasing those guidelines, including the Clinical Pharmacogenetics Implementation Consortium, Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety and the French National Network of Pharmacogenetics	110	161	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Currently, there are few organizations/associations responsible for releasing those guidelines, including the Clinical Pharmacogenetics Implementation Consortium, Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety and the French National Network of Pharmacogenetics	163	199	DATABASE	Dutch Pharmacogenetics Working Group
Several large resources of curated relations between biomedical entities are currently available, such as the Pharmacogenomics Knowledge Base (PharmGKB) or the Comparative Toxicogenomics Database (CTD)	143	151	DATABASE	PharmGKB
Analyses with the use of imputation-based methods to combine genotype data from both studies and to test untyped SNPs from the HapMap database identified several SNPs within a 5 kb region of HNF1A intron 1 with the strongest evidence of association with CRP phenotype	127	133	DATABASE	HapMap
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	96	100	TECHNIQUE	qPCR
Five institutional cohorts with NGS data were retrieved from different research projects at INMEGEN, sequencing files were filtered for 55 pharmacogenes present in all cohorts to identify novel and known variation	32	35	TECHNIQUE	NGS
General clinical examination methods, office measurement and daily blood pressure monitoring, tolerance evaluation, and genotyping using the ABCB1 polymorphic marker C3435T by the PCR-RFLP method (polymerase chain reaction and restriction fragment length polymorphism) were used	197	222	TECHNIQUE	polymerase chain reaction
On the other hand, limited cost and wide availability make thiopurines a reasonable option in settings of limited resources and increasing prevalence of IBD	106	123	CHALLENGE	limited resources
With the advent of significant technological advances comes another challenge: how can we harness the data to inform clinically actionable measures and how can we use it to develop better predictive risk models? We propose to apply the principles artificial intelligence to develop a medication optimization platform to prevent, manage and treat different diseases	247	270	ANALYTICAL_METHOD	artificial intelligence
PCR and next generation sequencing were used for the analysis	8	34	TECHNIQUE	next generation sequencing
PCR and next generation sequencing were used for the analysis	0	3	TECHNIQUE	PCR
Genotyping was performed using PCR-RFLP and direct Sanger sequencing	31	34	TECHNIQUE	PCR
In this work, an ultra-high-performance liquid chromatography (UHPLC)-tandem mass spectrometry method has been established and validated for detection of dexmedetomidine in plasma from pediatric population	70	94	TECHNIQUE	tandem mass spectrometry
In a logistic regression analysis, higher CYP2C19 activity (OR (95% CI): 4	5	24	ANALYTICAL_METHOD	logistic regression
The candidate gene approach has been traditionally utilized to determine the contribution of genetic variation to a particular phenotype; however, the sequencing of the human genome and the genetic resource provided by the International HapMap Project has allowed researchers to perform genome-wide studies without a priori knowledge	237	243	DATABASE	HapMap
Recent work has demonstrated the usefulness of cell-based models for pharmacogenomic discovery using the HapMap samples, which are a panel of well-genotyped, human lymphoblastoid cell lines (LCLs) derived from 90 Utah residents with ancestry from northern and western Europe (CEU), 90 Yoruba in Ibadan, Nigeria (YRI), 45 Japanese in Tokyo, Japan (JPT) and 45 Han Chinese in Beijing, China (CHB)	105	111	DATABASE	HapMap
Using the examples of the authors' Tier 1/Green classification for KRAS and Tier 2/Yellow for TPMT, I discuss differences between the guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and those by the National Comprehensive Cancer Network (NCCN)	159	210	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Rapid advances in biochemical and next-generation sequencing (NGS) technologies have enabled several strategies for precise genotyping and phasing of candidate HLA alleles	62	65	TECHNIQUE	NGS
Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively	28	47	ANALYTICAL_METHOD	logistic regression
A novel research field in bioinformatics is pharmacogenomics and the corresponding applications of artificial intelligence tools	99	122	ANALYTICAL_METHOD	artificial intelligence
Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)	105	113	DATABASE	PharmGKB
An area of recent interest is the potential for machine learning (ML) applications within pharmacology	48	64	ANALYTICAL_METHOD	machine learning
Using polymerase chain reaction sequence-specific primer-based genotyping, the HLA-B*5701 allele was observed in 20 patients (4	6	31	TECHNIQUE	polymerase chain reaction
However, due to lack of efficacy or adverse safety profiles, there is currently a limited selection of anti-obesity drugs on the market	24	32	CHALLENGE	efficacy
The Clinical Pharmacogenetics Implementation Consortium (CPIC<sup>®</sup> ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next-generation sequencing (NGS) has the potential to accelerate the early detection of disorders and the identification of pharmacogenetics markers to customize treatments	28	31	TECHNIQUE	NGS
This review explains the historical facts that led to the development of NGS along with the strengths and weakness of NGS, with a special emphasis on the analytical aspects used to process NGS data	73	76	TECHNIQUE	NGS
There are solutions to all the steps necessary for performing NGS in the clinical context where the majority of them are very efficient, but there are some crucial steps in the process that need immediate attention	62	65	TECHNIQUE	NGS
All drugs within the deployment manuals, TCCC guidelines and EWS book, were identified and the list was cross-referenced to the Clinical Pharmacogenetics Implementation Consortium guidelines and genes-drugs interactions list as well as the Food and Drug Administration Table of Pharmacogenomics Biomarkers in Drug Labeling	128	179	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcase<i>CYP2D6</i>, a gene that metabolizes approximately 25% of all prescribed drugs	159	167	DATABASE	PharmGKB
To evaluate the use of drugs with pharmacogenomic (PGx) guidelines from the Clinical Pharmacogenetics Implementation Consortium in early childhood	76	127	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A series of papers have been published describing DNA biochips as alternative to conventional microarray platforms to facilitate and ameliorate the signal readout	94	104	TECHNIQUE	microarray
Due to the lack of precise diagnostic criteria, current search strategy for monogenic diabetes is predominantly based on atypical clinical course of diabetes and intuition of the attending physician	130	138	CHALLENGE	clinical
A molecular docking in silico approached the binding of plant constituents to the vascular endothelial growth factor receptors 1 and 2 (VEGFR1, VEGFR2)	2	19	ANALYTICAL_METHOD	molecular docking
Selected phytochemicals from Korean plants were analyzed in more detail using microarray-based mRNA expression profiles and molecular docking to VEGFR1 and VEGFR2	124	141	ANALYTICAL_METHOD	molecular docking
The last two decades have witnessed important genomic discoveries in ALL, enabled by advances in next-generation sequencing (NGS) technologies to characterize the landscape of germline and somatic alterations in ALL, some of which have important diagnostic, prognostic and therapeutic implications	125	128	TECHNIQUE	NGS
ML is a sub-field of artificial intelligence, and to date, it has demonstrated satisfactory performance on a wide range of tasks in biomedicine	21	44	ANALYTICAL_METHOD	artificial intelligence
Research has indicated that endothelin receptor antagonists may be more effective in women and there have been some minor differences found in certain races and ethnicities, but these findings are muddled by the impact of socioeconomic factors and a lack of representation of non-White patients in clinical trials	298	306	CHALLENGE	clinical
Research has indicated that endothelin receptor antagonists may be more effective in women and there have been some minor differences found in certain races and ethnicities, but these findings are muddled by the impact of socioeconomic factors and a lack of representation of non-White patients in clinical trials	72	81	CHALLENGE	effective
The advent of novel technologies such as genomewide association studies and next generation sequencing will likely lead to the identification of additional genetic biomarkers	76	102	TECHNIQUE	next generation sequencing
The surface of the microarray is functionalized with self-assembled monolayers of mercaptoundodecanoic acid or thiolated DNA	19	29	TECHNIQUE	microarray
We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background	62	78	ANALYTICAL_METHOD	machine learning
These include difficulty in identifying SNPs with sufficiently robust evidence to guide clinical decision making, lack of clinician training on how to order and use genotype data, lack of clinical decision support (CDS) to guide treatment, and limited reimbursement	63	69	CHALLENGE	robust
These include difficulty in identifying SNPs with sufficiently robust evidence to guide clinical decision making, lack of clinician training on how to order and use genotype data, lack of clinical decision support (CDS) to guide treatment, and limited reimbursement	88	96	CHALLENGE	clinical
Starting with predicted functional germline variants obtained through whole-exome sequencing (WES) data of the Quebec childhood ALL cohort we performed exome-wide association studies with ASNase-related toxicities	70	92	TECHNIQUE	whole-exome sequencing
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has categorized over 35 gene-drug pairs as "level A," for which there is sufficiently strong evidence to recommend that genetic information be used to guide drug prescribing	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Recently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) have revised recommendations for the translation of CYP2D6 genotype to phenotype	14	65	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Over the past two decades, Next-Generation Sequencing (NGS) has revolutionized the approach to cancer research	55	58	TECHNIQUE	NGS
Applications of NGS include the identification of tumor specific alterations that can influence tumor pathobiology and also impact diagnosis, prognosis and therapeutic options	16	19	TECHNIQUE	NGS
Pharmacogenomics (PGx) studies the role of inheritance of individual genetic patterns in drug response and has taken advantage of NGS technology as it provides access to high-throughput data that can, however, be difficult to manage	130	133	TECHNIQUE	NGS
Machine learning (ML) has recently been used in the life sciences to discover hidden patterns from complex NGS data and to solve various PGx problems	107	110	TECHNIQUE	NGS
In this review, we provide a comprehensive overview of the NGS approaches that can be employed and the different PGx studies implicating the use of NGS data	59	62	TECHNIQUE	NGS
PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan™ microarray (including <i>CYP3A5*3</i> , <i>*6</i> , and <i>*7</i> )	32	56	TECHNIQUE	tandem mass spectrometry
Gene-based prescribing recommendations are available to healthcare providers through Food and Drug Administration-approved drug labeling and Clinical Pharmacogenetics Implementation Consortium guidelines	141	192	DATABASE	Clinical Pharmacogenetics Implementation Consortium
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	23	40	ANALYTICAL_METHOD	feature selection
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	112	131	ANALYTICAL_METHOD	logistic regression
Our data revealed that the MFNN models were superior to the logistic regression model	60	79	ANALYTICAL_METHOD	logistic regression
DNA was extracted from buccal swabs obtained from 636 non-related Southeastern European Caucasian individuals and was analyzed by real-time PCR	140	143	TECHNIQUE	PCR
A sizable fraction of patients experiences adverse drug events or lack of drug efficacy	79	87	CHALLENGE	efficacy
Plasma levels of (R)- and (S)-salbutamol were determined by an enantioselective liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay	128	133	TECHNIQUE	LC-MS
Plasma levels of (R)- and (S)-salbutamol were determined by an enantioselective liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay	102	126	TECHNIQUE	tandem mass spectrometry
Although methotrexate is widely used in clinical practice there remains significant lack of understanding of its mechanisms of action and the factors that contribute to the variability in toxicity and response seen clinically	40	48	CHALLENGE	clinical
Genotype-guided dosing recommendations were informed by Clinical Pharmacogenetics Implementation Consortium guidelines	56	107	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis, Gene Ontology term enrichment analysis, and gene set enrichment analysis were performed	69	82	DATABASE	Gene Ontology
Although logistic and economic limitations to clinical pharmacogenomics are being superseded by external measures such as preemptive genotyping, implementation by clinicians has met resistance, partly due to a lack of education	46	54	CHALLENGE	clinical
A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP	2	18	ANALYTICAL_METHOD	machine learning
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	222	273	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	289	325	DATABASE	Dutch Pharmacogenetics Working Group
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	28	31	TECHNIQUE	NGS
NGS and related technologies are increasing knowledge in the research sphere, yet rates of genomic literacy remain low, resulting in a widening gap in knowledge translation to the patient	0	3	TECHNIQUE	NGS
Although notable progress has been made in the therapeutic management of patients with chronic kidney disease in both conservative and renal replacement treatments (dialysis and transplantation), the occurrence of medication-related problems (lack of efficacy, adverse drug reactions) still represents a key clinical issue	251	259	CHALLENGE	efficacy
Although notable progress has been made in the therapeutic management of patients with chronic kidney disease in both conservative and renal replacement treatments (dialysis and transplantation), the occurrence of medication-related problems (lack of efficacy, adverse drug reactions) still represents a key clinical issue	308	316	CHALLENGE	clinical
Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB	100	108	DATABASE	PharmGKB
We developed a cohort-based CNV detection workflow to extract CNVs from read counts of targeted NGS of 340 genes involved in absorption, distribution, metabolism and excretion (ADME) of drugs	96	99	TECHNIQUE	NGS
Our straightforward CNV detection workflow can be easily applied to any NGS coverage data and helped to analyze CNVs in an ADME-NGS panel of 340 pharmacogenes to improve genotype-phenotype correlations	72	75	TECHNIQUE	NGS
Data science and machine learning play a crucial role in the processing and interpretation of results, using enormous databases and statistics to discover new and support current genotype-phenotype correlations	17	33	ANALYTICAL_METHOD	machine learning
Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2-OS and HOS cell growth, including cDNA microarray and RT-PCR assays	197	212	TECHNIQUE	cDNA microarray
cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers were all modified by OGE treatment	0	15	TECHNIQUE	cDNA microarray
Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2-OS and HOS cell growth, including cDNA microarray and RT-PCR assays	202	212	TECHNIQUE	microarray
cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers were all modified by OGE treatment	5	15	TECHNIQUE	microarray
Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2-OS and HOS cell growth, including cDNA microarray and RT-PCR assays	220	223	TECHNIQUE	PCR
Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2-OS and HOS cell growth, including cDNA microarray and RT-PCR assays	217	223	TECHNIQUE	RT-PCR
RT-PCR analysis also confirmed the down-regulation of SKA2 and BUB1B, and the up-regulation of PPP1R15A, SQSTM1, HSPA1B, and DDIT4 by OGE treatment	0	6	TECHNIQUE	RT-PCR
Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2-OS and HOS cell growth, including cDNA microarray and RT-PCR assays	16	28	TECHNIQUE	Western blot
We develop a unified estimating equation approach to proving asymptotic independence between a filtering statistic and an interaction test statistic in a range of situations, including marginal association and interaction in a generalized linear model with a canonical link	227	245	ANALYTICAL_METHOD	generalized linear
The association between genotypes and OS of patients was assessed using Kaplan-Meier survival curves and Cox proportional hazards regression analysis	72	93	ANALYTICAL_METHOD	Kaplan-Meier survival
There was no significant difference between GSTM1 genotypes, according to Kaplan-Meier survival analysis (log-rank test, P=0	74	95	ANALYTICAL_METHOD	Kaplan-Meier survival
Polymorphisms in the patients were genotyped using the following methods: Pyrosequencing, to identify GSTP1 Ile105Val; a relative quantification method, to identify the copy number variation in GSTM1; and polymerase chain reaction followed by gel electrophoresis, to identify the null vs	205	230	TECHNIQUE	polymerase chain reaction
Genome-wide patterns of pharmacogenomic variation-6311 drug response-associated variants for <i>All of Us</i> and 5966 variants for <i>UKB</i>-were analyzed with machine learning classifiers to predict participants' self-identified race and ethnicity	162	178	ANALYTICAL_METHOD	machine learning
Several polymorphisms are described in the literature and included in the personalized medicine database PharmGKB, but there are no carboxylesterase genotypes referenced in Food and Drug Administration approved drug labeling	105	113	DATABASE	PharmGKB
The current version is Web-based and responsive to different screen sizes (desktop, tablet, mobile), features improved usability, and expands the number of gene-drug recommendations provided based on Clinical Pharmacogenetics Implementation Consortium dosing guidelines	200	251	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Based on the PharmGKB database, we successfully genotyped 50 VIP variants located in 27 genes in the Tibetan population	13	21	DATABASE	PharmGKB
CircRNA expression profile data were obtained from GEO datasets, and the differentially expressed circRNAs (DECs) were identified through utilizing R package (Limma) firstly	51	54	DATABASE	GEO
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	193	201	DATABASE	PharmGKB
The advent of next generation DNA sequencing (NGS) has revolutionized clinical medicine by enabling wide-spread testing for genomic anomalies and polymorphisms	46	49	TECHNIQUE	NGS
We present Flype, a web-based bioinformatics platform built by a small group of bioinformaticians working in a community hospital setting, to address these challenges by allowing us to: (a) securely accept data from a variety of sources, (b) send orders to a variety of destinations, (c) perform secondary analysis and annotation of NGS data, (d) provide a central repository for all genomic variants, (e) assist with tertiary analysis and clinical interpretation, (f) send signed out data to our EHR as both PDF and discrete data elements, (g) allow population frequency analysis and (h) update variant annotation when literature knowledge evolves	333	336	TECHNIQUE	NGS
We discuss the multiple use cases Flype supports such as (a) in-house NGS tests, (b) in-house pharmacogenomics (PGX) tests, (c) dramatic scale-up of genomic testing using an external lab, (d) consumer genomics using two external partners, and (e) a variety of reporting tools	70	73	TECHNIQUE	NGS
Multiple logistic regression was then performed to identify the factors associated with rapid CKD progression	9	28	ANALYTICAL_METHOD	logistic regression
After adjusting for potential confounding factors via multiple logistic regression, the factors associated with rapid CKD progression were <i>CYP3A5*3/*3</i> polymorphism (adjusted Odds Ratio [aOR] 4	63	82	ANALYTICAL_METHOD	logistic regression
Genotyping was performed by TaqMan real-time polymerase chain reaction (PCR) (pharmacokinetics genes: cytochrome P450 2D6 (CYP2D6) *4 (rs3892097), *5 (gene deletion), *10 (rs1065852) and *41 (rs28371725), ATP-binding cassette transporter B1 (ABCB1) 2677 G>T/A (rs2032582) and 3435C>T (rs1045642) and pharmacodynamics genes: dopamine receptor D2 (DRD2) Tag-SNP (C>T) (rs4436578), DRD2 Tag1A (C>T) (rs1800497), leptin gene (LEP) -2548G>A (rs7799039), ghrelin gene (GHRL) -604G>A (rs27647) and brain-derived neurotrophic factor (BDNF) 196G>A (rs6265))	45	70	TECHNIQUE	polymerase chain reaction
Drug levels were analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS)	51	75	TECHNIQUE	tandem mass spectrometry
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	134	185	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	116	124	DATABASE	PharmGKB
Yet, the complexity of the <i>CYP3A</i> locus and the lack of distinct drug metabolizer phenotypes has limited the identification and clinical application of CYP3A genetic variants compared to other Cytochrome P450 enzymes	134	142	CHALLENGE	clinical
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Up-to-date information can be found at PharmGKB (http://www	39	47	DATABASE	PharmGKB
We developed and validated a liquid chromatography tandem mass spectrometry method (UPLC-MS/MS) for the simultaneous determination of Ara-C and Ara-U metabolite in human plasma	51	75	TECHNIQUE	tandem mass spectrometry
An actionable gene-drug pair associated with the 28 genes tested (Clinical Pharmacogenetics Implementation Consortium (CPIC) level A or B, Pharmacogenomics Knowledge Base (PharmGKB) level 1A or B, or US Food and Drug Administration (FDA) recommendation and a PharmGKB level) was present in 98	66	117	DATABASE	Clinical Pharmacogenetics Implementation Consortium
An actionable gene-drug pair associated with the 28 genes tested (Clinical Pharmacogenetics Implementation Consortium (CPIC) level A or B, Pharmacogenomics Knowledge Base (PharmGKB) level 1A or B, or US Food and Drug Administration (FDA) recommendation and a PharmGKB level) was present in 98	172	180	DATABASE	PharmGKB
Quantitative trait locus (QTL) mapping in a BALB/c F2 reduced complexity cross revealed one major QTL on chromosome 15 underlying brain oxymorphone concentration that explained 32% of the female variance	0	24	ANALYTICAL_METHOD	Quantitative trait locus
Hippocampal and striatal cis-expression QTL (eQTL) and exon-level eQTL analysis identified <i>Zhx2</i>, a candidate gene coding for a transcriptional repressor with a private BALB/cJ retroviral insertion that reduces <i>Zhx2</i> expression and sex-dependent dysregulation of cytochrome P450 enzymes	45	49	TECHNIQUE	eQTL
Whole brain proteomics corroborated the <i>Zhx2</i> eQTL and identified upregulated CYP2D11 that could increase brain oxymorphone in BALB/cJ females	52	56	TECHNIQUE	eQTL
Genotyping of nine CYP2C9 alleles (*1,*2, *3, *4, *5, *6, *8, *11, and *13) was performed using restriction fragment length polymorphism-PCR assays and the Tag-It™ Mutation Detection System	137	140	TECHNIQUE	PCR
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for the treatment of liver fibrosis, and molecular docking was carried out to verify the results of network pharmacology analysis	0	13	DATABASE	Gene Ontology
2559 Gene Ontology biological processes underlying PKSH have been explored for the treatment of liver fibrosis, in which the response to oxidative stress plays a vital role	5	18	DATABASE	Gene Ontology
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for the treatment of liver fibrosis, and molecular docking was carried out to verify the results of network pharmacology analysis	142	159	ANALYTICAL_METHOD	molecular docking
The papers span a wide range of topics including practical solutions for data and knowledge integration for translational medicine, hypothesis based querying , understanding kidney and urinary pathways, mining the pharmacogenomics literature; theoretical research into the orthogonality of biomedical ontologies, the representation of diseases, the representation of research hypotheses, the combination of ontologies and natural language processing for an annotation framework, the generation of textual definitions, and the discovery of gene interaction networks	422	449	ANALYTICAL_METHOD	natural language processing
The application of machine learning (ML) in pharmacogenomics holds great potential - namely, it can be used to unravel complicated genetic relationships that could explain response to therapy	19	35	ANALYTICAL_METHOD	machine learning
Cox and logistic regression models with Elastic net penalty were employed	0	3	ANALYTICAL_METHOD	Cox
Cox and logistic regression models with Elastic net penalty were employed	8	27	ANALYTICAL_METHOD	logistic regression
<b>Aim:</b> To develop and assess an augmented reality tool for pharmacogenomics (PGx) education based on artificial intelligence	106	129	ANALYTICAL_METHOD	artificial intelligence
Evidence-based guidelines and summary statistics from the US Food and Drug Administration and the Clinical Pharmacogenetics Implementation Consortium were analyzed for ethnic differences in outcomes	98	149	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Excess iron can be accumulated because of the lack of an effective excretory mechanism leading to toxic effects	57	66	CHALLENGE	effective
The scarcity of effective therapies can be reflected by the lack of reliable biomarkers to adapt anticancer drugs prescription to tumors' and patients' features	16	25	CHALLENGE	effective
Besides the widely used PCR technique, there are several alternative approaches for genomic DNA amplification suitable for supporting the detection of genomic variation	24	27	TECHNIQUE	PCR
The ultimate goal is to link OMICs technologies with innovative analysis tools, such as artificial intelligence at an early stage	88	111	ANALYTICAL_METHOD	artificial intelligence
Monte Carlo simulations were performed to optimise the dosage regimen	0	11	ANALYTICAL_METHOD	Monte Carlo
A260/A280 and A260/A230 ratios along with PCR amplification give a clear idea about the procedure that was followed to extract the DNA	42	45	TECHNIQUE	PCR
We anticipate, in part due to exciting rapid developments in Next Generation Sequencing technologies, machine learning methods and national biobanks, that the field will make great advances in the upcoming years towards unlocking the full potential of genomic data	102	118	ANALYTICAL_METHOD	machine learning
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	213	264	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	195	203	DATABASE	PharmGKB
The rapid clinical implementation of next generation sequencing techniques is  due to its ability to sequence a large number of genetic regions at lower costs  than conventional techniques	37	63	TECHNIQUE	next generation sequencing
However, there is a lack of robust methods for targeted haplotyping	28	34	CHALLENGE	robust
Using RNA-Seq, a high-throughput sequencing method, we characterized transcriptomic changes in four primary human ASM cell lines that were treated with dexamethasone--a potent synthetic glucocorticoid (1 µM for 18 hours)	6	13	TECHNIQUE	RNA-Seq
Quantitative RT-PCR and Western blotting showed that dexamethasone treatment significantly increased CRISPLD2 mRNA and protein expression in ASM cells	13	19	TECHNIQUE	RT-PCR
With the advent of next-generation sequencing (NGS) and the demand for a personalized healthcare system, the fields of precision medicine and gene therapy are advancing in new directions	47	50	TECHNIQUE	NGS
We report here a polymerase chain reaction-restriction fragment length polymorphism approach that is sensitive and adaptable in detection and broad identification of fungal pathogens in potato crops, with a view to future decentralized agrigenomic surveillance programs	17	42	TECHNIQUE	polymerase chain reaction
4%) of SULT1A1, were identified using qPCR and TaqMan assays in the donors' genomic DNA	38	42	TECHNIQUE	qPCR
Using isotope-dilution ultraperformance liquid chromatography coupled with tandem mass spectrometry, we quantified methyleugenol DNA adducts in 121 human surgical liver samples	75	99	TECHNIQUE	tandem mass spectrometry
SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively	74	86	TECHNIQUE	Western blot
This regimen change is based on evidence of the efficacy equivalence of these two drugs and the lack of an increase in overall toxic effects when capecitabine is used	48	56	CHALLENGE	efficacy
We studied common and rare <i>SLCO1B1</i> variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records	142	164	TECHNIQUE	whole-exome sequencing
We used a logistic regression model to identify patient variables that predicted successful enrollment after subjects were contacted and evaluated the reasons that clinical trial eligible subjects refused enrollment	10	29	ANALYTICAL_METHOD	logistic regression
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	99	102	DATABASE	GEO
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	237	240	DATABASE	PFS
Multivariate Cox-proportional hazards models also showed that the "GG" genotype was associated with a longer time to complete/partial response (adjusted P = 0	13	16	ANALYTICAL_METHOD	Cox
However, there is a lack of information concerning the evidence-based clinical annotations of specific <i>CYP2E1</i> genetic variants	70	78	CHALLENGE	clinical
The Pharmacogenomics Knowledgebase (PharmGKB; www	36	44	DATABASE	PharmGKB
The PharmGKB website provides a diverse array of PGx information, from annotations of the primary literature to guidelines for adjusting drug treatment based on genetic information	4	12	DATABASE	PharmGKB
PharmGKB was found over 17 years ago, but continues to be a vital resource for the entire PGx community and the general public	0	8	DATABASE	PharmGKB
High-throughput next generation sequencing (NGS) is a shotgun approach applied in a parallel fashion by which the genome is fragmented and sequenced through small pieces and then analyzed either by aligning to a known reference genome or by de novo assembly without reference genome	16	42	TECHNIQUE	next generation sequencing
High-throughput next generation sequencing (NGS) is a shotgun approach applied in a parallel fashion by which the genome is fragmented and sequenced through small pieces and then analyzed either by aligning to a known reference genome or by de novo assembly without reference genome	44	47	TECHNIQUE	NGS
We summarized and discussed challenges, wet-lab methods, and bioinformatics algorithms in sequencing "complex" XMET genes, which may provide insightful information in the application of NGS technology for implementation in toxicogenomics and pharmacogenomics	186	189	TECHNIQUE	NGS
The Clinical Pharmacogenetics Implementation Consortium Guideline provides dosing recommendations for escitalopram on <i>CYP2C19</i> genotypes on the basis of the studies on Caucasian population	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Therefore, in this study, we compared the two CNN models, GoogLeNet and AlexNet, along with the least absolute shrinkage and selection operator (LASSO) model as a baseline model	145	150	ANALYTICAL_METHOD	LASSO
The AlexNet and GoogLeNet showed better performances in comparison to LASSO	70	75	ANALYTICAL_METHOD	LASSO
In silico analysis of genetic variants related to each drug was performed on such databases as PharmGKB, Ensembl Genome Browser, www	95	103	DATABASE	PharmGKB
com, and SNPedia, with an extensive literature review of papers (to May 10, 2020) on Covid-19 treatments using Medline, Embase, International Pharmaceutical Abstracts, PharmGKB, and Google Scholar	168	176	DATABASE	PharmGKB
Further, the advent of new technologies, including microarray-based genotyping as well as high throughput next generation sequencing has opened new avenues for SNPs to be used in clinical practice	51	61	TECHNIQUE	microarray
Further, the advent of new technologies, including microarray-based genotyping as well as high throughput next generation sequencing has opened new avenues for SNPs to be used in clinical practice	106	132	TECHNIQUE	next generation sequencing
PharmCAT incorporates a patient's genotypes, annotates PGx information (allele, genotype, and phenotype), and generates a report with PGx guideline recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and/or the Dutch Pharmacogenetics Working Group (DPWG)	173	224	DATABASE	Clinical Pharmacogenetics Implementation Consortium
PharmCAT incorporates a patient's genotypes, annotates PGx information (allele, genotype, and phenotype), and generates a report with PGx guideline recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and/or the Dutch Pharmacogenetics Working Group (DPWG)	243	279	DATABASE	Dutch Pharmacogenetics Working Group
Significant barriers, such as lack of professional guidelines, specialized training for interpretation of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, prevent preemptive PGx testing from being widely clinically implemented	172	180	CHALLENGE	clinical
However, the most recent Clinical Pharmacogenetics Implementation Consortium guidelines fell short of recommending pharmacogenomic testing for oxycodone treatment	25	76	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A potential genotype predicted phenotype was considered an altered metabolizer when it resulted in medication therapy modification based on Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	140	191	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	41	65	DATABASE	Genetic Testing Registry
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	172	180	DATABASE	PharmGKB
Gene expression profiles predicting sensitivity and resistance of tumor cells to induction by curcumin and AA were determined by microarray-based mRNA expressions, COMPARE, and hierarchical cluster analyses	177	197	ANALYTICAL_METHOD	hierarchical cluster
Then, we performed transcriptomic microarray-based COMPARE and hierarchical cluster analyses of mRNA expression to identify mRNA expression profiles predicting sensitivity or resistance towards withanolides	63	83	ANALYTICAL_METHOD	hierarchical cluster
Then, we performed transcriptomic microarray-based COMPARE and hierarchical cluster analyses of mRNA expression to identify mRNA expression profiles predicting sensitivity or resistance towards withanolides	34	44	TECHNIQUE	microarray
The variants were genotyped, and the concentrations were quantified by high performance liquid chromatography-tandem mass spectrometry in 646 participants of the Cholesterol and Pharmacogenetics clinical trial of 40 mg/d SV for 6 weeks	110	134	TECHNIQUE	tandem mass spectrometry
The purpose of this study was to ascertain allele frequencies for VIPs and to predict medication requirements using Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines in Hmong and compare with published data for East Asians	116	167	DATABASE	Clinical Pharmacogenetics Implementation Consortium
<b>Materials & methods:</b> We selected 66 VIP variants from PharmGKB (www	61	69	DATABASE	PharmGKB
The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations for ondansetron	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next-generation sequencing (NGS) methods have become more commonly performed in clinical and research laboratories	28	31	TECHNIQUE	NGS
The results obtained from microarray were further validated by real-time reverse transcription-PCR	26	36	TECHNIQUE	microarray
The results obtained from microarray were further validated by real-time reverse transcription-PCR	95	98	TECHNIQUE	PCR
A LASSO Cox regression model of pyroptosis-related genes was built to accurately and conveniently predict the one-, two-, and three-year overall survival rates of GBM patients	8	11	ANALYTICAL_METHOD	Cox
A LASSO Cox regression model of pyroptosis-related genes was built to accurately and conveniently predict the one-, two-, and three-year overall survival rates of GBM patients	2	7	ANALYTICAL_METHOD	LASSO
In addition, we used Monte Carlo simulations to propose dose recommendations for different subgroup patients	21	32	ANALYTICAL_METHOD	Monte Carlo
We will highlight challenges associated with PGx testing, including a lack of diversity in PGx studies as well as general limitations that impact the broad adoption of PGx testing	78	87	CHALLENGE	diversity
Genetic polymorphisms were detected by using polymerase chain reaction restriction fragment length polymorphism	45	70	TECHNIQUE	polymerase chain reaction
cyclin D1 (CCND1-G870A), γ-glutamyl hydrolase (GGH-C452T), methylenetetrahydrofolate reductase (MTHFR-C677T and MTHFR-A1298C), thymidylate synthase promoter (TYMS-TSER), thiopurine methyltransferase (TPMT*3A and TPMT*3C) and inosine triphosphate pyrophosphatase (ITPA-C94A), in Caucasian (n = 94, age < 20) and Vietnamese (n = 141, age < 16 years) childhood ALL and (b) to assess the impact of a multilocus genetic risk score (MGRS) on relapse-free survival (RFS) using a Cox proportional-hazards regression model	472	475	ANALYTICAL_METHOD	Cox
In addition to next-generation sequencing (NGS), primary tumor cells for <i>in vivo</i> and <i>in vitro</i> drug screening, imaging biomarker 3'-Deoxy-3'-18F-fluorothymidine positron emission tomography, and circulating tumor DNA (ctDNA) detection methods are being developed and may represent the future direction of precision medicine	43	46	TECHNIQUE	NGS
These methods aim to improve the prediction of the cancer cell lines sensitivity to a given treatment by incorporating drug's chemical information in the input or using a priori feature selection	178	195	ANALYTICAL_METHOD	feature selection
With omics and pharmacogenomics data being available for over 1000 cancer cell lines, several machine learning and deep learning algorithms have been proposed for drug sensitivity prediction	94	110	ANALYTICAL_METHOD	machine learning
It has been 12 years since the Allele Frequency Net Database (AFND; http://www	31	51	DATABASE	Allele Frequency Net
We did CYP2C19 (Phase I DME) genotyping in 132 unrelated healthy subjects of either sex by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique	91	116	TECHNIQUE	polymerase chain reaction
Analytical validity is a prerequisite to use a next generation sequencing (NGS)-based application as an in vitro diagnostic test or a companion diagnostic in clinical practice	47	73	TECHNIQUE	next generation sequencing
Analytical validity is a prerequisite to use a next generation sequencing (NGS)-based application as an in vitro diagnostic test or a companion diagnostic in clinical practice	75	78	TECHNIQUE	NGS
Currently, in the United States and the European Union, the intended use of such NGS-based tests does not refer to guided drug therapy on the basis of pharmacogenetic profiling of drug metabolizing enzymes, although the value of pharmacogenetic testing has been reported	81	84	TECHNIQUE	NGS
However, in research, a large variety of NGS-based tests are used and have been confirmed to be at least comparable to array-based testing	41	44	TECHNIQUE	NGS
Expert groups such as the Association for Molecular Pathology and the Clinical Pharmacogenetics Implementation Consortium have published recommendations for standardizing laboratory genetic testing, reporting and terminology	70	121	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Other resources such as PharmGKB, ClinVar, ClinGen and PharmVar have established databases of nomenclature for pharmacogenetic alleles and variants	34	41	DATABASE	ClinVar
Other resources such as PharmGKB, ClinVar, ClinGen and PharmVar have established databases of nomenclature for pharmacogenetic alleles and variants	24	32	DATABASE	PharmGKB
Lack of standardized approaches and terminology in clinical laboratory processes, ordering of the test and reporting of test results all impede this workflow	51	59	CHALLENGE	clinical
We, therefore, developed such a panel, hereafter called the PGx-Passport, based on the actionable Dutch Pharmacogenetics Working Group (DPWG) guidelines	98	134	DATABASE	Dutch Pharmacogenetics Working Group
We discuss possible reasons for these inconsistent findings and propose new study designs	38	59	CHALLENGE	inconsistent findings
next generation sequencing) and increasing knowledge of molecular pathways foster the disclosure of pharmacogenetic syndromes, which are classified as rare diseases	0	26	TECHNIQUE	next generation sequencing
19% of all samples had one or more Clinical Pharmacogenetics Implementation Consortium Level A actionable variants	35	86	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene - drug interaction guidelines but diagnostic test criteria remain largely unknown	9	60	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene - drug interaction guidelines but diagnostic test criteria remain largely unknown	76	112	DATABASE	Dutch Pharmacogenetics Working Group
The effect of variables on toxicity was assessed by a Cox-proportional Hazard model and response by logistic regression	54	57	ANALYTICAL_METHOD	Cox
The effect of variables on toxicity was assessed by a Cox-proportional Hazard model and response by logistic regression	100	119	ANALYTICAL_METHOD	logistic regression
Monte Carlo simulation based on the final model was carried out to determine the optimal dosage regimen	0	11	ANALYTICAL_METHOD	Monte Carlo
We then extracted and compared the associated prescribing recommendations for these pairs developed by the Clinical Pharmacogenomics Implementation Consortium, the Dutch Pharmacogenetics Working Group or approved product labels in the US, Canada, Europe, and Asia	164	200	DATABASE	Dutch Pharmacogenetics Working Group
A total of 120 samples were subjected to <i>SLC6A4</i> long-read SMRT sequencing, primarily selected based on available short-read sequencing data	120	141	TECHNIQUE	short-read sequencing
Short-read genome sequencing from the 1000 Genomes (1KG) Project (~5X) and the Genetic Testing Reference Material Coordination Program (~45X), as well as high-depth short-read capture-based sequencing (~330X), could not identify the 5-HTTLPR short (S) allele, nor could short-read sequencing phase any identified variants	270	291	TECHNIQUE	short-read sequencing
In contrast, the Clinical Pharmacogenetics Implementation Consortium (CPIC) published their guideline on simvastatin, but not on atorvastatin	17	68	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Dutch Pharmacogenetics Working Group (DPWG) recommends an alternative agent to atorvastatin and simvastatin or a dose adjustment depending on other risk factors for statin-induced myopathy in SLCO1B1 rs4149056 CC or TC carriers	4	40	DATABASE	Dutch Pharmacogenetics Working Group
This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts	136	152	ANALYTICAL_METHOD	machine learning
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy	4	40	DATABASE	Dutch Pharmacogenetics Working Group
The clinical and biological heterogeneity of psychiatric disorders, the pharmacokinetic and pharmacodynamics properties of the compounds, the lack of translatable biomarkers possibly explain these difficulties	4	12	CHALLENGE	clinical
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	110	117	DATABASE	ClinVar
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	97	105	DATABASE	PharmGKB
The assessment of single-nucleotide variants (SNVs) is used with growing frequency in pharmacogenetic practice, and recently, high-throughput genomic analyses obtained through next-generation sequencing (NGS) have been recognized as powerful tools to identify common, rare and novel variants	204	207	TECHNIQUE	NGS
In this study, we investigated the variability of 35 genes included in the ADME core panel (absorption, distribution, metabolism, and excretion) by whole-exome sequencing (WES) of 509 unrelated Colombian individuals with no previous reports of adverse drug reactions	148	170	TECHNIQUE	whole-exome sequencing
ACC/AHA guidelines do not recommend routine use of CYP2C19 in clinical practice, whereas Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend its use to identify poor/intermediate metabolizers of Clopidogrel and suggest alternative P2Y12 inhibitors among ACS patients undergoing percutaneous coronary intervention	89	140	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Cox proportional hazards models were fitted to estimate hazard rate ratios of successful tSCC	0	3	ANALYTICAL_METHOD	Cox
Genetic variations of three key INH-metabolizing enzymes (NAT2, CYP2E1, and GSTM1) were investigated by application PCR- and Next-generation sequencing-based methods	116	119	TECHNIQUE	PCR
Blood plasma concentrations of isoniazid (INH) and its metabolites acetylisoniazid (AcINH) and isonicotinic acid (INA) were determined at three time points (pre-dose (0 h), 2 h and 6 h after drug intake) using liquid chromatography-tandem mass spectrometry	232	256	TECHNIQUE	tandem mass spectrometry
The impact of gene variants on drug responses was assessed using Pharmacogenomics Knowledgebase (PharmGKB) and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	111	162	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The impact of gene variants on drug responses was assessed using Pharmacogenomics Knowledgebase (PharmGKB) and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	97	105	DATABASE	PharmGKB
Triple-negative breast cancer (TNBC) is a highly aggressive disease with historically poor outcomes, primarily due to the lack of effective targeted therapies	130	139	CHALLENGE	effective
The genotype and phenotype of 13 clinically important ADME genes implemented in the Clinical Pharmacogenetics Implementation Consortium guidelines were compared among different ethnic groups	84	135	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This GeneFocus provides a comprehensive overview and summary of CYP2C19 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	193	244	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Day 7 plasma LF concentration and the polymerase chain reaction (PCR) - corrected adequate clinical and parasitological response (ACPR) at day 28 were determined	38	63	TECHNIQUE	polymerase chain reaction
Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of <i>ABCC4</i> gene as predisposing factors of RTD	11	30	ANALYTICAL_METHOD	logistic regression
Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of <i>ABCC4</i> gene as predisposing factors of RTD	0	30	ANALYTICAL_METHOD	Univariate logistic regression
This article reviews the historical accomplishments made by the human genome project, future applications of genomic expression profiles with the use of microarray gene chip technology, and the pharmacogenomic translational application of these models to dermatology	153	163	TECHNIQUE	microarray
In fact, drug prescribing in the paediatric population is often based on extrapolation from clinical trials conducted on adults as there is often a lack of paediatric data	92	100	CHALLENGE	clinical
We investigated the pharmacogenetic variation of 110 genes in patients receiving acenocumarol using a targeted NGS approach	111	114	TECHNIQUE	NGS
Our results offer an initial insight into the use of a targeted NGS approach in the pharmacogenomics of coumarins in Mexican Mestizos	64	67	TECHNIQUE	NGS
We cover work on the following: genome-wide association studies, whole-exome sequencing studies, copy number variation studies, gene expression, polygenic risk scores, gene-environment interaction, experimental animal systems, human cell models, imaging genetics, pharmacogenetics, and studies of endophenotypes	65	87	TECHNIQUE	whole-exome sequencing
The International HapMap Project has recently made available genotypes and frequency data for phase 3 (NCBI build 36, dbSNPb129) of the HapMap providing an enriched genotype dataset for approximately 1	18	24	DATABASE	HapMap
The International HapMap Project has recently made available genotypes and frequency data for phase 3 (NCBI build 36, dbSNPb129) of the HapMap providing an enriched genotype dataset for approximately 1	103	107	DATABASE	NCBI
Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies	76	84	CHALLENGE	efficacy
The current Dutch Pharmacogenetics Working Group (DPWG) guideline, describes the gene-drug interaction between CYP2D6 and the opioids codeine, tramadol and oxycodone	12	48	DATABASE	Dutch Pharmacogenetics Working Group
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing	39	90	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To this end, we performed a genome-wide screening for eQTLs for 409 genes encoding major drug metabolism enzymes, transporters and transcription factors, in publically available eQTL datasets generated from the HapMap lymphoblastoid cell lines and human liver and brain tissue	211	217	DATABASE	HapMap
Recent expression quantitative traits loci (eQTL) mapping in a few human cells/tissues have identified a number of single nucleotide polymorphisms (SNPs) significantly associated with mRNA expression of many XMET genes	44	48	TECHNIQUE	eQTL
To this end, we performed a genome-wide screening for eQTLs for 409 genes encoding major drug metabolism enzymes, transporters and transcription factors, in publically available eQTL datasets generated from the HapMap lymphoblastoid cell lines and human liver and brain tissue	54	58	TECHNIQUE	eQTL
Many of these miRs were also expressed in the same tissue that the eQTL were identified	67	71	TECHNIQUE	eQTL
Studies used polymerase chain reaction and single nucleotide polymorphism genotyping methodology	13	38	TECHNIQUE	polymerase chain reaction
Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes	12	31	ANALYTICAL_METHOD	logistic regression
Furthermore, we comprehensively review the recent developments of computational methods in drug response prediction, covering network, machine learning, and deep learning technologies and strategies to evaluate immunotherapy response	135	151	ANALYTICAL_METHOD	machine learning
The genotyping for the selected SNPs, SLC22A16 T > C (rs714368), and CBR1 C > T (rs20572), was performed by RT-PCR	108	114	TECHNIQUE	RT-PCR
Fifty-one pediatric GS patients and 100 healthy individuals were genotyped using different methodologies, polymerase chain reaction (PCR) followed by acrylamide electrophoresis, fragment length analysis and/or DNA sequencing	133	136	TECHNIQUE	PCR
Fifty-one pediatric GS patients and 100 healthy individuals were genotyped using different methodologies, polymerase chain reaction (PCR) followed by acrylamide electrophoresis, fragment length analysis and/or DNA sequencing	106	131	TECHNIQUE	polymerase chain reaction
Samples from 23 children were available for DNA extraction, from which 12 selected polymorphism were genotyped by real-time PCR	124	127	TECHNIQUE	PCR
We found a significant association between A allele of the TNF-α promoter (−308 A/G) and a lack of efficacy after NSAID administration (p < 0	99	107	CHALLENGE	efficacy
Clinical Pharmacogenetics Implementation Consortium guidelines were used to determine CYP2C19 and CYP2D6 phenotypes	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This scoring system facilitates the translation of highly complex <i>CYP2D6</i> diplotype data into a patient&rsquo;s phenotype to guide drug therapy and is at the core of all <i>CYP2D6</i> gene/drug pair guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC)	230	281	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We performed a survival study and logistic regression to examine the influence of demographic and initial clinical factors on disease progression	34	53	ANALYTICAL_METHOD	logistic regression
It represents an attractive independent QC option for NGS-based diagnostic laboratories, and provides cost-efficient means for determining gender, ethnic ancestry, and sample kinships, that are important for data interpretation of NGS-based genetic tests	54	57	TECHNIQUE	NGS
Based on PharmGKB expert guidelines we identified at least one "actionable" variant in all 135 (100%) tested patients	9	17	DATABASE	PharmGKB
In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches	147	164	ANALYTICAL_METHOD	molecular docking
In this review, the use of observational studies, as well as, the use of adaptive trials and next generation sequencing to develop the required level of evidence for clinical implementation are discussed	93	119	TECHNIQUE	next generation sequencing
This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients	70	121	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Common barriers to the implementation of PGx included cost, concerns over incorporation into current workflow and a lack of knowledge about PGx; whilst frequent enablers included optimism that PGx could lead to precision medicine, reduce ADRs and become a more routine part of psychiatric clinical care	289	297	CHALLENGE	clinical
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	81	132	DATABASE	Clinical Pharmacogenetics Implementation Consortium
First, the most relevant clinical applications already subject to validated international guidelines (Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group), and ready to be implemented in routine clinical settings, are discussed to illustrate the clinical potential of PD-associated PGx biomarkers (G6PD, HLA-B*57:01, HLA-B*15:02, and VKORC1)	102	153	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	141	177	DATABASE	Dutch Pharmacogenetics Working Group
First, the most relevant clinical applications already subject to validated international guidelines (Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group), and ready to be implemented in routine clinical settings, are discussed to illustrate the clinical potential of PD-associated PGx biomarkers (G6PD, HLA-B*57:01, HLA-B*15:02, and VKORC1)	158	194	DATABASE	Dutch Pharmacogenetics Working Group
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	181	189	DATABASE	PharmGKB
Fifty patients with cardiovascular diseases and 50 healthy individuals underwent whole-exome sequencing	81	103	TECHNIQUE	whole-exome sequencing
Association with toxicities was evaluated retrospectively using logistic regression analysis	64	83	ANALYTICAL_METHOD	logistic regression
Lack of knowledge among clinicians regarding pharmacogenetics is often cited as one of the barriers delaying its clinical uptake, albeit there are many other, more crucial aspects that impede the implementation of pharmacogenetics into routine medical practice	113	121	CHALLENGE	clinical
Research Advances in Drug Discoveries and Therapeutics</b> ● Design, synthesis and preliminary activity assay of influenza virus neuraminidase inhibitors by Wenfang Xu (Shandong University, China) ● Infection disease models with silkworms to evaluate the therapeutic effects of drug candidates by Kazuhisa Sekimizu (The University of Tokyo, Japan) ● Japan's governmental approaches to facilitate drug development process by Makoto Shimoaraiso (Ministry of Foreign Affairs of Japan, Japan) ● Effective detection of the epidermal growth factor receptor mutation by the peptide nucleic acid-locked nucleic acid PCR Clamp by Sakuo Hoshi (The University of Tokyo Hospital, Japan) ● Design and synthesis of p53-MDM2 binding inhibitors by Yongzhou Hu (Zhejiang University, China) <b>Session II	608	611	TECHNIQUE	PCR
The present study aimed to screen members of the Li nationality in southern China for genotype frequencies of VIP variants and to determine differences between the Li ethnicity and global human population samples in HapMap	216	222	DATABASE	HapMap
The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB: http://www	58	66	DATABASE	PharmGKB
The PharmGKB currently contains information on over 500 drugs, 500 diseases, and 700 genes with genotyped variants	4	12	DATABASE	PharmGKB
The advent of cost-effective high-throughput genotyping techniques coupled with the existence of Clinical Pharmacogenetics Implementation Consortium (CPIC) dosing guidelines for pharmacogenetic "actionable variants" have increased the clinical applicability of PGx testing	97	148	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We developed two methods, multiplex sequence-specific primer PCR (PCR-SSP) and real-time PCR (RT-PCR), tailored for different clinical settings	61	64	TECHNIQUE	PCR
PCR-SSP achieved a limit of detection as low as 100 pg of genomic DNA, while RT-PCR reached 1 pg	0	3	TECHNIQUE	PCR
We developed two methods, multiplex sequence-specific primer PCR (PCR-SSP) and real-time PCR (RT-PCR), tailored for different clinical settings	94	100	TECHNIQUE	RT-PCR
PCR-SSP achieved a limit of detection as low as 100 pg of genomic DNA, while RT-PCR reached 1 pg	77	83	TECHNIQUE	RT-PCR
A total of 404 Roma and 396 Hungarian healthy subjects were genotyped for -163C>A, -729C>T, -2467delT and -3860G>A variants of CYP1A2 by RT-PCR and PCR-RFLP technique	137	143	TECHNIQUE	RT-PCR
Overcoming two knowledge barriers, that is, lack of information and clinical guidelines on PGx tests, might enhance physicians' readiness to adopt PGx testing	68	76	CHALLENGE	clinical
Samples were genotyped for single-nucleotide variants in drug metabolizing enzyme genes of commonly prescribed antidepressants (cytochrome P450 [CYP] 1A2, 2B6, 2C9, 2C19, 2D6, 3A4, and 3A5), and the frequency of normative metabolizer status was compared to reference populations data from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	289	340	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We sought to better understand its lack of clinical uptake within primary care	43	51	CHALLENGE	clinical
Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body	28	54	TECHNIQUE	next generation sequencing
Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body	56	59	TECHNIQUE	NGS
This review article talks about different types of NGS derived PGx variants in clinical studies and try to display the current and newly developed approaches to deal with pharmacogenetic data with/without clear guidelines for considering in clinical settings	51	54	TECHNIQUE	NGS
Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data	26	36	TECHNIQUE	microarray
Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i	13	21	CHALLENGE	clinical
For promising SNPs, we examined single-tissue expression quantitative trait loci (eQTL) data in the GTEx database	82	86	TECHNIQUE	eQTL
In silico eQTL data indicated that zonisamide sensitivity is associated with higher MDM4 expression	10	14	TECHNIQUE	eQTL
The <i>ADRB2</i> region containing the Arg16Gly (rs1042713) and Gln27Glu (rs1042714) variants were amplified by polymerase chain reaction, whereas <i>ARG1</i> rs2781659 (A>G) and <i>THRB</i> rs892940 (G>A) SNPs were genotyped by high-resolution melting (HRM) analysis	254	257	TECHNIQUE	HRM
The <i>ADRB2</i> region containing the Arg16Gly (rs1042713) and Gln27Glu (rs1042714) variants were amplified by polymerase chain reaction, whereas <i>ARG1</i> rs2781659 (A>G) and <i>THRB</i> rs892940 (G>A) SNPs were genotyped by high-resolution melting (HRM) analysis	112	137	TECHNIQUE	polymerase chain reaction
Subsequently, the PharmGKB database was utilized to filter through all variant annotations associated with the relevant genes	18	26	DATABASE	PharmGKB
Furthermore, we performed a machine learning analysis and determined that Native American admixture and heart failure were strongly predictive of AF in PHR	28	44	ANALYTICAL_METHOD	machine learning
The method involves allele-specific PCR amplification of genomic DNA with two stem-loop primers accompanied by two different universal fluorescent primers	36	39	TECHNIQUE	PCR
Urinary and plasma steroids were quantified with gas chromatography coupled with triple-quadrupole mass spectrometry (GC-MS), and the concentrations of midazolam and its metabolites were quantified with liquid chromatography coupled with electrospray tandem mass spectrometry (LC-MS/MS)	251	275	TECHNIQUE	tandem mass spectrometry
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	70	89	ANALYTICAL_METHOD	logistic regression
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	93	112	ANALYTICAL_METHOD	logistic regression
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	363	393	ANALYTICAL_METHOD	Univariate logistic regression
Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression	141	160	ANALYTICAL_METHOD	logistic regression
We searched PubMed entries and the Lattes database of Brazilian Pharmacogenetics Network investigators, for pharmacogenetic/genomic (PGx) studies in the Brazilian population, focusing on the drugs and genes included in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	223	274	DATABASE	Clinical Pharmacogenetics Implementation Consortium
<b>Methods:</b> In 110 RA Slovenian patients, data on clinical factors and 34 polymorphisms in MTX pathway were analyzed by Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression to select variables associated with the disease activity as measured by Disease Activity Score (DAS28) score after 6 months of MTX monotherapy	173	178	ANALYTICAL_METHOD	LASSO
54 VIP variants were selected from the Pharmacogenomics Knowledge Base (PharmGKB) and genotyped in 200 Yi individuals	72	80	DATABASE	PharmGKB
Using random forest models, the major variants influencing LDL-C levels were summarized in a weighted GRS (wGRS)	6	19	ANALYTICAL_METHOD	random forest
Validation with quantitative real-time polymerase chain reaction confirmed the lithium-induced downregulation of ZNF493 in LR (p =	39	64	TECHNIQUE	polymerase chain reaction
Given the potential of real-world evidence (RWE) to inform understanding of the risk-benefit profile of next-generation sequencing (NGS)-based testing, we undertook a study to describe the current landscape of whether and how payers use RWE as part of their coverage decision making and potential solutions for overcoming barriers	132	135	TECHNIQUE	NGS
The amount of OATP1B1 in crude membrane fractions was quantified using a liquid chromatography tandem mass spectrometry-based quantitative targeted absolute proteomics analysis	102	125	TECHNIQUE	mass spectrometry-based
The amount of OATP1B1 in crude membrane fractions was quantified using a liquid chromatography tandem mass spectrometry-based quantitative targeted absolute proteomics analysis	95	119	TECHNIQUE	tandem mass spectrometry
However, their wider clinical implementation has been limited by a lack of robust evidence	75	81	CHALLENGE	robust
However, their wider clinical implementation has been limited by a lack of robust evidence	21	29	CHALLENGE	clinical
Evaluate the impact of CYP2C19 genetic variation detected by next-generation sequencing (NGS) with comprehensive annotation and functional studies	89	92	TECHNIQUE	NGS
Multivariable logistic regression analysis was performed to estimate the odds ratios (ORs) and 95% confidence intervals (CI), adjusting for age, sex, and principal components for ancestry	14	33	ANALYTICAL_METHOD	logistic regression
In silico analyses were then performed to identify expression quantitative loci (eQTL) single-nucleotide polymorphisms (SNPs) that are in high linkage disequilibrium (LD) with the top SNPs	81	85	TECHNIQUE	eQTL
The purpose of this study was to identify genetic variants associated with ONJ in patients of European ancestry treated with iv BPs using whole-exome sequencing (WES)	138	160	TECHNIQUE	whole-exome sequencing
We used a Cox regression model to evaluate patient's survival and toxicity experience and its association with both baseline characteristics, and a-priori determined genetic polymorphisms	10	13	ANALYTICAL_METHOD	Cox
Among the barriers to the implementation process is the lack of clinical decision support system (CDSS) tools to aid health providers in managing PGx information in the clinical context	64	72	CHALLENGE	clinical
Drug addiction is a serious relapsing disease that has high costs to society and to the individual addicts	55	65	CHALLENGE	high costs
Long read data from a single 24-hour nanopore sequencing run was used to reconstruct haplotypes, which were confirmed by HapMap data and statistically phased Complete Genomics and Sequenom genotypes	121	127	DATABASE	HapMap
In this context, next-generation sequencing (NGS) has become essential	45	48	TECHNIQUE	NGS
Indeed, different NGS systems are able to detect several clinically relevant low-frequency hot-spot mutations simultaneously in a single run	18	21	TECHNIQUE	NGS
Using the in vitro diagnostic (IVD) NGS panel Myriapod NGS Cancer panel DNA (Diatech Pharmacogenetics) on MiSeq platform (Illumina), we reanalysed ctDNA extracted from a retrospective series of n=40 patients with advanced NSCLC previously tested with a custom NGS panel (SiRe) on Thermo Fisher Ion S5 Plus system	36	39	TECHNIQUE	NGS
All NGS platforms featured a high degree of concordance	4	7	TECHNIQUE	NGS
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	150	181	TECHNIQUE	Genome-Wide Association Studies
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	144	147	TECHNIQUE	NGS
This review will highlight important pharmacogenomic discoveries which have been facilitated by the human genome project and other milestone projects such as the International HapMap and 1000 genomes, and by the continued development of genotyping and sequencing technologies, including rapid point of care pre-treatment genetic testing	176	182	DATABASE	HapMap
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are periodically updated at http://www	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: http://www	192	200	DATABASE	PharmGKB
A generative pretrained transformer (GPT) is an artificial intelligence (AI) tool that generates language resembling human-like writing enabling users to engage in a manner that is practically identical to speaking with a human being	48	71	ANALYTICAL_METHOD	artificial intelligence
Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%	25	41	ANALYTICAL_METHOD	machine learning
Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%	42	55	ANALYTICAL_METHOD	random forest
We conducted a multi-site whole-exome sequencing study to investigate whether rare coding variants confer an increased risk of SRM	26	48	TECHNIQUE	whole-exome sequencing
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	159	175	ANALYTICAL_METHOD	machine learning
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	95	102	TECHNIQUE	RNA-Seq
Expression quantitative trait loci (eQTL) analysis can provide insights into the genetic regulation of gene expression at a genomic level and this information is proving extremely useful in many different areas of research	36	40	TECHNIQUE	eQTL
Thus far, four genome-wide eQTL studies have been performed using human livers	27	31	TECHNIQUE	eQTL
However, the utility of liver eQTL data has not yet been fully explored or realized in pharmacogenomics	30	34	TECHNIQUE	eQTL
As further liver eQTL research is undertaken, the genetic regulation of gene expression will become much better characterized and this knowledge will create a rational basis for the prospective pharmacogenomic study of many drugs	17	21	TECHNIQUE	eQTL
As an unbiased, cell-based model for pharmacogenomic discovery, a tremendous resource of whole-genome molecular targets has been accumulated for the HapMap lymphoblastoid cell lines (LCLs) during the past decade	149	155	DATABASE	HapMap
VKORC1 3673G>A, 5417G>T, CYP2C9*3 and CYP4F2 rs2108622 were genotyped by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP)	83	108	TECHNIQUE	polymerase chain reaction
A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD)	45	61	ANALYTICAL_METHOD	machine learning
In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data	88	104	ANALYTICAL_METHOD	machine learning
First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD	74	90	ANALYTICAL_METHOD	machine learning
In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging	87	103	ANALYTICAL_METHOD	machine learning
In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms	217	233	ANALYTICAL_METHOD	machine learning
In a binary logistic regression analysis the odds ratio (OR) was 8	12	31	ANALYTICAL_METHOD	logistic regression
This new document replaces the prior Clinical Pharmacogenetics Implementation Consortium guideline for rasburicase therapy in the context of G6PD genotype (updates at: www	37	88	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Comparison with a validated laboratory-based first-tier real-time polymerase chain reaction (PCR) assay demonstrated 100% concordance	66	91	TECHNIQUE	polymerase chain reaction
Genotyping was performed by real-time polymerase chain reaction	38	63	TECHNIQUE	polymerase chain reaction
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy	4	40	DATABASE	Dutch Pharmacogenetics Working Group
In this <i>in silico</i> study several compounds with herbal origin suggested to have antidepressant activity were analyzed on their CYP2D6 wild-type and <i>CYP2D6*53</i> inhibition potential using molecular docking	198	215	ANALYTICAL_METHOD	molecular docking
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	242	252	TECHNIQUE	microarray
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	224	227	TECHNIQUE	NGS
Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications	36	87	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications	108	116	DATABASE	PharmGKB
Large-scale Genome-Wide Association Studies (GWAS) and meta-analyses have revealed common disease-associated variants in the population that may contribute cumulatively to RA pathogenesis	12	43	TECHNIQUE	Genome-Wide Association Studies
Fentanyl concentrations were measured by ultra-performance liquid chromatography combined with tandem mass spectrometry (UPLC-MS/MS)	95	119	TECHNIQUE	tandem mass spectrometry
The study was screened using the Illumina GoldenGate assay for genomic DNA from 450 interethnic subjects, including 11 pharmacogenetic core variants and 76 HapMap tagging SNPs	156	162	DATABASE	HapMap
Methods combining PCR with MALDI-ToF MS have allowed for sensitive, economical, and multiplexed pharmacogenomic testing results to be delivered in a timely fashion	18	21	TECHNIQUE	PCR
A major impediment has been the lack of a human cardiomyocyte cell line	42	47	CHALLENGE	human
<i>Cis</i>-eQTL analysis of variants with (MAF ≥ 2%) revealed significant associations for 90 variants in 31 genes after Bonferroni correction, most of which were located in non-coding regions	11	15	TECHNIQUE	eQTL
We developed a panel-based NGS pipeline for comprehensive analysis of 340 genes involved in absorption, distribution, metabolism and excretion (ADME) of drugs, other xenobiotics, and endogenous substances	27	30	TECHNIQUE	NGS
We applied the ADME NGS panel to sequence genomic DNA from 150 Caucasian liver donors with available comprehensive gene expression data	20	23	TECHNIQUE	NGS
miRNA targeting information derive from both experimental data and computational predictions, and protein-drug interactions are annotated by the Pharmacogenomics Knowledge base (PharmGKB)	178	186	DATABASE	PharmGKB
Antipsychotics, including risperidone (RIS), are frequently indicated for various autism spectrum disorder (ASD) manifestations; however, "actionable" PGx testing in psychiatry regarding antipsychotic dosing and selection has limited applications in routine clinical practice because of the lack of standard guidelines, mostly due to the inconsistency and scarcity of genetic variant data	258	266	CHALLENGE	clinical
It is currently unknown if the rs2289669 locus is a cis-eQTL, which would validate its role as predictor of metformin efficacy	56	60	TECHNIQUE	eQTL
We mined next generation sequencing (NGS) data from 11,889 unrelated Saudi nationals, to determine the presence and frequencies of known functional SNP variants in 8 clinically relevant pharmacogenes (CYP2C9, CYP2C19, CYP3A5, CYP4F2, VKORC1, DPYD, TPMT and NUDT15), recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and collectively identified 82 such star alleles	285	336	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We mined next generation sequencing (NGS) data from 11,889 unrelated Saudi nationals, to determine the presence and frequencies of known functional SNP variants in 8 clinically relevant pharmacogenes (CYP2C9, CYP2C19, CYP3A5, CYP4F2, VKORC1, DPYD, TPMT and NUDT15), recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and collectively identified 82 such star alleles	9	35	TECHNIQUE	next generation sequencing
We mined next generation sequencing (NGS) data from 11,889 unrelated Saudi nationals, to determine the presence and frequencies of known functional SNP variants in 8 clinically relevant pharmacogenes (CYP2C9, CYP2C19, CYP3A5, CYP4F2, VKORC1, DPYD, TPMT and NUDT15), recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and collectively identified 82 such star alleles	37	40	TECHNIQUE	NGS
Important among these are the lack of racial and ethnic diversity in genomics studies and biorepositories; the resulting misclassification of benign variants as pathogenic in minorities; and the importance of ensuring ancestry-matched controls in variant interpretation	56	65	CHALLENGE	diversity
The reasons for this are several, but two of the most significant are limited evidence about the clinical implications of the variants and a lack of a comprehensive knowledge base that captures genetic variants, their phenotypic associations, and other pertinent phenotypic information that is openly accessible to clinical groups attempting to interpret sequencing data	97	105	CHALLENGE	clinical
However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or lack of treatment efficacy	127	135	CHALLENGE	efficacy
We also searched the PharmGKB website for levels of evidence of variant-drug combinations and for drug labels and clinical guidelines	21	29	DATABASE	PharmGKB
These findings are consistent in the literature when not restricting to older adults, suggesting that similar treatment recommendations may be provided for older adults regarding genetic variation, such as those outlined for CYP2D6 by the Clinical Pharmacogenetics Implementation Consortium	239	290	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Meanwhile, the lack of efficacy is in this process is quite as costly as drug toxicity, especially for very expensive drugs, and there is a widespread need for clinically and commercially robust pharmacogenetic testing to be applied	23	31	CHALLENGE	efficacy
Meanwhile, the lack of efficacy is in this process is quite as costly as drug toxicity, especially for very expensive drugs, and there is a widespread need for clinically and commercially robust pharmacogenetic testing to be applied	188	194	CHALLENGE	robust
In particular, this absence restricts the use of supervised machine learning	60	76	ANALYTICAL_METHOD	machine learning
Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome	92	102	CHALLENGE	high costs
Concentrations were quantified using ultra-high performance liquid chromatography coupled with tandem mass spectrometry and non-compartmental pharmacokinetics were evaluated	95	119	TECHNIQUE	tandem mass spectrometry
Of the 29 genes, 11 had guidelines published by the Clinical Pharmacogenetics Implementation Consortium	52	103	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Two logistic regression models accounted for two diplotypes in OCT1 and ABCB1, including statistically significant covariates	4	23	ANALYTICAL_METHOD	logistic regression
Our multinomial logistic regression results may benefit future predictive analyses in diabetic populations	16	35	ANALYTICAL_METHOD	logistic regression
Our multinomial logistic regression results may benefit future predictive analyses in diabetic populations	4	35	ANALYTICAL_METHOD	multinomial logistic regression
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	32	49	ANALYTICAL_METHOD	feature selection
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	11	27	ANALYTICAL_METHOD	machine learning
However, there is no evidence that machine learning approaches combining multi-omics measures (e	35	51	ANALYTICAL_METHOD	machine learning
The purpose of this communication is to introduce a recently published Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and PPI dosing	71	122	DATABASE	Clinical Pharmacogenetics Implementation Consortium
While it is arguably the most comprehensive source of genetic information, the NCBI's dbSNP database (National Center for Biotechnology Information database of single nucleotide polymorphisms; http://www	79	83	DATABASE	NCBI
The genotyping procedure included a one-round multiplex polymerase chain reaction (PCR) with simultaneous incorporation of a fluorescent label into the PCR product and subsequent hybridization on a biochip with immobilized probes	56	81	TECHNIQUE	polymerase chain reaction
<b>Background:</b> Patients with sickle cell disease (SCD) are exposed to numerous drugs over their lifespan, and many of these drugs have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for personalized dosing	139	190	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database	150	158	DATABASE	PharmGKB
However, uptake of this information has been slow due in large part to the lack of robust evidences demonstrating clinical utility	83	89	CHALLENGE	robust
However, uptake of this information has been slow due in large part to the lack of robust evidences demonstrating clinical utility	114	122	CHALLENGE	clinical
We then tested this score among valproate users of the UK Biobank for association with incident and recurrent ischemic stroke using Cox proportional hazard models	132	135	ANALYTICAL_METHOD	Cox
<b>Methods:</b> A cohort of 1347 kidney transplant recipients has been genotyped in the Leiden University Medical Center (LUMC) using next-generation sequencing (NGS)	162	165	TECHNIQUE	NGS
The risk alleles <i>HLA-A*31:01, HLA-B*15:02, HLA-B*15:11, HLA-B*57:01,</i> and <i>HLA-B*58:01</i> were retrieved from the NGS data	123	126	TECHNIQUE	NGS
For fast COLD-PCR, the optimal annealing temperature and critical denaturation temperature were determined and evaluated via Sanger sequencing of 27 randomly collected samples	14	17	TECHNIQUE	PCR
Using these findings, we have developed and validated an inexpensive allele-specific PCR assay to test for the presence of such population-enriched pharmacogenomic SNPs in Colombia	85	88	TECHNIQUE	PCR
Tests based upon variants in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines with high level evidence of a link to dihydropyrimidine dehydrogenase (DPD) phenotype and 5-FU toxicity are available to identify patients at high risk of severe adverse events (AEs)	33	84	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Areas covered: Here, the impact of hereditary genes considered in drug labels such as thiopurine S-methyltransferase (TPMT), UDP-glucuronosyltransferase 1A1 (UTG1A1) and dihydropyrimidine dehydrogenase (DPYD) are discussed with respect to guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC)	257	308	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In these patients, the association between the polymorphism and the presence of the metabolic syndrome was determined by implementing binary logistic regression models adjusted for variables associated with the metabolic syndrome	141	160	ANALYTICAL_METHOD	logistic regression
We measured variation in genotype and copy number in multiple LCLs derived from peripheral blood mononuclear cells (PBMCs) of single individuals as well as two comparison groups: (1) three types of differentiated cell lines (DCLs) and (2) triplicate HapMap samples	250	256	DATABASE	HapMap
7% (4 of 29) of immortalized cell lines harbored mosaic regions greater than 20 megabases, which were not present in PBMCs, DCLs, or HapMap replicate samples	133	139	DATABASE	HapMap
A lack of sector standards, a lack of clinical research, and a lack of guidelines were found to be the major factors for hindering PGx clinical application	38	46	CHALLENGE	clinical
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	243	266	ANALYTICAL_METHOD	boosted regression tree
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	170	186	ANALYTICAL_METHOD	lasso regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	144	163	ANALYTICAL_METHOD	logistic regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	15	31	ANALYTICAL_METHOD	machine learning
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	194	234	ANALYTICAL_METHOD	multivariate adaptive regression splines
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	54	65	ANALYTICAL_METHOD	naive Bayes
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	277	290	ANALYTICAL_METHOD	random forest
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	83	105	ANALYTICAL_METHOD	support vector machine
The fast advancing fields of molecular biology, gene sequencing, machine learning, and other technologies enable precision medicine to utilize this detailed information to enhance clinical management decision-making for an individual in the real time of the disease course	65	81	ANALYTICAL_METHOD	machine learning
Oral tolperisone 150 mg was given to sixty-four healthy Koreans, and plasma concentrations of tolperisone were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS)	145	169	TECHNIQUE	tandem mass spectrometry
Several Caucasian cohort studies have associated at least one loss-of-function CYP2C19 on Clopidogrel (LoF-Clopidogrel) with major adverse cardiovascular events (MACE), and only a couple have used Clinical Pharmacogenetics Implementation Consortium (CPIC<sup>®</sup> ) phenotype grouping to study the associations	197	248	DATABASE	Clinical Pharmacogenetics Implementation Consortium
However, there are no comprehensive guidelines on how to properly train and validate such machine learning models for drug sensitivity prediction	90	106	ANALYTICAL_METHOD	machine learning
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants	57	77	ANALYTICAL_METHOD	hierarchical cluster
Massively parallel, next generation sequencing (NGS), has allowed pharmacogenetics to be subsumed by pharmacogenomics with respect to the identification of variants associated with responders and non-responders, optimal drug response, and adverse drug reactions	20	46	TECHNIQUE	next generation sequencing
Massively parallel, next generation sequencing (NGS), has allowed pharmacogenetics to be subsumed by pharmacogenomics with respect to the identification of variants associated with responders and non-responders, optimal drug response, and adverse drug reactions	48	51	TECHNIQUE	NGS
The genotypes of 16 loci from 34 different genomic DNA (gDNA) samples derived using the TotalPlex system were consistent with the results of several standard genotyping methods, including automatic sequencing, PCR restriction fragment length polymorphism (RFLP) analysis, PCR, and allele-specific PCR (AS-PCR)	210	213	TECHNIQUE	PCR
Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications	36	87	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications	108	116	DATABASE	PharmGKB
Our study will elucidate the mechanism of QRLSF against ircAEs based on network pharmacology and molecular docking	97	114	ANALYTICAL_METHOD	molecular docking
The molecular docking verification of key targets and related phytomolecules was accomplished by AutoDock Vina software	4	21	ANALYTICAL_METHOD	molecular docking
The binding activities were estimated as good level by molecular docking	55	72	ANALYTICAL_METHOD	molecular docking
The progress of molecular biology with particular consideration of genotyping and DNA microarray technologies has created a basis for the dynamic progress of pharmacogenetics, allowing fast and sensitive determination of the individual pharmacogenetic profile, encompassing a large set of CYP alleles extended by allelic variants of genes encoding other enzymes participating in drug metabolism	86	96	TECHNIQUE	microarray
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	181	187	DATABASE	HapMap
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	106	114	DATABASE	PharmGKB
In addition, recently, Genome-Wide Association Studies (GWAS) found COVID-19-association signals at locus 3p21	23	54	TECHNIQUE	Genome-Wide Association Studies
The expression level of the CYP450 enzyme from liver microsomes was analysed by western blot (WB) analysis and quantitative real-time polymerase chain reaction (qRT-PCR)	134	159	TECHNIQUE	polymerase chain reaction
The aim of this review is to compile, compare and discuss available guidelines and recommendations by the main Pharmacogenetics Consortiums (Clinical Pharmacogenetics Implementation Consortium (CPIC); Dutch Pharmacogenetics Working Group (DPWG); the French Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx) and The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) regarding how to apply pharmacogenetic results to optimize pharmacotherapy in cardiology	141	192	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The aim of this review is to compile, compare and discuss available guidelines and recommendations by the main Pharmacogenetics Consortiums (Clinical Pharmacogenetics Implementation Consortium (CPIC); Dutch Pharmacogenetics Working Group (DPWG); the French Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx) and The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) regarding how to apply pharmacogenetic results to optimize pharmacotherapy in cardiology	201	237	DATABASE	Dutch Pharmacogenetics Working Group
7%) and lack of clinical guidelines (58	16	24	CHALLENGE	clinical
Isolation of the DNA was followed by the PCR amplification and restriction fragment length polymorphism	41	44	TECHNIQUE	PCR
gov; last accessed: 11 December 2007); and 2) the panel used in the International HapMap Project panel (www	82	88	DATABASE	HapMap
Deep learning is a subdiscipline of artificial intelligence that uses a machine learning technique called artificial neural networks to extract patterns and make predictions from large data sets	36	59	ANALYTICAL_METHOD	artificial intelligence
Deep learning is a subdiscipline of artificial intelligence that uses a machine learning technique called artificial neural networks to extract patterns and make predictions from large data sets	72	88	ANALYTICAL_METHOD	machine learning
Prospective identification of which individuals with diabetes mellitus (DM) are at greatest risk for developing cardiovascular disease (CVD) complications would have considerable public health importance by allowing the allocation of limited resources to be focused on those individuals who would most benefit from aggressive intervention	234	251	CHALLENGE	limited resources
These meetings have identified and begun to address significant obstacles to implementation, such as lack of evidence of efficacy, limited availability of genomics expertise and testing, lack of standards, and difficulties in integrating genomic results into electronic medical records	121	129	CHALLENGE	efficacy
Moreover, Malaysian women experience cancer fatalism, belief in alternative medicine, and lack of autonomy in decision making resulting in delays in seeking or avoidance of evidence-based medicine	64	75	CHALLENGE	alternative
This paper highlights ways that artificial intelligence can help usher in an age of personalized medicine	32	55	ANALYTICAL_METHOD	artificial intelligence
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	65	68	TECHNIQUE	PCR
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	33	64	TECHNIQUE	real-time reverse transcriptase
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	70	76	TECHNIQUE	RT-PCR
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	124	146	TECHNIQUE	whole-exome sequencing
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines exist for many medications commonly prescribed prior to hospital discharge, yet there are limited data regarding the contribution of gene-x-drug interactions to hospital readmissions	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Multivariable logistic regression analyzed the association between one or more gene-x-drug interactions with 90-day readmission	14	33	ANALYTICAL_METHOD	logistic regression
The intricate regulation of ADME gene expression implies that large-scale studies combining long-read next-generation sequencing (NGS) of complete genomes with phenotyping of patients taking different medications are essential to identify these missing heritabilities	130	133	TECHNIQUE	NGS
Recognizing that EHR vendors do not yet provide a standard set of CDS functions for pharmacogenetics, the Clinical Pharmacogenetics Implementation Consortium (CPIC) Informatics Working Group is developing and systematically incorporating a set of EHR-agnostic implementation resources into all CPIC guidelines	106	157	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The prevalence of artifacts, such as unbalanced amplification of alleles at specific sites (allelic dropout), is typically associated with PCR amplification of low quality/quantity DNA template, which is known to promote genotyping errors	139	142	TECHNIQUE	PCR
Our results show that, regardless of the lower DNA yield, extraction from plasma samples can still represent a valid alternative for real-time PCR genotyping application	143	146	TECHNIQUE	PCR
One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests	71	79	CHALLENGE	clinical
Here, we aim to identify drugs that potentially exhibit population differences in response using SNP data mining and analytics	101	112	ANALYTICAL_METHOD	data mining
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	255	259	ANALYTICAL_METHOD	CTDN
With the potential to increase efficiency from the suggested intelligible classifier model for a suggestive chemotherapeutic drugs response prediction, our study is important in particular for selecting an acceptable feature selection method	217	234	ANALYTICAL_METHOD	feature selection
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	31	38	ANALYTICAL_METHOD	Firefly
The comparison analysis demonstrates that the proposed model not only surpasses the prior state-of-the-art methods, but also uses Grey Wolf and Fire Fly Optimization to lessen multicollinearity and overfitting	130	139	ANALYTICAL_METHOD	Grey Wolf
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	172	180	ANALYTICAL_METHOD	Stacking
Institutional efforts led by the PGx Research Network, The PGx Knowledge Base, and The Clinical Pharmacogenetics Implementation Consortium, mine all available data for further validation or research in additional populations	87	138	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This data mining gives rise to a detailed classification of over 200 druggene pairs which, with enough documentation, may become part of a publishable guideline to aid clinicians in drug selection and dosing using genetics	5	16	ANALYTICAL_METHOD	data mining
Using the ACMG standards and guidelines for the interpretation of sequence variants, we provided interpretations for 268 variants, including 186 variants that were not reported or of uncertain significance in ClinVar, bringing the total number of variants with non-conflicting interpretations to 400	209	216	DATABASE	ClinVar
The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here, presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and antidepressants of the selective serotonin reuptake inhibitor type (SSRIs)	4	40	DATABASE	Dutch Pharmacogenetics Working Group
Unfortunately, the lack of efficacy and associated adverse effects, ranging from mild-to-moderate to potentially life-threatening, lead to therapy discontinuation	27	35	CHALLENGE	efficacy
Current machine learning tools often provide limited predictive performance and model interpretation in these settings	8	24	ANALYTICAL_METHOD	machine learning
Recently, DNA microarray and proteomic-based approaches have made substantial breakthrough into the study of various rheumatic diseases, thus allowing for the discovery of previously unknown proteins involved in CVD including some that may be suitable to be used as biomarkers	14	24	TECHNIQUE	microarray
Food and Drug Administration (FDA) and the European Medicine Agency (EMA), and occasionally some research consortia, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the Dutch Pharmacogenomics Working Group (DPWG)	129	180	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Structural variation was determined by long-range (XL)-PCR and digital droplet PCR (ddPCR)	84	89	TECHNIQUE	ddPCR
<b>Methods:</b> DNA from 48 self-identified Hmong participants were sequenced using a targeted next-generation sequencing (NGS) panel	123	126	TECHNIQUE	NGS
Star allele calls were made using Astrolabe, manual inspection of NGS variant calls and confirmatory Sanger sequencing	66	69	TECHNIQUE	NGS
Although some laboratories have adopted next-generation sequencing (NGS) as a testing platform for PGx and other molecular tests, most clinical laboratories that offer PGx tests still use targeted genotyping approaches	68	71	TECHNIQUE	NGS
Associations of tamoxifen, metabolites, activity biomarkers, and event-free survival with rapid (UM/EM, UM/IM, EM/EM, EM/IM, or EM/PM alleles) versus slow metabolizers (PM/IM or PM/PM) were investigated through random effects models, with 'study' as the random factor, and Cox regression models, adjusting for confounders	273	276	ANALYTICAL_METHOD	Cox
SNPTrack provides genetic analysis capabilities and captures analysis results in its database as SNP lists that can be cross-linked for biological interpretation to gene/protein annotations, Gene Ontology, and pathway analysis data	191	204	DATABASE	Gene Ontology
We compared pharmacogenomic guidance by Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), the US Food and Drug Administration (FDA), and by the European agencies the European Medicines Agency (EMA), College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board (CBG-MEB), and Federal Institute for Drugs and Medical Devices (FIDMD), collectively assigned as EMA/FIDMD+MEB shortened as EMA/FM	40	91	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We compared pharmacogenomic guidance by Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), the US Food and Drug Administration (FDA), and by the European agencies the European Medicines Agency (EMA), College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board (CBG-MEB), and Federal Institute for Drugs and Medical Devices (FIDMD), collectively assigned as EMA/FIDMD+MEB shortened as EMA/FM	100	136	DATABASE	Dutch Pharmacogenetics Working Group
Univariate and multivariate statistical analysis by logistic regression revealed 10 SNPs associated with severe adverse reactions to capecitabine (P<0	52	71	ANALYTICAL_METHOD	logistic regression
The <i>CYP3A5*3</i> polymorphism was not found to be associated with antihypertensive-related ADR across the genetic models tested, despite adjustment for other possible factors through multiple logistic regression (<i>p</i> > 0	195	214	ANALYTICAL_METHOD	logistic regression
Prescribing advice from two key organisations, the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium is summarised	96	147	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Prescribing advice from two key organisations, the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium is summarised	51	87	DATABASE	Dutch Pharmacogenetics Working Group
Patients were, on average, taking two medications with Clinical Pharmacogenetics Implementation Consortium guidelines	55	106	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We have implemented a new NGS strategy that combines a panel of genes related to familial hypercholesterolemia with genomic regions related to the pharmacogenomics of lipid-lowering drugs described in clinical practice guidelines and in EMA and FDA drug labels	26	29	TECHNIQUE	NGS
The Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B*57:01-abacavir, HLA-B*15:02-carbamazepine, and TPMT-thiopurines (i	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics	140	156	ANALYTICAL_METHOD	machine learning
Long-range PCR and CYP2D6 SMRT sequencing of 10 previously genotyped controls identified expected star (*) alleles, but also enabled suballele resolution, diplotype refinement, and discovery of novel alleles	11	14	TECHNIQUE	PCR
The cytochrome P450-2D6 (CYP2D6) enzyme metabolizes ∼25% of common medications, yet homologous pseudogenes and copy number variants (CNVs) make interrogating the polymorphic CYP2D6 gene with short-read sequencing challenging	191	212	TECHNIQUE	short-read sequencing
The present overview, however, has a narrower scope and is focused on germline cancer pharmacogenetics, more specifically, on drug/gene pairs for which pharmacogenetics-informed prescription guidelines have been published by the Clinical Pharmacogenetics Implementation Consortium and/or the Dutch Pharmacogenetic Working Group, namely, thiopurines/TPMT, fluoropyrimidines/UGT1A1, irinotecan/UGT1A1 and tamoxifen/CYP2D6	229	280	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Two signatures for prognosis and EGFRi sensitivity were developed via machine learning	70	86	ANALYTICAL_METHOD	machine learning
We found that after adjusting for known risk factors in multivariate Cox regression models, AKR1C3 rs12529 and AR-CAG repeat length remained significantly associated with prostate cancer-specific mortality (PCSM) after ADT (P ≤ 0	69	72	ANALYTICAL_METHOD	Cox
Research efforts should be focused on data analysis and designing prediction models using machine learning algorithms	90	106	ANALYTICAL_METHOD	machine learning
Bioinformatics tools and the implementation of artificial i Lack of association of the CEP72 rs924607 TT genotype with intelligence are expected to open the door wide for personalized medicine in the clinical practice of childhood ALL	200	208	CHALLENGE	clinical
Principal component analysis enables dimensional reduction of multivariate datasets that are typical in high-content screening	0	19	ANALYTICAL_METHOD	Principal component
With more and more Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines published, PGx is gradually shifting from the reactive testing of single gene toward the preemptive testing of multiple genes	19	70	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next-generation sequencing (NGS), including whole genome sequencing (WGS) and whole exome sequencing (WES), is increasingly being used for clinic care	28	31	TECHNIQUE	NGS
While NGS data have the potential to be repurposed to support clinical pharmacogenomics (PGx), current computational approaches have not been widely validated using clinical data	6	9	TECHNIQUE	NGS
The mission of the Pharmacogenomics Knowledge Base (PharmGKB; www	52	60	DATABASE	PharmGKB
The PharmGKB website has evolved to highlight our knowledge curation and aggregation over our previous emphasis on collecting primary data	4	12	DATABASE	PharmGKB
We used bioinformatic analysis and quantitative reverse transcription polymerase chain reaction (RT-qPCR) assays to investigate the association between plasma microRNAs (miRNAs) and stable warfarin dosage in a Chinese Han population	70	95	TECHNIQUE	polymerase chain reaction
We used bioinformatic analysis and quantitative reverse transcription polymerase chain reaction (RT-qPCR) assays to investigate the association between plasma microRNAs (miRNAs) and stable warfarin dosage in a Chinese Han population	100	104	TECHNIQUE	qPCR
Our results show that, compared with the 11 populations in the HapMap data set, the differences between the CYP2E1 rs2070676 and CYP2D6 rs1065852 of the Zhuang nationality are the largest	63	69	DATABASE	HapMap
Despite dramatic advances, wide application of pharmacogenetics to clinical practice has been slow for a number of reasons, including lack of evidence-based therapeutic guidelines as well as ethical concerns and cost	67	75	CHALLENGE	clinical
The analysis was conducted using a decision tree, considering a 1-year time horizon, and taking as perspective that of the French national health insurance system	35	48	ANALYTICAL_METHOD	decision tree
Improving the genotype-phenotype correlation through new lab techniques and implementation of artificial intelligence in the future may lead to personalized medicine, able to predict ADR and consequently to choose the appropriate compound and dosage for each patient	94	117	ANALYTICAL_METHOD	artificial intelligence
Recent advances in pharmacogenomics, noninvasive biomarkers, and artificial intelligence (AI) technologies have the promise of transforming the way we individualize treatment and monitor allograft function	65	88	ANALYTICAL_METHOD	artificial intelligence
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell lines panel	42	62	ANALYTICAL_METHOD	hierarchical cluster
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell lines panel	98	108	TECHNIQUE	microarray
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	221	228	DATABASE	ClinVar
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	207	215	DATABASE	PharmGKB
<b>Results:</b> We observed a total of 24 known actionable pharmacogenetic variants (PharmGKB 1A or 1B level of evidence), comprising approximately 26 drugs, of which, 12 were rare, with the population frequency below 1%	85	93	DATABASE	PharmGKB
Furthermore, we identified an additional 61 variants with PharmGKB 2A or 2B clinical annotations	58	66	DATABASE	PharmGKB
Clinician self-efficacy, lack of stakeholder knowledge, and the cost of the intervention were commonly cited barriers	15	23	CHALLENGE	efficacy
Incorporating cutting-edge technologies like artificial intelligence and machine learning is crucial for consolidating diverse forms of data, examining multiple variables, establishing databases of clinical indicators to aid decision-making, and formulating ethical protocols to address concerns	45	68	ANALYTICAL_METHOD	artificial intelligence
Incorporating cutting-edge technologies like artificial intelligence and machine learning is crucial for consolidating diverse forms of data, examining multiple variables, establishing databases of clinical indicators to aid decision-making, and formulating ethical protocols to address concerns	73	89	ANALYTICAL_METHOD	machine learning
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	229	235	DATABASE	HapMap
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	161	169	DATABASE	PharmGKB
PharmGKB-based inputs include the following: (i) gene name (HUGO), (ii) drug name and (iii) disease-related keywords	0	8	DATABASE	PharmGKB
Genotyping of CYP2C9 and VKORC1 was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique	54	79	TECHNIQUE	polymerase chain reaction
CPIC (Clinical Pharmacogenetics Implementation Consortium) is an International Consortium creating guidelines for facilitating use of pharmacogenetic tests for patient care and helps clinicians ensuring a safer drug delivery to the patient	6	57	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To gain a better understanding of the genetic variants associated with carboplatin-induced cytotoxicity in individuals of African descent, we present a step-wise approach integrating genotypes, gene expression, and sensitivity of HapMap cell lines to carboplatin	230	236	DATABASE	HapMap
Gene expression of 89 HapMap YRI cell lines was determined using the Affymetrix GeneChip Human Exon 1	22	28	DATABASE	HapMap
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	191	194	DATABASE	GEO
Accordingly, our objective was to comprehensively compare essential elements from clinical pharmacogenetics recommendations contained within Clinical Pharmacogenetics Implementation Consortium guidelines, US Food and Drug Administration drug labels and clinical practice guidelines from US professional medical organizations across therapeutic areas	141	192	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The CPNDS database was mined and details of CADRs and key clinical data from cases were extracted	4	9	DATABASE	CPNDS
For network pharmacology, the 12 common interacting genes/proteins had the highest associations with Pertussis pathway, AGE-RAGE signaling pathway in diabetic complications, and colorectal cancer in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses	244	248	DATABASE	KEGG
To better understand the potential generalizability of such findings, we investigated the presence of this exon 4 deletion in our Canadian patient population, using a TaqMan assay	167	179	TECHNIQUE	TaqMan assay
With the surge of artificial intelligence and greater availability of large-scale datasets, machine learning especially deep learning methods are gaining popularity in the field of computational models for anti-cancer drug synergy prediction	18	41	ANALYTICAL_METHOD	artificial intelligence
With the surge of artificial intelligence and greater availability of large-scale datasets, machine learning especially deep learning methods are gaining popularity in the field of computational models for anti-cancer drug synergy prediction	92	108	ANALYTICAL_METHOD	machine learning
Here, we present a structured overview of available large-scale databases and machine learning especially deep learning methods in computational predictive models for anti-cancer drug synergy prediction	78	94	ANALYTICAL_METHOD	machine learning
We provide a unified framework for machine learning models and detail existing model architectures as well as their contributions and limitations, shedding light into the future design of computational models	35	51	ANALYTICAL_METHOD	machine learning
We have recently developed a rapid and cost-effective method for single nucleotide polymorphism (SNP) detection, named Smart Amplification Process 2 (SmartAmp2), which enables us to detect genetic polymorphisms or mutations in 30 to 45min under isothermal conditions without DNA isolation and PCR amplification	293	296	TECHNIQUE	PCR
The enzymatic activity of DPD was evaluated by quantification of dihydro-5-FU, a metabolite of 5-FU, using high-performance liquid chromatography-tandem mass spectrometry	146	170	TECHNIQUE	tandem mass spectrometry
Due to the lack of specificity in clinical symptoms and pathological features, there are still no reliable diagnostic biomarkers, so drug-induced liver injury is a diagnosis of exclusion	34	42	CHALLENGE	clinical
The genetic associations were tested using logistic regression analyses	43	62	ANALYTICAL_METHOD	logistic regression
We conducted logistic regression models to examine the association of genetic variants with CAA/L during acute KD and with persistence >6 weeks using an additive model between cases and 238 controls with no CAA	13	32	ANALYTICAL_METHOD	logistic regression
Functional mapping and annotation (FUMA) analysis identified 12 genomic risk loci with eQTL or chromatin interactions mapped to 48 genes	87	91	TECHNIQUE	eQTL
We performed a Whole Genome Sequencing (WGS) association analysis in a racially diverse cohort of KD patients treated with IVIG, both using AHA guidelines	15	38	TECHNIQUE	Whole Genome Sequencing
One reason for this poor implementation is the current lack of evidence of improved clinical outcomes with pharmacogenetic tests	84	92	CHALLENGE	clinical
PubMed, ScienceDirect, Web of Science, and PharmGKB, from inception to 30 June 2022 for this review	43	51	DATABASE	PharmGKB
These are laboratories of general, molecular and population genetics, bioinformatics, pharmacogenomics, microbiota, genome editing, mathematical and digital technologies, non-invasive technologies for the diagnosis of endocrinopathies, cellular technologies, artificial intelligence and a fundamentally new laboratory of metabolic visualization and radioteranostics	259	282	ANALYTICAL_METHOD	artificial intelligence
Finding these relationships requires diverse computational approaches ranging from machine learning to dynamic modeling	83	99	ANALYTICAL_METHOD	machine learning
With the completion of genome sequencing in humans and model organisms, together with the advent of DNA microarray technology, the transcriptional cascades and networks underlying neurodegeneration in ALS are being elucidated providing new potential pharmacological targets	104	114	TECHNIQUE	microarray
Gaps were found, such as lack of studies investigating the prospective use of pharmacogenomics testing to improve clinical outcomes and lack of strong evidence on the clinical validity and utility of pharmacogenomics testing in the medication management of older adults	114	122	CHALLENGE	clinical
Genotyping was performed using SNaPshot<sup>®</sup> and real-time polymerase chain reaction methods	66	91	TECHNIQUE	polymerase chain reaction
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	42	52	TECHNIQUE	microarray
Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	11	30	ANALYTICAL_METHOD	logistic regression
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	93	112	ANALYTICAL_METHOD	logistic regression
Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	0	30	ANALYTICAL_METHOD	Univariate logistic regression
Finally, we discuss the suitability and indications of different techniques, such as microarrays and RNA-sequencing (RNA-Seq) techniques to understand gene expression differences or to reveal variation in expression levels of coding and non-coding genes	101	108	TECHNIQUE	RNA-Seq
The Pharmacogenomics Knowledgebase (PharmGKB) provides highly curated information on the effect of genetic variation on drug response and side effects for a wide range of drugs	36	44	DATABASE	PharmGKB
PharmGKB's scientific curators triage, review and annotate a large number of papers each year but the task is challenging	0	8	DATABASE	PharmGKB
We present the PGxMine resource, a text-mined resource of pharmacogenomic associations from all accessible published literature to assist in the curation of PharmGKB	157	165	DATABASE	PharmGKB
An evaluation by PharmGKB curators found that 57 of the top 100 associations not found in PharmGKB led to 83 curatable papers and a further 24 associations would likely lead to curatable papers through citations	17	25	DATABASE	PharmGKB
We developed a supervised machine learning pipeline to extract associations between a variant (DNA and protein changes, star alleles and dbSNP identifiers) and a chemical	26	42	ANALYTICAL_METHOD	machine learning
To develop a gold nanoparticle-based visual DNA microarray for simple and rapid screening of EGFR gene mutations	48	58	TECHNIQUE	microarray
Future randomized controlled trials in multiethnic settings using population-specific dosing algorithms will allow us to further ascertain the generalizability and cost-effectiveness of pharmacogenetics-guided warfarin therapy	143	159	CHALLENGE	generalizability
We argue that the current pandemic will likely strip the limited resources from other diseases such as malaria, human immunodeficiency virus (HIV) infection, and among others affecting the African continent	57	74	CHALLENGE	limited resources
Pharmacogenomics associated treatment response varies from 20% to 95%, resulting in from lack of efficacy to serious toxicity	97	105	CHALLENGE	efficacy
However, many drugs with dosing recommendations from the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium are used in primary care	102	153	DATABASE	Clinical Pharmacogenetics Implementation Consortium
However, many drugs with dosing recommendations from the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics Implementation Consortium are used in primary care	57	93	DATABASE	Dutch Pharmacogenetics Working Group
The aim of this study is to track differences in the distribution of gene polymorphisms among obese non-PCOS and non-obese patients concerning three distinct genes which are involved in the ovarian stimulation mechanism: PvuII polymorphism of ESR1 gene, RsaI polymorphism of ESR2 gene and Ser680Asn variation of FSHR gene, using restriction fragment length polymorphism analysis and real-time polymerase chain reaction	393	418	TECHNIQUE	polymerase chain reaction
The COVID-19 pandemic has accelerated the deployment of digital technologies such as the Internet of Things and artificial intelligence in diverse fields of biomedicine	112	135	ANALYTICAL_METHOD	artificial intelligence
The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines with strong evidence for 24 genes that affect 72 medications	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
There is still, however, a lack of clarity surrounding the clinical features and response periods across samples that respond to ketamine	59	67	CHALLENGE	clinical
Multivariate logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR	13	32	ANALYTICAL_METHOD	logistic regression
With the rising attention for personalized and precision medicine, scientists and clinicians have now turned to artificial intelligence systems to provide them with solutions for therapeutics development	112	135	ANALYTICAL_METHOD	artificial intelligence
However, the most important limitation to the implementation is the lack of high-quality, rigorous pediatric prospective clinical studies, so adequately powered interventional clinical trials that support incorporation of pharmacogenetics into the care of children are still needed	121	129	CHALLENGE	clinical
As ASD is also highly genetically heterogeneous, testing should address a wide range of variant types, including both large (historically detected by microarray) and small (detected by sequencing), at least across all genes (exome)	150	160	TECHNIQUE	microarray
To unequivocally address their unresolved intimate structures in blood, we scrutinized the size distribution of circulating cell-free DNA (cfDNA) using whole-genome sequencing (WGS) from both double- and single-strand DNA library preparations (DSP and SSP, n = 7) and using quantitative PCR (Q-PCR, n = 116)	287	290	TECHNIQUE	PCR
By COMPARE and hierarchical cluster analyses, candidate genes were identified, which significantly predicted sensitivity or resistance of cell lines to miltirone	15	35	ANALYTICAL_METHOD	hierarchical cluster
Very recently, machine learning regression has been used to investigate how well cancer cell line sensitivity to drugs is predicted depending on the type of molecular profile	15	31	ANALYTICAL_METHOD	machine learning
However, no study to date has exploited GDSC data to systematically compare the performance of machine learning models based on multi-gene expression data against that of widely-used single-gene markers based on genomics data	95	111	ANALYTICAL_METHOD	machine learning
R code to facilitate the construction of alternative machine learning models and their validation in the presented benchmark is available at http://ballester	53	69	ANALYTICAL_METHOD	machine learning
An innovative multimodal targeted next generation sequencing (mmNGS) approach with custom primers designed for the most commonly reported SNPs of genes belonging to DNA repair, CDDP transport or detoxification, or associated with CDPP-related toxicity was applied	34	60	TECHNIQUE	next generation sequencing
Here, we describe an approach to HLA-B typing using next generation sequencing (NGS) on the MinION™ nanopore sequencer, combined with data analysis with the SeqNext-HLA software package	52	78	TECHNIQUE	next generation sequencing
Here, we describe an approach to HLA-B typing using next generation sequencing (NGS) on the MinION™ nanopore sequencer, combined with data analysis with the SeqNext-HLA software package	80	83	TECHNIQUE	NGS
We demonstrate here that nanopore sequencing of barcoded, pooled, 943 bp polymerase chain reaction (PCR) amplicons of 49 DNA samples generated ample read depth for all samples	100	103	TECHNIQUE	PCR
We demonstrate here that nanopore sequencing of barcoded, pooled, 943 bp polymerase chain reaction (PCR) amplicons of 49 DNA samples generated ample read depth for all samples	73	98	TECHNIQUE	polymerase chain reaction
Nevertheless, genome-wide expression signatures are still limited in real clinical utility because of insufficient data utilization, a lack of critical validation, and inapposite machine learning algorithms	179	195	ANALYTICAL_METHOD	machine learning
Nevertheless, genome-wide expression signatures are still limited in real clinical utility because of insufficient data utilization, a lack of critical validation, and inapposite machine learning algorithms	74	82	CHALLENGE	clinical
We reviewed actionable gene-drug combinations recommended by both the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) as of February 2022, identifying high-risk phenotypes	137	173	DATABASE	Dutch Pharmacogenetics Working Group
The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings	128	149	CHALLENGE	inconsistent findings
Multivariate logistic regression revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in CTLA4, rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with paradoxical reactions	13	32	ANALYTICAL_METHOD	logistic regression
Here, we apply XGBoost integrated with a stringent feature selection approach, which is an algorithm that is advantageous for these high-dimensional problems	51	68	ANALYTICAL_METHOD	feature selection
For each model, some of the genes in the selected list had already been found to be individually linked to the response to that drug, providing additional evidence of the usefulness of these models and the merits of the feature selection scheme	220	237	ANALYTICAL_METHOD	feature selection
A way to generate predictive models for the remaining cases is with suitable machine learning algorithms that are yet to be applied to existing in vitro pharmacogenomics datasets	77	93	ANALYTICAL_METHOD	machine learning
Further work is still required in all of these areas, which really needs to progress on several fronts, including better standardized phenotyping, appropriate sample sizes through multicenter collaborations and judicious use of new technological advances such as genome-wide approaches, next generation sequencing and systems biology	287	313	TECHNIQUE	next generation sequencing
In this research, a universal multiplex PCR method combining capillary gel electrophoresis was established for simultaneous analysis of mutations in exons 18-21 of EGFR kinase domain gene	40	43	TECHNIQUE	PCR
Although some of these models are of crucial importance and have been used in clinical practice, these very valuable models have not been well adopted into cancer research to promote the development of cancer therapies due to the lack of integration and standards for the existing data of the pharmacogenetic studies	78	86	CHALLENGE	clinical
Candidate genetic variants (<i>TPMT</i> rs1142345, rs1800460, rs1800462, <i>GSTA1</i> rs3957357, <i>GSTM1</i><i>,</i> and <i>GSTT1</i> deletion) were determined by polymerase chain reaction (PCR) assays and pyrosequencing	191	194	TECHNIQUE	PCR
Candidate genetic variants (<i>TPMT</i> rs1142345, rs1800460, rs1800462, <i>GSTA1</i> rs3957357, <i>GSTM1</i><i>,</i> and <i>GSTT1</i> deletion) were determined by polymerase chain reaction (PCR) assays and pyrosequencing	164	189	TECHNIQUE	polymerase chain reaction
Genomic regions of these SNPs from genomic DNA were amplified with PCR and directly sequenced using Sanger sequencing except for the SNP rs1799853, which was detected using Sau96I restriction endonuclease-based digestion of variant alleles	67	70	TECHNIQUE	PCR
Multivariable logistic regression modeling estimated the independent effect of GC on physician-patient communication, as intention to treat (ITT) and per protocol (PP), adjusted for physician educational intervention	14	33	ANALYTICAL_METHOD	logistic regression
Many of these medications have Clinical Pharmacogenetics Implementation Consortium evidence-based guidelines for pharmacogenomics that are available to guide dosing	31	82	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Nowadays, a plethora of studies implement next generation sequencing to capture rare and novel pharmacogenomic (PGx) variants that influence drug response	42	68	TECHNIQUE	next generation sequencing
Several methods are used for the detection of CNVs, including approaches based on hybridization, such as arrays, PCR amplification, FRET and sequencing	113	116	TECHNIQUE	PCR
Notably, one of the major limitations in obtaining reproducible data across MS pharmacogenetics studies has been the lack of a consensus as to the appropriate method for determining clinical response	182	190	CHALLENGE	clinical
We also present a streamlined strategy that uses a single metric, the likelihood ratio, to compare exome methods, and we demonstrated its utility using the VarScan 2 and eXome Hidden Markov Model (XHMM) programs using paired normal and tumour exome data from chronic lymphocytic leukaemia patients	176	189	ANALYTICAL_METHOD	Hidden Markov
015), a lack of pharmacogenetic testing in clinical guidelines and treatment standards (p = 0	43	51	CHALLENGE	clinical
In this study, we aimed to characterize Clinical Pharmacogenetics Implementation Consortium (CPIC) actionable prescription (Rx) patterns and their temporal relationship with PGx testing in the MHS	40	91	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The multivariate logistic regression analysis reveals the utilization of VCORC1 genetic evaluation is valuable in warfarin dosing (low and moderate vs	17	36	ANALYTICAL_METHOD	logistic regression
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	52	56	TECHNIQUE	eQTL
We then tested the associations of eQTL with longitudinal change in airway responsiveness to methacholine (LnPC20) on ICS	35	39	TECHNIQUE	eQTL
We identified 2484 cis-eQTL affecting 767 genes following dexamethasone treatment	23	27	TECHNIQUE	eQTL
A significant over-representation of lnPC20-associated cis-eQTL [190 single-nucleotide polymorphisms (SNPs)] among differentially expressed genes (odds ratio = 1	59	63	TECHNIQUE	eQTL
These results indicate that identifying eQTL after relevant environmental perturbation enables identification of true pharmacogenetic variants	40	44	TECHNIQUE	eQTL
Pharmacogenetic analysis recommendations have recently been proposed by the Clinical Pharmacogenetics Implementation Consortium (CPIC)	76	127	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Promising approaches include ADME-optimized prediction frameworks, machine learning algorithms, deep mutational scanning and phenoconversion predictions	67	83	ANALYTICAL_METHOD	machine learning
The perceived largest barrier to clinical implementation of PGx was the high cost of PGx testing, followed by a lack of PGx education for healthcare providers or lack of clinical PGx experts	33	41	CHALLENGE	clinical
Physicians without clinical PGx experience or with indirect experience reported that the largest barrier to clinical implementation of PGx was the high cost of PGx testing, while physicians with clinical PGx experience pointed out that a lack of patients' education was the major concern, followed by a lack of PGx education for healthcare providers or lack of clinical PGx experts	19	27	CHALLENGE	clinical
Using ArrayTrack, users can select an analysis method from the ArrayTrack tool box, apply the method to selected microarray data and the analysis results can be directly linked to individual gene, pathway, and Gene Ontology analysis	210	223	DATABASE	Gene Ontology
Nevertheless, in some instances, even drugs effective in a population display lack of efficacy or adverse drug reactions in individual patients, often in an apparently unpredictable fashion	86	94	CHALLENGE	efficacy
Nevertheless, in some instances, even drugs effective in a population display lack of efficacy or adverse drug reactions in individual patients, often in an apparently unpredictable fashion	44	53	CHALLENGE	effective
Genotyping of the rs1800460, rs1800462, and rs1142345 SNPs was performed by polymerase chain reaction (PCR) followed by sequencing	103	106	TECHNIQUE	PCR
Genotyping of the rs1800460, rs1800462, and rs1142345 SNPs was performed by polymerase chain reaction (PCR) followed by sequencing	76	101	TECHNIQUE	polymerase chain reaction
RT-PCR and whole-cell patch-clamp studies revealed that GnRH neurons expressed both nicotinic (α4β2, α3β4, and α7) and muscarinic (M1-M5) AChRs	0	6	TECHNIQUE	RT-PCR
We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins	61	76	ANALYTICAL_METHOD	dynamic residue
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy	4	40	DATABASE	Dutch Pharmacogenetics Working Group
The prioritization of germline mutations with ClinVar, SIFT, Polyphen2, and Combined Annotation Dependent Depletion (CADD) highlighted 18 predicted deleterious/pathogenic mutations, including two recurrent deleterious mutations, i	46	53	DATABASE	ClinVar
However, the translational aspects of such tests have been limited due to the lack of robust population-based evidence	86	92	CHALLENGE	robust
Polymerase chain reaction (PCR) is a laboratory technique used to amplify a targeted region of DNA, demarcated by a set of oligonucleotide primers	27	30	TECHNIQUE	PCR
Selected deletions and duplications were confirmed by MLPA or ddPCR	62	67	TECHNIQUE	ddPCR
Patients with cystic fibrosis (CF) are exposed to many drugs in their lifetime and many of these drugs have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines that are available to guide dosing	108	159	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Clinical Pharmacogenetics Implementation Consortium recommends a starting dose for tacrolimus of 0	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	227	238	ANALYTICAL_METHOD	data mining
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	243	259	ANALYTICAL_METHOD	machine learning
Although the value of pharmacogenomics to improve patient outcomes has become increasingly clear, adoption in medical practice has been slow, which can be attributed to several factors, including complicated and expensive testing procedures and required equipment, lack of training by private practice physicians, and reluctance of both private and commercial payers to reimburse for such testing	91	96	CHALLENGE	clear
antidepressant or neuroleptic treatment are poorly understood and the lack of efficacy in many of the patients together with side effects can both limit therapy and compliance	78	86	CHALLENGE	efficacy
The Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network (CPIC) is an international community-driven organisation that is developing peer-reviewed, freely available gene/drug guidelines that are published in full at PharmGKB (http://www	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network (CPIC) is an international community-driven organisation that is developing peer-reviewed, freely available gene/drug guidelines that are published in full at PharmGKB (http://www	256	264	DATABASE	PharmGKB
With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of ticagrelor in the antiplatelet efficacy and safety, through pharmacogenomics research	179	187	CHALLENGE	efficacy
Such a long duration therapy and high dose of antibiotics result in adverse drug reactions (ADRs)	7	20	CHALLENGE	long duration
Over the last decade, next-generation sequencing (NGS) methods have become increasingly used in various areas of human genomics	50	53	TECHNIQUE	NGS
In addition, conventional short-read sequencing methods face difficulties in the interrogation of complex pharmacogenes and high NGS test costs require stringent evaluations of cost-effectiveness to decide about reimbursement by national healthcare programs	129	132	TECHNIQUE	NGS
Here, we illustrate current challenges and discuss future directions toward the clinical implementation of NGS to inform genotype-guided decision-making	107	110	TECHNIQUE	NGS
In addition, conventional short-read sequencing methods face difficulties in the interrogation of complex pharmacogenes and high NGS test costs require stringent evaluations of cost-effectiveness to decide about reimbursement by national healthcare programs	26	47	TECHNIQUE	short-read sequencing
Adverse drug reactions and lack of therapeutic efficacy associated with currently prescribed pharmacotherapeutics may be attributed, in part, to inter-individual variability in drug metabolism	47	55	CHALLENGE	efficacy
The COMPARE and hierarchical cluster analyses of transcriptome-wide expression profiles of tumor cell lines of the National Cancer Institute identified genes involved in various cellular processes (immune response, inflammation signaling, cell migration and microtubule formation) significantly correlated with log<sub>10</sub>IC<sub>50</sub> values for sanguinarine	16	36	ANALYTICAL_METHOD	hierarchical cluster
It also plays a fundamental role in nucleic acid sequencing applications, including Next Generation Sequencing (NGS)-based ones	112	115	TECHNIQUE	NGS
Some other fields of applications that use PCR on a regular basis include oncology, genetics, microbiology, biochemistry, immunogenetics, NGS, ecology, comparative genome evolution, ancestry DNA, pharmacogenomics, personalized medicine, and even general medicine	138	141	TECHNIQUE	NGS
Some other fields of applications that use PCR on a regular basis include oncology, genetics, microbiology, biochemistry, immunogenetics, NGS, ecology, comparative genome evolution, ancestry DNA, pharmacogenomics, personalized medicine, and even general medicine	43	46	TECHNIQUE	PCR
Quantitative polymerase chain reaction (PCR) is the basis of a variety of scientific applications and publications in a broad range of interests	13	38	TECHNIQUE	polymerase chain reaction
For this purpose we determined the genotype profile and allele frequency of 216 randomly selected healthy volunteers using real-time polymerase chain reaction (RT-PCR)	133	158	TECHNIQUE	polymerase chain reaction
For this purpose we determined the genotype profile and allele frequency of 216 randomly selected healthy volunteers using real-time polymerase chain reaction (RT-PCR)	160	166	TECHNIQUE	RT-PCR
Over the last 2 decades, the Pharmacogenomics Knowledgebase (PharmGKB) has built a unique repository of PGx knowledge, including annotations of clinical guideline and regulator-approved drug labels in addition to evidence-based drug pathways and annotations of the scientific literature	61	69	DATABASE	PharmGKB
All of this knowledge is freely accessible on the PharmGKB website	50	58	DATABASE	PharmGKB
In the first of a series of PharmGKB tutorials, we introduce the PharmGKB coronavirus disease 2019 (COVID-19) portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB	28	36	DATABASE	PharmGKB
This paper is intended as a resource to help users become quickly acquainted with the wealth of information stored in PharmGKB	118	126	DATABASE	PharmGKB
We constructed the predictive model using logistic regression	42	61	ANALYTICAL_METHOD	logistic regression
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	199	207	DATABASE	PharmGKB
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	42	62	ANALYTICAL_METHOD	hierarchical cluster
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	98	108	TECHNIQUE	microarray
A machine learning classifier method was used to discover classification rules for our dataset	2	18	ANALYTICAL_METHOD	machine learning
The present chapter briefly reviews the methodological and historical aspect of the basic SNP detecting techniques that lie in the basis of the modern high-throughput technologies, providing at the same time detailed guide on the application of one of the most advanced SNP microarray platform on the market: the genome-wide SNP Array 6	274	284	TECHNIQUE	microarray
For the detection of the CYP2C9*2 and CYP2C9*3 genotypes, we used real-time-polymerase chain reaction with TaqMan® probes	76	101	TECHNIQUE	polymerase chain reaction
The nation-wide project Genomic Medicine Sweden (GMS) is undertaking large-scale sequencing to predict risk of drug toxicity and lack of efficacy in malignant diseases	137	145	CHALLENGE	efficacy
The nation-wide project Genomic Medicine Sweden (GMS) is undertaking large-scale sequencing to predict risk of drug toxicity and lack of efficacy in malignant diseases	69	80	CHALLENGE	large-scale
After 1 week on each regimen, raltegravir and raltegravir-glucuronide plasma and urine concentrations were measured by liquid chromatography-tandem mass spectrometry in multiple samples obtained over 12 h (arm A) or 24 h (arm B) and analyzed by noncompartmental methods	141	165	TECHNIQUE	tandem mass spectrometry
We therefore employed a real-time polymerase chain reaction (qPCR) assay system to test genomic DNA extracted from saliva samples targeting the NAT2 gene responsible for isoniazid metabolism to describe the frequency of human single nucleotide polymorphisms in NAT2 within populations of children and adults in Tanzania, ascribe those polymorphisms to acetylator phenotype, and correlate to serum isoniazid exposures	34	59	TECHNIQUE	polymerase chain reaction
We therefore employed a real-time polymerase chain reaction (qPCR) assay system to test genomic DNA extracted from saliva samples targeting the NAT2 gene responsible for isoniazid metabolism to describe the frequency of human single nucleotide polymorphisms in NAT2 within populations of children and adults in Tanzania, ascribe those polymorphisms to acetylator phenotype, and correlate to serum isoniazid exposures	61	65	TECHNIQUE	qPCR
This article reviews current guidelines from the United States Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Dutch Pharmacogenetics Working Group (DPWG) and explores potential future directions	103	154	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This article reviews current guidelines from the United States Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Dutch Pharmacogenetics Working Group (DPWG) and explores potential future directions	171	207	DATABASE	Dutch Pharmacogenetics Working Group
6% in the evaluation by means of logistic regression	33	52	ANALYTICAL_METHOD	logistic regression
In this study, we present the development of two 5' nuclease real-time polymerase chain reaction (PCR) test panels, capable of detecting eight of the most clinically relevant alleles of the <i>CYP2D6</i> gene (*2, *3, *4, *6, *9, *10, 17, *41) and the three most common nonfunctional alleles of <i>CYP2C19</i> (*2, *3, *4)	71	96	TECHNIQUE	polymerase chain reaction
However, the degree of variation at the CYP2D6 locus and homology with its pseudogenes make interrogating CYP2D6 by short-read sequencing challenging	116	137	TECHNIQUE	short-read sequencing
We emphasize the potential of NGS for preemptive pharmacogenotyping, which is crucial to population-specific clinical studies and patient care	30	33	TECHNIQUE	NGS
<b>Methods:</b> Retrospective sub-analysis of CYP-GUIDES data comprising CYP2D6 phenotypes was reclassified using standardized CYP2D6 genotype to phenotype recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG)	181	232	DATABASE	Clinical Pharmacogenetics Implementation Consortium
<b>Methods:</b> Retrospective sub-analysis of CYP-GUIDES data comprising CYP2D6 phenotypes was reclassified using standardized CYP2D6 genotype to phenotype recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG)	244	280	DATABASE	Dutch Pharmacogenetics Working Group
In this study, a specific, accurate and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) has been developed for determination of methotrexate (MTX), 6-mercaptopurine (MP) and its metabolite 6-thioguanine nucleotide (TG) in human plasma	72	96	TECHNIQUE	tandem mass spectrometry
The detection was performed by tandem mass spectrometry in MRM mode via electrospray ionization source in positive ionization mode	31	55	TECHNIQUE	tandem mass spectrometry
As of February 29, 2020, the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) Genetic Testing Registry contained 64,860 genetic tests for 12,268 conditions and 18,686 genes from 560 laboratories, and the Food and Drug Administration had 404 entries for pharmacogeneomic biomarkers used in drug labeling	118	142	DATABASE	Genetic Testing Registry
As of February 29, 2020, the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) Genetic Testing Registry contained 64,860 genetic tests for 12,268 conditions and 18,686 genes from 560 laboratories, and the Food and Drug Administration had 404 entries for pharmacogeneomic biomarkers used in drug labeling	112	116	DATABASE	NCBI
In addition, immunoblotting confirmed the approximate binding site of Class I correctors, demonstrating that these small molecules act via a similar mechanism in vitro, and in silico molecular docking generated binding poses for their complex with the cryo-electron microscopy structure to suggest the putative corrector binding site is a multi-domain pocket near residues F374-L375	183	200	ANALYTICAL_METHOD	molecular docking
Although the pharmacy profession is expected to lead the translation of pharmacogenomics into widespread clinical implementation, there is a reported lack of preparedness among its members	105	113	CHALLENGE	clinical
We demonstrate that deep neural networks outperform the current state in machine learning frameworks	73	89	ANALYTICAL_METHOD	machine learning
Meanwhile, we found several VIP variants that might alter the drug metabolism of cisplatin-cyclophosphamide (CYP2E1), vitamin E (CYP4F2), asthma amlodipine, chlorthalidone, and lisinopril (ACE) through PharmGKB	202	210	DATABASE	PharmGKB
<b>Methods:</b> A decision-analytic model comprising a linked decision tree and Markov model were created in R comparing pharmacogenetic testing with current prescribing practice	62	75	ANALYTICAL_METHOD	decision tree
To extract knowledge and pattern out of this genomic data, artificial intelligence especially deep learning methods has been instrumental	59	82	ANALYTICAL_METHOD	artificial intelligence
The latest development of artificial intelligence (AI) methodologies and tools, coupled with advancements in large-scale data management and powerful graphic processing computing units, potentiate the integration of these large data sources into relevant biological networks, which will enhance our understanding of cancer MDR	26	49	ANALYTICAL_METHOD	artificial intelligence
The Pharmacogenomics Knowledgebase (PharmGKB), a database that links genetic variation and drug interaction in the body, was queried to identify polymorphisms associated with heroin dependence in the context of opioid related disorders/OUD	36	44	DATABASE	PharmGKB
Important online resources such as PharmGKB	35	43	DATABASE	PharmGKB
We evaluate the performance of our algorithm compared to well-known regularization methods such as LASSO, Ridge and Elastic net regression in the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (Sanger) pharmacogenomics datasets, demonstrating that incorporation of the biological priors selected by our model confers improved predictability and interpretability, despite much fewer predictors, over existing state-of-the-art methods	99	104	ANALYTICAL_METHOD	LASSO
We evaluate the performance of our algorithm compared to well-known regularization methods such as LASSO, Ridge and Elastic net regression in the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (Sanger) pharmacogenomics datasets, demonstrating that incorporation of the biological priors selected by our model confers improved predictability and interpretability, despite much fewer predictors, over existing state-of-the-art methods	106	111	ANALYTICAL_METHOD	Ridge
To determine the polymorphism, we extracted DNA from peripheral blood and used polymerase chain reaction (PCR) to amplify intron 3 of the CYP 3A5	106	109	TECHNIQUE	PCR
To determine the polymorphism, we extracted DNA from peripheral blood and used polymerase chain reaction (PCR) to amplify intron 3 of the CYP 3A5	79	104	TECHNIQUE	polymerase chain reaction
We evaluated the clinical validity of a combinatorial pharmacogenomic test and single-gene Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines against patient outcomes and medication blood levels to assess their ability to inform prescribing in major depressive disorder (MDD)	91	142	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We analyzed the pharmacogenomics data of 961 cell lines tested with 265 anti-cancer drugs and developed different machine learning approaches for dissecting the genome systematically and predict drug responses using both drug-unspecific and drug-specific genes	114	130	ANALYTICAL_METHOD	machine learning
We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB	171	179	DATABASE	PharmGKB
We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB	30	57	ANALYTICAL_METHOD	natural language processing
Multi-gene panel sequencing using next-generation sequencing (NGS) methods is a key tool for genomic medicine	62	65	TECHNIQUE	NGS
In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)	206	225	ANALYTICAL_METHOD	logistic regression
As the field progresses, the abstract anticipates a future characterized by the integration of artificial intelligence in diagnostics and treatment	95	118	ANALYTICAL_METHOD	artificial intelligence
These genotypic changes could partly explain the lack of efficacy of treatment in certain patients	57	65	CHALLENGE	efficacy
The OATP1B1 phenotypes were assigned according to their function by following the guidelines from the Clinical Pharmacogenetics Implementation Consortium for SLCO1B1 and Simvastatin-Induced Myopathy	102	153	DATABASE	Clinical Pharmacogenetics Implementation Consortium
1297G>A were performed by polymerase chain reaction followed by melting curve analysis (HRM-PCR) and TaqMan® genotyping assay, respectively	88	91	TECHNIQUE	HRM
1297G>A were performed by polymerase chain reaction followed by melting curve analysis (HRM-PCR) and TaqMan® genotyping assay, respectively	26	51	TECHNIQUE	polymerase chain reaction
Genotyping was performed by using real-time polymerase chain reaction-based methods	44	69	TECHNIQUE	polymerase chain reaction
A decreased hydrophobic interactions and weaker substrate binding affinity was observed in the mutant compared to the wild- type (WT) using molecular docking	140	157	ANALYTICAL_METHOD	molecular docking
CluGO was utilized for Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis	74	87	DATABASE	Gene Ontology
CluGO was utilized for Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis	64	68	DATABASE	KEGG
GO and KEGG enrichment analysis of the overlapping targets and the 2 clusters was mainly grouped into immunity, inflammation, estrogen, anxiety, and depression processes	7	11	DATABASE	KEGG
A total of 300 patients with T2DM and 200 control subjects were enrolled to identify <i>MTNR1B</i> rs10830963 and rs1387153 genotypes by real-time polymerase chain reaction (PCR), with subsequent high-resolution melting (HRM) analysis	221	224	TECHNIQUE	HRM
A total of 300 patients with T2DM and 200 control subjects were enrolled to identify <i>MTNR1B</i> rs10830963 and rs1387153 genotypes by real-time polymerase chain reaction (PCR), with subsequent high-resolution melting (HRM) analysis	147	172	TECHNIQUE	polymerase chain reaction
These genetic variants called very important pharmacogenetic (VIP) variants played a role in drugs metabolism, which have been summarized in the PharmGKB database	145	153	DATABASE	PharmGKB
In this study, we genotyped 80 VIP variants from the PharmGKB in 100 members of Blang volunteers from Yunnan province	53	61	DATABASE	PharmGKB
CYP2D6 phenotypes were determined based on Clinical Pharmacogenetics Implementation Consortium guidelines and CYP2D6 inhibitors causing phenoconversion	43	94	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Discontinuation of risperidone due to lack of efficacy was more frequent in the CYP2D6 normal metabolizers and ultrarapid metabolizers compared with intermediate metabolizers (IMs) and phenoconverted poor metabolizers (pPMs) (54	46	54	CHALLENGE	efficacy
<b><i>Conclusions:</i></b> CYP2D6 phenotype is associated with discontinuation of risperidone due to lack of efficacy and the dose of risperidone that induced hyperprolactinemia, as well as discontinuation of paliperidone due to adverse effects	109	117	CHALLENGE	efficacy
In addition, pharmacometric modeling and artificial intelligence improve phenotype prediction	41	64	ANALYTICAL_METHOD	artificial intelligence
Based on COMPARE and hierarchical cluster analyses, we found gene expression profiles that predicted sensitivity or resistance of 47 tumor cell lines toward PT	21	41	ANALYTICAL_METHOD	hierarchical cluster
Moreover, PT also showed epigenetic effect by inhibition of HDAC activity as shown using both molecular docking and HDAC activity assay	94	111	ANALYTICAL_METHOD	molecular docking
Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system	193	197	TECHNIQUE	eQTL
This may potentially reduce the number of patients returning to clinical care and streamline the use of limited resources across the healthcare system	104	121	CHALLENGE	limited resources
Implementation of PGx into routine clinical care has been slow, especially in resource-limited settings, because of perceived high costs relative to uncertain benefit	126	136	CHALLENGE	high costs
Results are returned within 5 hr along with clinical decision support that includes interpretation of results and prescribing recommendations for anti-platelet therapy based on the Clinical Pharmacogenetics Implementation Consortium guidelines	181	232	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Clinical Pharmacogenetics Implementation Consortium provides PGx-based guidelines for several oncolytic therapies used to treat cancer and for supportive care	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The logistic regression analysis indicated that the *15 haplotype was associated with susceptibility to DILI (p = 0	4	23	ANALYTICAL_METHOD	logistic regression
The International HapMap project has made publicly available extensive genotypic data on a number of lymphoblastoid cell lines (LCLs)	18	24	DATABASE	HapMap
This intrinsic growth rate was estimated for each of over 500 HapMap cell lines	62	68	DATABASE	HapMap
We compared the data with information on Han Chinese of the same region, which we downloaded from the HapMap database	102	108	DATABASE	HapMap
The Guideline module provides Clinical Pharmacogenetics Implementation Consortium (CPIC) drug guideline recommendations based on the translation of genotypic data in genes having guidelines	30	81	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The increasing availability of next generation sequencing (NGS) for personal genomics could promote pharmacogenomics (PGx) discovery and application	31	57	TECHNIQUE	next generation sequencing
The increasing availability of next generation sequencing (NGS) for personal genomics could promote pharmacogenomics (PGx) discovery and application	59	62	TECHNIQUE	NGS
However, current tools for analysis and interpretation of pharmacogenomic variants from NGS data are inadequate, as none offer comprehensive analytic functions in a simple, web-based platform	88	91	TECHNIQUE	NGS
We describe PharmVIP, a web-based PGx tool, for one-stop comprehensive analysis and interpretation of genome-wide variants obtained from NGS platforms	137	140	TECHNIQUE	NGS
PharmVIP is a new integrated NGS workflow for the PGx community to facilitate discovery and clinical application	29	32	TECHNIQUE	NGS
To provide an expanded view of genetic variants associated with the development of HTN, this study was performed using publicly available databases such as PubMed, Scopus, Web of Science, African Journal Online, PharmGKB searching for relevant papers between 1984 and 2020	212	220	DATABASE	PharmGKB
To evaluate the interest of such pharmacogenetic information, we designed an "in house" pipeline to determine the status of 122 PharmGKB (Pharmacogenomics Knowledgebase) variant-drug combinations in 31 genes	128	136	DATABASE	PharmGKB
We performed a retrospective analysis of drug plasma concentrations and treatment efficacy in patients bearing at least one relevant PharmGKB variant	133	141	DATABASE	PharmGKB
For PharmGKB level 1A variants, CYP2C9 status for phenytoin prescription was the only relevant information	4	12	DATABASE	PharmGKB
Lack of efficacy is costly due to adverse drug reactions and increased hospital stays	8	16	CHALLENGE	efficacy
GA‑associated target genes were then clustered based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis	56	69	DATABASE	Gene Ontology
Recent improvements in cost and throughput of next generation sequencing (NGS) are now making whole-genome profiling a plausible alternative for clinical procedures	46	72	TECHNIQUE	next generation sequencing
Recent improvements in cost and throughput of next generation sequencing (NGS) are now making whole-genome profiling a plausible alternative for clinical procedures	74	77	TECHNIQUE	NGS
Beyond classical pharmacogenetic/pharmacogenomic traits for drug metabolism, NGS screening programs of cancer genomes may lead to the identification of novel cancer-driving mutations	77	80	TECHNIQUE	NGS
An additional advantage is that cancer NGS profiling is now leading to discovering targetable mutations, e	39	42	TECHNIQUE	NGS
We present a narrative review of publications in databases (PubMed, Springer, Scopus, Web of Science E-Library) and online resources: The Human Protein Atlas; GeneCards: The Human Gene Database; US National Library of Medicine; SNPedia; OMIM Online Mendelian Inheritance in Man; The PharmGKB	283	291	DATABASE	PharmGKB
Despite increased awareness of the potential of herb-drug interactions (HDIs), the lack of rigorous clinical evidence regarding the significance provides a challenge for clinicians and consumers to make rational decisions about the safe combination of herbal and conventional medicines	100	108	CHALLENGE	clinical
Allele and genotype frequency distributions of CYP2D6*10 variants and predicted phenotypes including extensive metabolizers, intermediate metabolizers, and poor metabolizers were analysed in blood samples of 300 unrelated healthy individuals in an Iranian population using polymerase chain reaction (PCR)-restriction fragment length polymorphism, PCR-single-strand conformation polymorphism, and direct genomic DNA sequencing	300	303	TECHNIQUE	PCR
Allele and genotype frequency distributions of CYP2D6*10 variants and predicted phenotypes including extensive metabolizers, intermediate metabolizers, and poor metabolizers were analysed in blood samples of 300 unrelated healthy individuals in an Iranian population using polymerase chain reaction (PCR)-restriction fragment length polymorphism, PCR-single-strand conformation polymorphism, and direct genomic DNA sequencing	273	298	TECHNIQUE	polymerase chain reaction
Although next-generation sequencing (NGS) is increasingly implemented in drug development and clinical trials, translation of the obtained genomic information into actionable clinical advice lags behind	37	40	TECHNIQUE	NGS
Complex regions in the human genome such as repeat motifs, pseudogenes and structural (SVs) and copy number variations (CNVs) present ongoing challenges to accurate genetic analysis, particularly for short-read Next-Generation-Sequencing (NGS) technologies	239	242	TECHNIQUE	NGS
To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci	61	64	TECHNIQUE	PCR
Methods Genotyping was performed in 443 DNA samples using polymerase chain reaction-restriction fragment length polymorphism	58	83	TECHNIQUE	polymerase chain reaction
According to guidelines produced by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Working Group (DPWG), most medicines with drug-gene interactions (DGIs) are prescribed in primary care	40	91	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy	39	90	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We describe methods for discovering genetic factors in drug response, including genome-wide association studies (GWAS), expression analysis, and other methods such as chemoinformatics and natural language processing (NLP)	188	215	ANALYTICAL_METHOD	natural language processing
The variability and the complexity of natural language in expressing similar relationships causes the extracted relationships to be highly heterogeneous, which makes the construction of knowledge bases difficult and poses a challenge in using these for data mining or question answering	253	264	ANALYTICAL_METHOD	data mining
This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability	44	95	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Here, we evaluated whether the publicly available, online Pharmacogenomics Knowledge Base (PharmGKB) could facilitate such assessments by efficiently identifying relevant peer-reviewed manuscripts	91	99	DATABASE	PharmGKB
When direct inclusion in PharmGKB was the search criterion, recall was 33% and precision was 16%	25	33	DATABASE	PharmGKB
However, recall increased to 78% when citation within a PharmGKB-identified manuscript was added as a search criterion	56	64	DATABASE	PharmGKB
Thus, we conclude that PharmGKB can facilitate the systematic assessment of pharmacogenetic assays through the efficient identification of relevant peer-reviewed manuscripts	23	31	DATABASE	PharmGKB
In this study, we leveraged PharmGKB, a comprehensive pharmacogenomics (PGx) knowledgebase, to formulate a terminology for drug response phenotypes that can represent relationships between genetic variants and treatments	28	36	DATABASE	PharmGKB
Phenotypes were assigned based on Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	34	85	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Whole exome sequencing (WES) has the potential of identifying secondary findings that are predictive of poor pharmacotherapy outcomes	0	22	TECHNIQUE	Whole exome sequencing
Multivariable logistic regression analysis was employed to investigate the independent risk factors for bleeding and to develop a risk scoring system	14	33	ANALYTICAL_METHOD	logistic regression
Although first studies were performed using RT-PCR analysis to monitor the acute phase of the reaction, nowadays high-density expression platforms represent a more integrative way for providing a complete view of gene expression	44	50	TECHNIQUE	RT-PCR
, frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases	178	185	DATABASE	ClinVar
, frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases	138	146	DATABASE	PharmGKB
We generated a subset of 14 genes implicated in metabolic pathways of common medications used in anesthesia and assessed them by whole-exome sequencing (WES)	129	151	TECHNIQUE	whole-exome sequencing
Encouraging results alternating with inconsistent findings made antidepressant pharmacogenetics a stimulating but often discouraging field that requires careful discussion about cumulative evidence and methodological issues	37	58	CHALLENGE	inconsistent findings
Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence	57	65	DATABASE	PharmGKB
A multivariate analysis by logistic regression confirmed its significant contribution (p = 0	27	46	ANALYTICAL_METHOD	logistic regression
In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients	37	40	TECHNIQUE	NGS
Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy)	90	115	TECHNIQUE	polymerase chain reaction
Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy)	117	123	TECHNIQUE	RT-PCR
Genetic association and gene expression studies have been aimed at classifying risk for and severity in disease, as well as in predicting outcomes	0	19	ANALYTICAL_METHOD	Genetic association
The RIF plasma concentration was measured using the LC-MS/MS method in the blood samples collected pre-dose and 2 and 6 h post-dose, whilst the DILI status was established using the results from blood biochemical analysis performed before and 10-12 days after treatment onset	52	57	TECHNIQUE	LC-MS
The genotyping was conducted using a targeted NGS approach	46	49	TECHNIQUE	NGS
We included PGx recommendations from two international PGx consortia (Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG))	70	121	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We included PGx recommendations from two international PGx consortia (Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG))	133	169	DATABASE	Dutch Pharmacogenetics Working Group
We were able to correctly infer genotypes for the warfarin-related loci VKORC1 and CYP2C9 alleles 2, 3, 5, and 11 and also clopidogrel-related CYP2C19 alleles 2 and 17 for a small sample of Brazilian individuals, as well as for HapMap samples	228	234	DATABASE	HapMap
We focus on machine learning-based approaches, particularly similarity-based methods that use drug and target similarities, which show relationships among drugs and those among targets, respectively	12	28	ANALYTICAL_METHOD	machine learning
This article reviews the similarity-based machine learning methods for predicting drug-target interactions, which are state-of-the-art and have aroused great interest in bioinformatics	42	58	ANALYTICAL_METHOD	machine learning
Approximately one-third of Food and Drug Administration (FDA)-approved drugs with PGx information in drug labels and half of the European labels posted on PharmGKB website contain recommendations on genetic testing	155	163	DATABASE	PharmGKB
PharmGKB is an online pharmacogenomics resource that collates the latest data and clinical guidelines on genetic variation and drug responses	0	8	DATABASE	PharmGKB
The lesson consisted of 1) a didactic lecture on pharmacogenetic principles, 2) an overview of the PharmGKB website by the instructor, and 3) patient cases that used the PharmGKB website to answer questions and make recommendations about drug therapy	99	107	DATABASE	PharmGKB
Students reviewed the patient cases in small groups, used PharmGKB to answer questions and design treatment plans, and presented their recommendations to instructors and other students	58	66	DATABASE	PharmGKB
Genetic association analyses were conducted using the additive model and multivariable logistic regression	0	19	ANALYTICAL_METHOD	Genetic association
Genetic association analyses were conducted using the additive model and multivariable logistic regression	87	106	ANALYTICAL_METHOD	logistic regression
Using a retrospective matched case-control study, 190 RHTN patients (cases: blood pressure (BP) ≥ 140/90 mmHg on ≥3 anti-hypertensives or BP < 140/90 mmHg on >3 anti-hypertensives) and 189 non-RHTN patients (controls: <3 anti-hypertensives, BP < 140/90 or ≥140/90 mmHg), 12 single nucleotide polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), quantitative PCR and Sanger sequencing	395	398	TECHNIQUE	PCR
Using a retrospective matched case-control study, 190 RHTN patients (cases: blood pressure (BP) ≥ 140/90 mmHg on ≥3 anti-hypertensives or BP < 140/90 mmHg on >3 anti-hypertensives) and 189 non-RHTN patients (controls: <3 anti-hypertensives, BP < 140/90 or ≥140/90 mmHg), 12 single nucleotide polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), quantitative PCR and Sanger sequencing	327	352	TECHNIQUE	polymerase chain reaction
State-of-the-art knowledge in PGx is mainly available in reference databases such as PharmGKB and reported in scientific biomedical literature	85	93	DATABASE	PharmGKB
<b>Methods |</b> A systematic literature review was conducted, using the Medline and PharmGKB databases, which focused on published guidelines for dosage modification or selection of drugs based on germline mutations in genes with pharmacokinetic or pharmacodynamic impact	85	93	DATABASE	PharmGKB
However, there is a lack of awareness of pharmacogenetic clinical practise guidelines	57	65	CHALLENGE	clinical
From our in-house WGS (PCR-free 60× PE150) data of 547 individuals we extracted PGx variants with drug-dosing recommendations of the Dutch Pharmacogenetics Working Group (DPWG)	133	169	DATABASE	Dutch Pharmacogenetics Working Group
The presence of HLA-B*1502 allele was determined using real-time polymerase chain reaction (PCR)	65	90	TECHNIQUE	polymerase chain reaction
Another critical initiative is the introduction of hydroxyurea safely and effectively into global regions that have a high disease burden of SCA but limited resources, such as sub-Saharan Africa, the Caribbean, and India	149	166	CHALLENGE	limited resources
We developed and validated following the guidelines of the Scientific Working Group on DNA Analysis Methods a tetraplex PCR yielding four amplicons of 597, 803, 1142, and 1659 bp encompassing the entire CYP2D6 gene to analyze eleven SNP positions by SNaPshot minisequencing	120	123	TECHNIQUE	PCR
Nevertheless, DNA recovered from forensic samples could be of poor quality and not suitable for long polymerase chain reaction required to type CYP2D6 gene prior to SNaPshot minisequencing analysis performed to define alleles with different enzymatic activity	101	126	TECHNIQUE	polymerase chain reaction
In order to extend this set, we then mined the largest publicly available pharmacogenomics dataset, which involves approximately 1,000 molecularly annotated cancer cell lines and their response to 265 anti-cancer compounds, and used regularized linear regression models (Elastic Net, LASSO) to predict drug responses based on SLC and ABC data (expression levels, SNVs, CNVs)	271	282	ANALYTICAL_METHOD	Elastic Net
In order to extend this set, we then mined the largest publicly available pharmacogenomics dataset, which involves approximately 1,000 molecularly annotated cancer cell lines and their response to 265 anti-cancer compounds, and used regularized linear regression models (Elastic Net, LASSO) to predict drug responses based on SLC and ABC data (expression levels, SNVs, CNVs)	284	289	ANALYTICAL_METHOD	LASSO
The differentially expressed genes from 6 normal and 40 cirrhotic liver tissues which were collected from GEO data were assessed by pharmacokinetic analysis using a connectivity map to identify agents that commonly revert abnormal hepatocytes and HSCs to normal conditions	106	109	DATABASE	GEO
Genomics and biomarkers can provide more accurate anesthetic protocols, while artificial intelligence can simplify anesthetic procedures and reduce anesthetic risks, and real-time monitoring tools can improve perioperative safety and efficacy	78	101	ANALYTICAL_METHOD	artificial intelligence
The aim of this paper is to present and summarize the applications of these related fields in anesthesiology by reviewing them, exploring the potential of advanced technologies in the implementation and development of personalized anesthesia, realizing the future integration of new technologies into clinical practice, and promoting multidisciplinary collaboration between anesthesiology and disciplines such as genomics and artificial intelligence	426	449	ANALYTICAL_METHOD	artificial intelligence
Therefore, we have recently developed a rapid and cost-effective method for SNP detection, named Smart Amplification Process 2 (SmartAmp2), which enables us to detect genetic polymorphisms or mutations in 30-45 min under isothermal conditions without DNA isolation and PCR amplification	269	272	TECHNIQUE	PCR
The predictive properties of those variables associated with R dosage were tested using a multiple linear regression model as well as regression trees	134	150	ANALYTICAL_METHOD	regression trees
Application of PINDeL on an independent dataset of 24320 proteins, which are not used for training, validation, or testing purposes, predicts 6448 new disease-protein associations of which we verify 3196 disease-proteins through experimental evidence like disease ontology, Gene Ontology, and KEGG pathway enrichment analyses	274	287	DATABASE	Gene Ontology
Application of PINDeL on an independent dataset of 24320 proteins, which are not used for training, validation, or testing purposes, predicts 6448 new disease-protein associations of which we verify 3196 disease-proteins through experimental evidence like disease ontology, Gene Ontology, and KEGG pathway enrichment analyses	293	297	DATABASE	KEGG
The Gene Ontology(GO) biological process enrichment analysis was performed by CluoGO plug-in	4	17	DATABASE	Gene Ontology
Kyoto Encyclopedia of Genes and Genomes(KEGG) signaling pathway enrichment analysis was performed by R 4	40	44	DATABASE	KEGG
Active compounds and potential targets of CF-LS were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP), and the potential targets of MF were obtained from GeneCards, Online Mendelian Inheritance in Man(OMIM), and Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB)	319	327	DATABASE	PharmGKB
RT-PCR and ELISA were used to verify the effect of CF-LS on the targets of signaling pathways related to vascular endothelial cells predicted by the network pharmacology	0	6	TECHNIQUE	RT-PCR
The PharmGKB is a publicly available online resource that aims to facilitate understanding how genetic variation contributes to variation in drug response	4	12	DATABASE	PharmGKB
This unit describes how to navigate the PharmGKB Web site to retrieve detailed information on genes and important variants, as well as their relationship to drugs and diseases	40	48	DATABASE	PharmGKB
Workflow on how to use PharmGKB to facilitate design of the pharmacogenomic study is also described in this unit	23	31	DATABASE	PharmGKB
On the other hand, severe neurotoxicity and lack of response are still clinical challenges	71	79	CHALLENGE	clinical
Food and Drug Administration, the European Medicine Agency and the Clinical Pharmacogenetics Implementation Consortium	67	118	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A systematic search was performed in June 2016 of articles relevant to this issue in indexed journals and in scientific databases (PubMed and PharmGKB)	142	150	DATABASE	PharmGKB
Meanwhile, there are now adequate data to allow dosing recommendations as have been developed by bodies including the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) in several settings, including TPMT/thiopurines, CYP2C19/clopidogrel, CYP2D6/codeine, VKORC1-CYP2C9/warfarin, HLA-B*5701/abacavir, SLCO1B1/simvastatin and HLAB*5801/allopurinol	170	221	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Meanwhile, there are now adequate data to allow dosing recommendations as have been developed by bodies including the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) in several settings, including TPMT/thiopurines, CYP2C19/clopidogrel, CYP2D6/codeine, VKORC1-CYP2C9/warfarin, HLA-B*5701/abacavir, SLCO1B1/simvastatin and HLAB*5801/allopurinol	118	154	DATABASE	Dutch Pharmacogenetics Working Group
In the present study, we genotyped 85 very important pharmacogenetic (VIP) variants (selected from the PharmGKB database) in the Uygur population and compared our data with other eleven populations from the HapMap data set	207	213	DATABASE	HapMap
In the present study, we genotyped 85 very important pharmacogenetic (VIP) variants (selected from the PharmGKB database) in the Uygur population and compared our data with other eleven populations from the HapMap data set	103	111	DATABASE	PharmGKB
For the network pharmacology of the NRICM101, the 434 common interacting genes/proteins had the highest associations with the interleukin (IL)-17 signaling pathway in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses	212	216	DATABASE	KEGG
In light of the lack of standardized medications for treating COVID-19 symptoms, traditional Chinese medicine (TCM) has emerged as a potentially viable strategy based on numerous studies and clinical manifestations	191	199	CHALLENGE	clinical
Multivariate logistic regression models adjusted on treatment arm and T stage determined the SNPs prognostic and predictive values for tumor response	13	32	ANALYTICAL_METHOD	logistic regression
Based on the concept of precision pharmacy, we adopted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children, and elderly patients	152	168	ANALYTICAL_METHOD	machine learning
A major limitation in implementing pharmacogenetic testing in the clinical setting is the lack of clinical trials demonstrating that such testing can improve drug therapy by reducing toxicity and increasing efficacy	207	215	CHALLENGE	efficacy
A major limitation in implementing pharmacogenetic testing in the clinical setting is the lack of clinical trials demonstrating that such testing can improve drug therapy by reducing toxicity and increasing efficacy	66	74	CHALLENGE	clinical
However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence	17	25	CHALLENGE	clinical
The NIH initiated the PharmGKB in April 2000	22	30	DATABASE	PharmGKB
PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways	0	8	DATABASE	PharmGKB
There is great variability in patient response with these agents, and there is still no clear method of selecting the preferred therapeutic agent for efficacy or lack of adverse events	88	93	CHALLENGE	clear
There is great variability in patient response with these agents, and there is still no clear method of selecting the preferred therapeutic agent for efficacy or lack of adverse events	150	158	CHALLENGE	efficacy
The sequence variants for DRD1, DRD2, DRD3, DAT1, and COMT were determined through the polymerase chain reaction-restriction fragment length polymorphism technique	87	112	TECHNIQUE	polymerase chain reaction
Next-generation sequencing (NGS) has enabled the discovery of a multitude of novel and mostly rare variants in pharmacogenes that may alter a patient's therapeutic response to drugs	28	31	TECHNIQUE	NGS
Here, we discuss the role of NGS in variant discovery, paving the way for more comprehensive genotype-guided pharmacotherapy that can translate to improved clinical care	29	32	TECHNIQUE	NGS
An automated pipeline, lmPGX, was developed as an end-to-end solution that produces two versions of a pharmacogenomic report, presenting either Clinical Pharmacogenetics Implementation Consortium or US Food and Drug Administration guidelines for 12 genes	144	195	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Pharmacists are uniquely positioned to become wellversed in the interpretation of PGx data, critically evaluating the "green-yellow-red" result categories that seemingly signal "go, caution, stop" regarding the use of a particular medication	148	150	DATABASE	GO
Immunosuppressive drugs, in the setting of kidney transplantation, require a precise dosage to avoid either adverse events (overdosage) or a lack of efficacy (underdosage)	149	157	CHALLENGE	efficacy
Montaser P45 Clustering based gene expression feature selection method: A computational approach to enrich the classifier efficiency of differentially expressed genes Heba Abusamra, Vladimir B	46	63	ANALYTICAL_METHOD	feature selection
Haroon Hamed, Mourad Assidi, Mohammed Al-Qahtani, Ishtiaq Qadri P53 Selection of flavonoids against obesity protein (FTO) using <i>in silico</i> and <i>in vitro</i> approaches Shilu Mathew, Lobna Mira, Manal Shaabad, Shireen Hussain, Mourad Assidi, Muhammad Abu-Elmagd, Mohammed Al-Qahtani P54 Computational selection and <i>in vitro</i> validation of flavonoids as new antidepressant agents Shilu Mathew, Manal Shaabad, Lobna Mira, Shireen Hussain, Mourad Assidi, Muhammad Abu-Elmagd, Mohammed Al-Qahtani P55 <i>In Silico</i> prediction and prioritization of aging candidate genes associated with progressive telomere shortening Ahmed Rebai, Mourad Assidi, Abdelbaset Buhmeida, Muhammad Abu-Elmagd, Ashraf Dallol, Jerry W Shay P56 Identification of new cancer testis antigen genes in diverse types of malignant human tumour cells Mikhlid H Almutairi P57 More comprehensive forensic genetic marker analyses for accurate human remains identification using massively parallel sequencing (MPS) Angie Ambers, Jennifer Churchill, Jonathan King, Monika Stoljarova, Harrell Gill-King, Mourad Assidi, Muhammad Abu-Elmagd, Abdelbaset Buhmeida, Muhammad Al-Qatani, Bruce Budowle P58 Flow cytometry approach towards treatment men infertility in Saudi Arabia Muhammad Abu-Elmagd, Farid Ahmed, Ashraf Dallol, Mourad Assidi, Taha Abo Almagd, Sahar Hakamy, Ashok Agarwal, Muhammad Al-Qahtani, Adel Abuzenadah P59 Tissue microarray based validation of CyclinD1 expression in renal cell carcinoma of Saudi kidney patients Sajjad Karim, Hans-Juergen Schulten, Ahmad J Al Sayyad, Hasan MA Farsi, Jaudah A Al-Maghrabi, Abdelbaset Buhmaida, Zeenat Mirza, Reem Alotibi, Alaa Al-Ahmadi, Nuha A Alansari, Alaa A Albogmi, Maha M Al-Quaiti, Fai T Ashgan, Afnan Bandah, Mohammed H Al-Qahtani P60 Assessment of gold nanoparticles in molecular diagnostics and DNA damage studies Rukhsana Satar, Mahmood Rasool, Waseem Ahmad, Nazia Nazam, Mohamad I Lone, Muhammad I Naseer, Mohammad S Jamal, Syed K Zaidi, Peter N Pushparaj, Mohammad A Jafri, Shakeel A Ansari, Mohammed H Alqahtani P61 Surfing the biospecimen management and processing workflow at CEGMR Biobank Hanan Bashier, Abrar Al Qahtani, Shilu Mathew, Amal M	1405	1415	TECHNIQUE	microarray
To address this problem, we used approximate string matching method and data mining approach to improve the searching of pharmacogenomics database	72	83	ANALYTICAL_METHOD	data mining
During the past two decades the first sequencing of the human genome was performed showing its high degree of inter-individual differentiation, as a result of large international research projects (Human Genome Project, the 1000 Genomes Project International HapMap Project, and Programs for Genomic Applications NHLBI-PGA)	259	265	DATABASE	HapMap
Preliminary studies utilizing artificial intelligence-based prediction models have shown promising results	30	53	ANALYTICAL_METHOD	artificial intelligence
Machine learning is the most widely used branch of artificial intelligence	51	74	ANALYTICAL_METHOD	artificial intelligence
Here, we review the current state in the area of using machine learning to predict treatment response	55	71	ANALYTICAL_METHOD	machine learning
In addition, examples of machine learning algorithms being employed in clinical practice are offered	25	41	ANALYTICAL_METHOD	machine learning
Across studies, HCPs and consumers mostly perceived value in PGx, however, both groups reported barriers to utilization, including cost, lack of consistent recommendations across guidelines, and limited knowledge among HCPs; test accuracy, clear testing benefits, and genomic information confidentiality among consumers	240	245	CHALLENGE	clear
These have been overcome by the advent of next generation sequencing (NGS) methods which facilitate and accelerate the analysis of multiple genes and samples	42	68	TECHNIQUE	next generation sequencing
These have been overcome by the advent of next generation sequencing (NGS) methods which facilitate and accelerate the analysis of multiple genes and samples	70	73	TECHNIQUE	NGS
In this review we describe recent applications of NGS in genomics, transcriptomics and epigenomics for a better comprehension of solid tumor metabolisms	50	53	TECHNIQUE	NGS
Due to the limited knowledge about and understanding of pharmacogenomics, there is a lack of interest among pharmacy students in implementing pharmacogenomics testing in clinical practice	170	178	CHALLENGE	clinical
DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NFκB as potential transcription factor involved in cryptotanshinone's mode of action	34	44	TECHNIQUE	microarray
Random forest and regression trees were used for variable selection and model building	18	34	ANALYTICAL_METHOD	regression trees
More recent studies implemented polygenic risk score, gene-based and machine learning methods to explore the genetics of TRS, reporting promising findings	69	85	ANALYTICAL_METHOD	machine learning
It brings together two emerging health technologies to deliver better individualised care: the many "-omics" arising from increased capacity to understand the human genome and "big data" and data analytics, including artificial intelligence (AI)	217	240	ANALYTICAL_METHOD	artificial intelligence
Functional annotation of nearest genes to candidate SNPs was also carried out by using comprehensive databases and tools such as BioMart-Ensembl, UCSC, NCBI, and WebGestalt software	152	156	DATABASE	NCBI
In this research study, using Genome-Wide Association Studies (GWAS) data analysis methods, such as the SimpleM statistical approach and genomic connection matrix, we tried to discover the novel candidate SNPs that were involved in response to statin drugs	30	61	TECHNIQUE	Genome-Wide Association Studies
Based on network pharmacology and molecular docking, this study discusses the potential mechanism of Gancao Xiexin decoction in the treatment of Behçet disease (BD) to provide a more reliable theoretical basis for the treatment of BD	34	51	ANALYTICAL_METHOD	molecular docking
However, to date, none of the published in vitro F<sub>T</sub> values has been validated against or compared with in vivo F<sub>T</sub> values due to the lack of clinical data from selective substrates or inhibitors	162	170	CHALLENGE	clinical
The factors associated with the decision to test were evaluated using χ(2) and multivariate logistic regression	92	111	ANALYTICAL_METHOD	logistic regression
The Clinical Pharmacogenetics Implementation Consortium (CPIC<sup>®</sup>) establishes evidence-based guidelines for utilizing pharmacogenetic information for certain priority drugs	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Rich pharmacokinetic sampling prior to and following the last dose was conducted, and the plasma concentrations of artemether/dihydroartemisinin and lumefantrine/desbutyl-lumefantrine were quantified using tandem mass spectrometry	206	230	TECHNIQUE	tandem mass spectrometry
This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin-induced myopathy	41	92	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Multivariate logistic regression analysis was used to structure a nomogram	13	32	ANALYTICAL_METHOD	logistic regression
It is a consensus that Next-Generation Sequencing (NGS) is the primary source of this revolution and the development of relevant consortia translating pharmacogenomics into clinical practice	51	54	TECHNIQUE	NGS
In light of the latest advancements in artificial intelligence and machine learning techniques, numerous biomarkers and genetic loci associated with psychiatric diseases and relevant treatments are being discovered in precision psychiatry research by employing neuroimaging and multi-omics	39	62	ANALYTICAL_METHOD	artificial intelligence
In this review, we focus on the latest developments for precision psychiatry research using artificial intelligence and machine learning approaches, such as deep learning and neural network algorithms, together with multi-omics and neuroimaging data	92	115	ANALYTICAL_METHOD	artificial intelligence
Firstly, we review precision psychiatry and pharmacogenomics studies that leverage various artificial intelligence and machine learning techniques to assess treatment prediction, prognosis prediction, diagnosis prediction, and the detection of potential biomarkers	91	114	ANALYTICAL_METHOD	artificial intelligence
In light of the latest advancements in artificial intelligence and machine learning techniques, numerous biomarkers and genetic loci associated with psychiatric diseases and relevant treatments are being discovered in precision psychiatry research by employing neuroimaging and multi-omics	67	83	ANALYTICAL_METHOD	machine learning
In this review, we focus on the latest developments for precision psychiatry research using artificial intelligence and machine learning approaches, such as deep learning and neural network algorithms, together with multi-omics and neuroimaging data	120	136	ANALYTICAL_METHOD	machine learning
Firstly, we review precision psychiatry and pharmacogenomics studies that leverage various artificial intelligence and machine learning techniques to assess treatment prediction, prognosis prediction, diagnosis prediction, and the detection of potential biomarkers	119	135	ANALYTICAL_METHOD	machine learning
In addition to common variants, recent advances in Next Generation Sequencing (NGS) technologies have resulted in the identification of a plethora of rare and population-specific pharmacogenetic variations with unclear functional consequences that are not accessible by conventional forward genetics strategies	79	82	TECHNIQUE	NGS
In this review, we discuss how comprehensive sequencing information can be translated into personalized pharmacogenomic advice in the age of NGS	141	144	TECHNIQUE	NGS
We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data for personalized clinical decision-support	109	112	TECHNIQUE	NGS
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www	180	188	DATABASE	PharmGKB
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www	116	124	DATABASE	PharmGKB
A best practice advisory (BPA) based on the Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy was placed in the electronic health record prescription medication ordering system	44	95	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A common barrier to implementation of precision medicine is the lack of use of published clinical practice guidelines	89	97	CHALLENGE	clinical
In addition, we preliminarily explored the machine learning-based methods for identifying mutation markers of anti-cancer drug sensitivity and produced optimistic results, which suggests that a reliable dataset may provide new insights and essential clues for future cancer pharmacogenomics studies	43	59	ANALYTICAL_METHOD	machine learning
To test the ability of machine learning (ML) approaches with clinical and genomic biomarkers to predict methotrexate treatment response in patients with early rheumatoid arthritis (RA)	23	39	ANALYTICAL_METHOD	machine learning
To benchmark Dutch pharmacists knowledge, experience and attitudes toward pharmacogenetics (PGx) with a specific focus on the effects of awareness of the Dutch Pharmacogenetics Working Group guidelines	154	190	DATABASE	Dutch Pharmacogenetics Working Group
We studied the genotype distributions and allele frequencies of 3 CYP2E1 polymorphisms: CYP2E11A, CYP2E17A, and CYP2E17C by polymerase chain reaction technique in a sample of 100 healthy subjects representing Tibetan population	124	149	TECHNIQUE	polymerase chain reaction
We systematically evaluated these methods by using a gold standard data set of gene-drug relations derived from PharmGKB	112	120	DATABASE	PharmGKB
In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database	150	158	DATABASE	PharmGKB
Genotyping was performed in 100 patients diagnosed with malignant glioma (50 anaplastic astrocytoma (AA) patients and 50 glioblastoma multiforme (GBM) patients) and 150 age and sex-matched controls by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) method, followed by sanger sequencing	270	273	TECHNIQUE	PCR
Genotyping was performed in 100 patients diagnosed with malignant glioma (50 anaplastic astrocytoma (AA) patients and 50 glioblastoma multiforme (GBM) patients) and 150 age and sex-matched controls by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) method, followed by sanger sequencing	201	226	TECHNIQUE	polymerase chain reaction
Societies such as the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF), the Dutch Pharmacogenetics Working Group (DPWG) or the Clinical Pharmacogenetics Implementation Consortium (CPIC) and regulatory agencies (e	142	193	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Societies such as the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF), the Dutch Pharmacogenetics Working Group (DPWG) or the Clinical Pharmacogenetics Implementation Consortium (CPIC) and regulatory agencies (e	91	127	DATABASE	Dutch Pharmacogenetics Working Group
However, because of the large number of clinical trials that failed to demonstrate benefit from vitamin E coupled with the lack of a mechanistic explanation for why vitamin E should be beneficial only in diabetic individuals with the Hp 2-2 genotype, enthusiasm for this pharmacogenomic paradigm has been limited	40	48	CHALLENGE	clinical
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	147	163	ANALYTICAL_METHOD	machine learning
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	11	28	CHALLENGE	limited resources
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	30	40	CHALLENGE	high costs
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	42	55	CHALLENGE	long duration
In this paper, we consider whether feature selection in a single database can benefit from incorporating similar databases	35	52	ANALYTICAL_METHOD	feature selection
We report that by using adaptive multi-task elastic net for feature selection and Random Forest for prediction, the prediction performance can be improved for pharmacogenomics databases	60	77	ANALYTICAL_METHOD	feature selection
We also present a simulation study to explain the robust feature selection benefit of adaptive multi task elastic net while dealing with noisy features	57	74	ANALYTICAL_METHOD	feature selection
The association between genotypes, alleles and blood pressure response to treatment was determined by conducting multivariate logistic regression model analysis	126	145	ANALYTICAL_METHOD	logistic regression
The objective of this study was to evaluate the evidence on cost-effectiveness of pharmacogenetic (PGx)-guided treatment for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	136	187	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Estimated PGx frequencies are disseminated via the PharmGKB (The Pharmacogenomics Knowledgebase: www	51	59	DATABASE	PharmGKB
The optical sensing method in a DNA microarray format was optimized and evaluated for the simultaneous identification of 28 polymorphisms associated with psychiatric pharmacogenomics	36	46	TECHNIQUE	microarray
With the advent of next-generation sequencing (NGS) and its rapidly increasing uptake into cancer research and clinical practice, an enormous amount of data to inform documented gene-drug associations will be collected that must be exploited to optimize patient benefit	47	50	TECHNIQUE	NGS
Specifically, it discusses the importance of germ line variation in cancer and the role of NGS in pharmacogenetic discovery and implementation	91	94	TECHNIQUE	NGS
In the context of a scenario in which massive amounts of NGS-based genetic information will be increasingly available to health stakeholders, this review explores the ongoing debate regarding the threshold of evidence necessary for implementation, provides an overview of recommendations in cancer by professional organizations and regulatory bodies, and discusses limitations of current guidelines and strategies to improve third-party coverage	57	60	TECHNIQUE	NGS
The manuscripts in following categories are welcome, but not limited to: Application of next generation sequencing in clinical diagnosis, including but not limited to rare genetic disease, complex inherited disease, prenatal/perinatal screening, oncology, organ transplantation and pathogen identification; Novel bioinformatics approaches in human genomics; Single cell sequencing, liquid biopsy and other emerging genomic assays in molecular genetics, pharmacogenomics, oncology and immuno-oncology; Integration of genomics with other "omics" technology in genetic medicine	88	114	TECHNIQUE	next generation sequencing
The pharmacogenetics and pharmacogenomics knowledge base (PharmGKB) aims at capturing relevant information about such interactions from several sources, including curation of the biomedical literature	58	66	DATABASE	PharmGKB
In this paper we discuss how the existing PharmGKB database can be used for such an evaluation task in a way similar to the usage of gold standard data derived from protein-protein interaction databases in one of the recent BioCreative shared tasks	42	50	DATABASE	PharmGKB
The International HapMap Project lymphoblastoid cell lines (LCLs) have been used to study genetic determinants responsible for expression variation and drug response	18	24	DATABASE	HapMap
Given the critical role played by DNA methylation in gene regulation and the fact that DNA methylation is currently the most studied epigenetic system, we suggest that profiling the variation in DNA methylation in the HapMap samples will provide new insights into the regulation of gene expression as well as the mechanisms of individual drug response at a new level of complexity	218	224	DATABASE	HapMap
TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions	99	150	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Expression quantitative trait loci (eQTL) analysis is a powerful approach toward identifying genetic loci associated with quantitative changes in gene expression	36	40	TECHNIQUE	eQTL
We applied genome-wide association analysis to a data set of >300 000 single-nucleotide polymorphisms and >48 000 mRNA expression phenotypes obtained by Illumina microarray profiling of 149 human surgical liver samples obtained from Caucasian donors with detailed medical documentation	162	172	TECHNIQUE	microarray
To overcome this hurdle, machine learning models have been extensively adapted in drug dose prediction	25	41	ANALYTICAL_METHOD	machine learning
In this tutorial, random forest and neural network models will be trained in tandem with a multiple linear regression model on the International Warfarin Pharmacogenetics Consortium dataset using the scikit-learn python library	18	31	ANALYTICAL_METHOD	random forest
This may in part be related to our limited understanding about genetic predictors of drug response in general, the challenges associated with determining efficacy of response to AADs, and lack of randomized genotype-directed clinical trials	154	162	CHALLENGE	efficacy
This may in part be related to our limited understanding about genetic predictors of drug response in general, the challenges associated with determining efficacy of response to AADs, and lack of randomized genotype-directed clinical trials	225	233	CHALLENGE	clinical
<b>Results:</b> None of the variants identified explained the discordances assuming that they are of uncertain significance according to the Clinical Pharmacogenetics Implementation Consortium classification	141	192	DATABASE	Clinical Pharmacogenetics Implementation Consortium
8%) were associated with an actionable recommendation based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) prescribing guidelines, with 205 (17	67	118	DATABASE	Clinical Pharmacogenetics Implementation Consortium
, the Pharmacogenomics Knowledgebase [PharmGKB<sup>®</sup>] and the NHGRI-EBI GWAS catalog) and the vast majority of variants (98%) and genes (94%) discovered in pharmacogenomic GWAS were novel (i	38	46	DATABASE	PharmGKB
Kaplan-Meier survival analyses were used to assess time to first withdrawal	0	21	ANALYTICAL_METHOD	Kaplan-Meier survival
Linear and logistic regression analyses were used to assess predictors of withdrawal symptomatology	11	30	ANALYTICAL_METHOD	logistic regression
Pharmacogenomic information associated with SJS/TEN has accumulated on several drugs in the last 15 years, with clinically useful information now included on drug labels in several countries/regions or guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) for implementation	220	271	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Results from the initial next generation sequencing studies indicate an enrichment of rare variants in pathways and genes that were previously found to be associated with BD	25	51	TECHNIQUE	next generation sequencing
(1) Background: This retrospective analysis utilizing electronic medical record (EMR) data from a tertiary integrated health system sought to identify patients and prescribers who would benefit from pharmacogenomic (PGx) testing based on Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	238	289	DATABASE	Clinical Pharmacogenetics Implementation Consortium
HLA-A, -B, -DRB1, and -DQB1 alleles were typed by polymerase chain reaction with sequence-specific primers	50	75	TECHNIQUE	polymerase chain reaction
Evidence-based guidelines and drug label annotations are available from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB)	76	127	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Evidence-based guidelines and drug label annotations are available from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB)	175	183	DATABASE	PharmGKB
Moreover, more population data sets containing next generation sequencing data spanning >3 million individuals have been added	47	73	TECHNIQUE	next generation sequencing
We genotyped 16 polymorphisms in genes for enzymes involved in the folate-methionine pathway and in methotrexate transport, and analysed their association with treatment efficacy and toxicity using classification and regression tree analysis and logistic regression	246	265	ANALYTICAL_METHOD	logistic regression
Patients carrying at least one variant allele had ~7-fold increased risk of treatment failure compared to patients with the wild-type genotype, as shown by the classification and regression tree analysis and logistic regression (odds ratio [OR], 6	208	227	ANALYTICAL_METHOD	logistic regression
Results of the PGx test along with predicted phenotypes and a therapeutic recommendation based on the Dutch Pharmacogenetics Working Group (DPWG) guidelines were transferred to the pharmacist and physician	102	138	DATABASE	Dutch Pharmacogenetics Working Group
A lack of clear regulatory guidance dealing with pharmacogenomic products has been a major barrier to progress in the field	10	15	CHALLENGE	clear
Genetic association studies have shown polymorphisms at specific loci may help identify individuals at greatest risk and response to oral antidiabetic drugs	0	19	ANALYTICAL_METHOD	Genetic association
788 pharmacogenetic alleles, distributed through 19 genes included in Clinical Pharmacogenetics Implementation Consortium guidelines were analyzed	70	121	DATABASE	Clinical Pharmacogenetics Implementation Consortium
These models were evaluated within the PLATO software package using pair wise logistic regression models	78	97	ANALYTICAL_METHOD	logistic regression
In light of recent advances in biomedical computing, big data science, and precision medicine, there is a mammoth demand for establishing algorithms in machine learning and systems genomics (MLSG), together with multi-omics data, to weigh probable phenotype-genotype relationships	152	168	ANALYTICAL_METHOD	machine learning
Extensive glucuronidation is an obstacle to oral bioavailability because the first-pass glucuronidation [or premature clearance by UDP-glucuronosyltransferases (UGTs)] of orally administered agents frequently results in poor oral bioavailability and lack of efficacy	258	266	CHALLENGE	efficacy
Based on the inferred TPMT/NUDT15 compound metabolic phenotypes, the Clinical Pharmacogenetics Implementation Consortium recommendations for starting thiopurine therapy with reduced doses or to consider dose reduction applied respectively to 3-5% and to 12-20% of the study cohorts	69	120	DATABASE	Clinical Pharmacogenetics Implementation Consortium
18%) previously reported variants in our population with annotations in the PharmGKB database	76	84	DATABASE	PharmGKB
The greatest obstacle to clinical implementation of cardiovascular pharmacogenetics may be the lack of both reproducibility and agreement about the validity and utility of the findings	25	33	CHALLENGE	clinical
In conclusion, the pharmacogenetic analysis confirmed that this patient’s genetic conditions, involving low expression of the VKA therapeutic target, required a lower dose than that established in clinical protocols as recommended by the Food and Drug Administration (FDA) and the PharmGKB® for coumarin drugs	281	289	DATABASE	PharmGKB
We decided to conduct a retrospective pharmacogenomic analysis including nucleotide genetic polymorphisms (SNPs) with different degrees of association with the dose/response to antivitamin K (AVK) drugs: rs2108622 (gene CYP4F2), rs9923231, rs7294 (gene VKORC1), rs1799853, and rs1057910 (CYP2C9 gene) using TaqMan® RT-PCR	318	321	TECHNIQUE	PCR
We decided to conduct a retrospective pharmacogenomic analysis including nucleotide genetic polymorphisms (SNPs) with different degrees of association with the dose/response to antivitamin K (AVK) drugs: rs2108622 (gene CYP4F2), rs9923231, rs7294 (gene VKORC1), rs1799853, and rs1057910 (CYP2C9 gene) using TaqMan® RT-PCR	315	321	TECHNIQUE	RT-PCR
Genotyping was performed using the polymerase chain reaction-restriction fragment length polymorphism method	35	60	TECHNIQUE	polymerase chain reaction
To test potential associations between noncoding and coding pharmacogenetic variants, we computed a drug-level GVB for 5099 drugs from DrugBank for 2504 genomes of the 1000 Genomes Project and evaluated the correlation between the long-known noncoding variant-drug associations in PharmGKB, with functionally relevant rare and common coding variants aggregated into GVBs	281	289	DATABASE	PharmGKB
We obtained the area under the receiver operating characteristics curve (AUC) by comparing the drug-level GVB ranks against the corresponding pharmacogenetic variants-drug associations in PharmGKB	188	196	DATABASE	PharmGKB
Recommended dosing regimens for pregnant WWE were selected using Monte Carlo simulation based on the established optimal model	65	76	ANALYTICAL_METHOD	Monte Carlo
Monte Carlo simulation based on optimal PopPK model revealed that the LTG dosage administered to carriers of the UGT2B7 rs4356975 CT or TT genotype required a 33-50% increase to reach the pre-pregnancy target concentration, and carriers of the ABCB1 rs1128503 GG genotype required a 33-66% lower dose of LTG than carriers of the ABCB1 rs1128503 AA or AG genotype	0	11	ANALYTICAL_METHOD	Monte Carlo
While detection of known variants has benefited from pharmacogenomic-dedicated bioinformatics tools before, in this paper we have tested novel deep computational analysis in addition to artificial intelligence as possible approaches for functional analysis of unknown markers within less studied drug-related genes	186	209	ANALYTICAL_METHOD	artificial intelligence
Response to medications, the principal treatment modality for acute and chronic diseases, is highly variable, with 40-70% of patients exhibiting lack of efficacy or adverse drug reactions	153	161	CHALLENGE	efficacy
The molecular docking studies revealed that Aliskiren and other clinically approved drug molecules have a high binding affinity with both wild and mutant structures of renin, CYP2D6, and CYP3A4 proteins	4	21	ANALYTICAL_METHOD	molecular docking
Plasma concentrations of isoniazid, acetyl-isoniazid, isonicotinic acid, rifampin, and 25-desacetylrifampin from 40 HIV therapy-naive patients were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) after the first dose and at steady state of antitubercular therapy	184	208	TECHNIQUE	tandem mass spectrometry
Consequently, drug response prediction suffers from limited generalizability	60	76	CHALLENGE	generalizability
By addressing the limitations of low generalizability, our approach contributes to advancing drug response prediction in precision oncology	37	53	CHALLENGE	generalizability
The CYP2C19 polymorphisms were genotyped using an Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) approach	123	126	TECHNIQUE	PCR
PGx recommendations from the Clinical Pharmacogenetics Implementation Consortium, U	29	80	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Here, we leverage publicly available, whole genome sequencing data collected from global populations, evolutionary characteristics, and annotated protein features to construct a new in silico machine learning pharmacogenetic identification method called XGB-PGX	192	208	ANALYTICAL_METHOD	machine learning
For another pharmacogenetic hurdle, the speed by which a pharmacogenetic profile for a certain drug can be obtained in an individual patient, there has been a revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a large number of genes up to the complete genome in a single reaction	220	246	TECHNIQUE	next generation sequencing
For another pharmacogenetic hurdle, the speed by which a pharmacogenetic profile for a certain drug can be obtained in an individual patient, there has been a revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a large number of genes up to the complete genome in a single reaction	248	251	TECHNIQUE	NGS
This paper will focus on the different NGS applications that may be useful for pharmacogenomics in children and the challenges that they bring on	39	42	TECHNIQUE	NGS
Several reasons can be found why the application of pharmacogenetics is less than initially anticipated, which include the contradictory results obtained for certain variants and the lack of guidelines for clinical implementation	206	214	CHALLENGE	clinical
Lack of evidence linking diagnostic tests to health outcomes has caused payers to be skeptical about the clinical usefulness of tests	105	113	CHALLENGE	clinical
Lack of clinically useful diagnostics as well as an evidence gap in terms of knowledge of drug and diagnostic clinical effectiveness appear to be hindering growth in personalized medicine	8	16	CHALLENGE	clinical
Because of the lack of prospective confirmation, these candidate genes have not yet been applied in clinical practice as the predictive biomarker	100	108	CHALLENGE	clinical
The major issue for clinicians is the lack of evidence that pharmacogenomic testing improves clinical outcomes and that testing is cost-effective	93	101	CHALLENGE	clinical
The major issue for clinicians is the lack of evidence that pharmacogenomic testing improves clinical outcomes and that testing is cost-effective	136	145	CHALLENGE	effective
pediatricians being aware of the Clinical Pharmacogenetics Implementation Consortium (CPIC)	33	84	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Associations between genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment)	141	160	ANALYTICAL_METHOD	logistic regression
The Pharmacogenomics Knowledgebase (PharmGKB) is a resource that collects, curates, and disseminates information about the impact of human genetic variation on drug responses	36	44	DATABASE	PharmGKB
Thus, PharmGKB is a useful source of high-quality information supporting personalized medicine-implementation projects	6	14	DATABASE	PharmGKB
Genomic DNA from 229 Yakut subjects were analyzed by real-time polymerase chain reaction (PCR) (SLCO1B1 +521T > C, VKORC1 -1639G>A, CYP2C19 +681G>A, +636G>A, CYP2C9 +430С>T, +1075A>C)	90	93	TECHNIQUE	PCR
Genomic DNA from 229 Yakut subjects were analyzed by real-time polymerase chain reaction (PCR) (SLCO1B1 +521T > C, VKORC1 -1639G>A, CYP2C19 +681G>A, +636G>A, CYP2C9 +430С>T, +1075A>C)	63	88	TECHNIQUE	polymerase chain reaction
The authors discuss the perspectives for the practical utilization of pharmacogenetics (identification of single candidate genes using PCR) and pharmacogenomics (using genome wide association studies (GWAS) to choose optimal treatment for osteoporosis)	135	138	TECHNIQUE	PCR
To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations	206	209	TECHNIQUE	NGS
In this review, main public-domain databases on genetic variations, including the two comprehensive genetic variation databases (dbSNP and HapMap), a pharmacogenomics database (PharmGKB), two resequencing-based genetic variation databases (SeattleSNPs and EGP), a population-based genetic variation database (JSNPs), and a copy-number variant database (DGV), and their utility in cancer research are discussed	139	145	DATABASE	HapMap
In this review, main public-domain databases on genetic variations, including the two comprehensive genetic variation databases (dbSNP and HapMap), a pharmacogenomics database (PharmGKB), two resequencing-based genetic variation databases (SeattleSNPs and EGP), a population-based genetic variation database (JSNPs), and a copy-number variant database (DGV), and their utility in cancer research are discussed	177	185	DATABASE	PharmGKB
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine	58	81	ANALYTICAL_METHOD	artificial intelligence
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine	92	108	ANALYTICAL_METHOD	machine learning
Recent advances in next-generation sequencing (NGS) have resulted in the identification of tens of thousands of rare pharmacogenetic variations with unknown functional effects	47	50	TECHNIQUE	NGS
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine	198	201	TECHNIQUE	NGS
This is done based on data curated and evaluated by experts such as the pharmacogenomics knowledge implementation (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), as well as drug regulatory authorities such as the US Food and Drug Administration (FDA) and European Medicinal Agency (EMA)	133	184	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This is done based on data curated and evaluated by experts such as the pharmacogenomics knowledge implementation (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), as well as drug regulatory authorities such as the US Food and Drug Administration (FDA) and European Medicinal Agency (EMA)	115	123	DATABASE	PharmGKB
This article investigates the number of drugs on the market with pharmacogenomics (PGx) biomarker data in their labels using two public sources - the US FDA and the PharmGKB	165	173	DATABASE	PharmGKB
A non-conditional logistic regression was used to identify the factors associated with hepatotoxicity	18	37	ANALYTICAL_METHOD	logistic regression
This study aimed to evaluate the level at which PGx was being used in clinical practice by comparing the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group guidelines and drug labels of the US Food and Drug Administration (FDA) and the Korea Ministry of Food and Drug Safety (MFDS)	105	156	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This study aimed to evaluate the level at which PGx was being used in clinical practice by comparing the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group guidelines and drug labels of the US Food and Drug Administration (FDA) and the Korea Ministry of Food and Drug Safety (MFDS)	161	197	DATABASE	Dutch Pharmacogenetics Working Group
Digital health, an emerging scientific domain, attracts increasing attention as artificial intelligence and relevant software proliferate	80	103	ANALYTICAL_METHOD	artificial intelligence
Effective interventions and treatments for complex diseases have been implemented globally, however, coverage in Africa has been comparatively lower due to lack of capacity, clinical applicability and knowledge on the genetic contribution to disease and treatment	174	182	CHALLENGE	clinical
They were ascertained from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and US Food and Drug Administration (FDA) labeling	27	78	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) enrichment analyses were performed by R language data packets to predict the mechanism of action	0	13	DATABASE	Gene Ontology
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) enrichment analyses were performed by R language data packets to predict the mechanism of action	15	17	DATABASE	GO
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) enrichment analyses were performed by R language data packets to predict the mechanism of action	65	69	DATABASE	KEGG
GO and KEGG enrichment analysis results of common targets mainly involved hormone-mediated signaling pathway, steroid hormone response, lipid transport and metabolism, regulation of cholesterol storage, cyclooxygenase pathway, and other biological pathways, as well asMM PPAR (peroxisome proliferators-activated receptor) signaling pathway, IL-17 (interleukin 17) signaling pathway, PI3K-Akt (protein kinase b) signaling pathway, FcεRI signaling pathway, and other related pathways	7	11	DATABASE	KEGG
Objective: bioinformatic methods and molecular docking technology were used to predict the active components, targets, and related biological pathways of the Xiexin capsule in the intervention for dyslipidemia, exploring its mechanism	37	54	ANALYTICAL_METHOD	molecular docking
Pharmacogenomics Knowledgebase (PharmGKB) aims to clarify the level of action for PGBMs (PGx levels) implied in each label as issued by the US Food and Drug Administration	32	40	DATABASE	PharmGKB
This growing epidemic is further exacerbated by a current lack of highly effective therapies for the arrhythmia stemming from our incomplete understanding of its complex pathophysiology	73	82	CHALLENGE	effective
Next-generation sequencing (NGS) technology has expanded in the last decades with significant improvements in the reliability, sequencing chemistry, pipeline analyses, data interpretation and costs	28	31	TECHNIQUE	NGS
Such advances make the use of NGS feasible in clinical practice today	30	33	TECHNIQUE	NGS
This review describes the recent technological developments in NGS applied to the field of oncology	63	66	TECHNIQUE	NGS
This study investigates how artificial intelligence (AI) and machine learning (ML) can address key challenges in integrating pharmacogenomics (PGx) into psychiatric care	28	51	ANALYTICAL_METHOD	artificial intelligence
This study investigates how artificial intelligence (AI) and machine learning (ML) can address key challenges in integrating pharmacogenomics (PGx) into psychiatric care	61	77	ANALYTICAL_METHOD	machine learning
The unique approach of our laboratory to the pharmacogenetic diagnostic service in oncology is to combine two real-time PCR methods, LightSNiP assay (TIB MOLBIOL), and more recently FRET (Fluorescent Resonance Energy Transfer) probes technology (Nuclear Laser Medicine), plus TaqMan assay (Thermo Fisher) for the confirmation of the presence of variant alleles on DNA from a second extraction	120	123	TECHNIQUE	PCR
The unique approach of our laboratory to the pharmacogenetic diagnostic service in oncology is to combine two real-time PCR methods, LightSNiP assay (TIB MOLBIOL), and more recently FRET (Fluorescent Resonance Energy Transfer) probes technology (Nuclear Laser Medicine), plus TaqMan assay (Thermo Fisher) for the confirmation of the presence of variant alleles on DNA from a second extraction	276	288	TECHNIQUE	TaqMan assay
Whereas unexpected genetic variants may be missed using a mutation-specific TaqMan assay, the information thus obtained can be useful to adjust the therapy in case of unexpected post-treatment toxicity	76	88	TECHNIQUE	TaqMan assay
This resistance may stem from sometimes conflicting findings among pharmacogenetic studies, a lack of stroke-specific randomized controlled trials to test the effectiveness of genetically-guided therapies, and the practical and cost-effective implementation of genetic testing within the clinic	159	168	CHALLENGE	effective
Using multivariate Cox models, the combined variable pre-existing psychiatric comorbidities/SLC22A2 variants and the use of non-tenofovir alafenamide containing antiretroviral regimens were predictors of dolutegravir discontinuation for neuropsychiatric symptoms	19	22	ANALYTICAL_METHOD	Cox
Available DNA samples from the LRF CLL4 trial, which compared chlorambucil, fludarabine, and FC, were screened by TaqMan real-time polymerase chain reaction assays for CYP2B6 SNPs c	131	156	TECHNIQUE	polymerase chain reaction
Future updates of the knowledge base will include additional emphasis on transcriptomics, proteomics, metabolomics, and other omics research; explore opportunities for leveraging data sets designed to support scientific discovery; and incorporate advanced machine learning bioinformatics capabilities	256	272	ANALYTICAL_METHOD	machine learning
Quality control of genome-wide data was performed according to standard criteria and linear/logistic regression models were used as appropriate under an additive hypothesis	92	111	ANALYTICAL_METHOD	logistic regression
All OSCC patients were graded based on their differentiation, and genetic analysis was performed by PCR-RFLP and sequencing	100	103	TECHNIQUE	PCR
Clinical trials guiding evidence for treatment are lacking due to the rarity of disease, heterogeneous clinical course, and lack of prognostic biomarkers, all of which contribute to difficulty in clinical trial design and implementation	0	8	CHALLENGE	clinical
It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon be a cost-effective methodology for clinical routine genotyping	68	71	TECHNIQUE	NGS
Using machine learning (ML) techniques with pharmacogenomics data provides one pathway toward individualized prediction of therapeutic outcomes of antidepressants	6	22	ANALYTICAL_METHOD	machine learning
The PharmVar-developed SLCO1B1 nomenclature has been incorporated by the Clinical Pharmacogenetics Implementation Consortium (CPIC) 2022 guideline on statin-associated musculoskeletal symptoms	73	124	DATABASE	Clinical Pharmacogenetics Implementation Consortium
A random forest (RF) model was then used to assess SNPs most predictive of PZQ efficacy, with a misclassification rate of 29%	2	15	ANALYTICAL_METHOD	random forest
Genotyping was done using PCR-RFLP method and validated by direct gene sequencing	26	29	TECHNIQUE	PCR
Molecular pathways (KEGG database) that included one or more of the genes associated with the phenotypes were investigated also in the STAR*D sample	20	24	DATABASE	KEGG
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy based on pharmacogenetic test results	4	40	DATABASE	Dutch Pharmacogenetics Working Group
These developments are paralleled by advances in machine learning, which have allowed us to parse the immense wealth of data and establish novel genetic markers and polygenic models for drug selection and dosing	49	65	ANALYTICAL_METHOD	machine learning
Next, binary logistic regression was applied to evaluate the association of the PGSs to SSRIs treatment response in a discovery sample (ISPC, N = 865), and in a replication cohort (STAR*D, N = 1,878)	13	32	ANALYTICAL_METHOD	logistic regression
Those phenotypes can range from life-threatening adverse drugs reactions at one end of the spectrum to equally serious lack of therapeutic efficacy at the other	139	147	CHALLENGE	efficacy
, Pharmacogenomics Knowledge Base, Clinical Pharmacogenetics Implementation Consortium) was low	35	86	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To evaluate the coverage and accuracy of whole-exome sequencing (WES) across vendors	41	63	TECHNIQUE	whole-exome sequencing
In this study, a genotyping panel has been developed for the Japanese population called PGx_JPN panel comprising 36 variants in 14 genes for drug-metabolizing enzymes and drug transporters using a mass spectrometry-based genotyping method, in which all the variants could be analyzed in two wells for multiplex analysis	197	220	TECHNIQUE	mass spectrometry-based
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	157	180	TECHNIQUE	mass spectrometry-based
In this study, we demonstrated that the mass spectrometry-based multiplex method could be useful for in the simultaneous genotyping of more than 30 variants, which are essential among the Japanese population in two wells, except for copy number variations	40	63	TECHNIQUE	mass spectrometry-based
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	132	144	TECHNIQUE	TaqMan assay
Reflecting on published proposals and materials presented by the US FDA, a decision tree for generating robust scientific data from samples collected from an already conducted trial to allow PRA is presented	75	88	ANALYTICAL_METHOD	decision tree
A multiple linear regression model revealed that the ABCC3 -211C/T polymorphism was not independently associated with ADP-induced MPA measurements; a multiple logistic regression model revealed that carrying the ABCC3 -211C allele was not associated with the risk of developing an ST event in clopidogrel-treated patients not harbouring CYP2C19*2, *3 and *17 variants	159	178	ANALYTICAL_METHOD	logistic regression
Minor allele frequencies (MAF) for the indicated SNPs for European, South Asian and East Asian populations were obtained from the NCBI website (https://www	130	134	DATABASE	NCBI
DNA microarray and next-generation DNA sequencing technologies are important tools for high-throughput genome research, in revealing both the structural and functional characteristics of genomes	4	14	TECHNIQUE	microarray
In the past decade the DNA microarray technologies have been widely applied in the studies of functional genomics, systems biology and pharmacogenomics	27	37	TECHNIQUE	microarray
Though it has not been long since the first emergence of this technology, with the fast and impressive improvement, the application of this technology has extended to almost all fields of genomics research, as a rival challenging the existing DNA microarray technology	247	257	TECHNIQUE	microarray
Part of the difficulty has stemmed from the only modest predictive capacity of previously identified gene variants, lack of replication of data in multiple studies, and the hesitancy of the clinical community to translate data gleaned from basic and translational research to routine clinical practice	190	198	CHALLENGE	clinical
The candidate gene approach "metabolism guided" now evolves towards more global strategies thanks to genome resequencing projects such HapMap that have considerably increased our knowledge of genetics variations in humans	135	141	DATABASE	HapMap
Lack of sufficient efficacy is the most common cause of attrition in late-phase drug development	19	27	CHALLENGE	efficacy
Food and Drug Administration (FDA) PGx labeling and in the Clinical Pharmacogenetics Implementation Consortium (CPIC) database	59	110	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy	90	93	TECHNIQUE	NGS
Cancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options	151	160	CHALLENGE	effective
Allele-specific polymerase chain reaction (PCR) and PCR with restriction fragment length polymorphism (RFLP) analysis were carried out to determine the prevalence of the most common TPMT genotypes (*2, *3A, *3B and *3C) in 50 MG patients from Southern Brazilian	16	41	TECHNIQUE	polymerase chain reaction
Recombinant proteins were analyzed by quantitative Western blot analysis and by a one-step fluorometric assay	51	63	TECHNIQUE	Western blot
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	150	173	ANALYTICAL_METHOD	artificial intelligence
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	178	194	ANALYTICAL_METHOD	machine learning
Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing	82	85	TECHNIQUE	PCR
The predicted drug targets were screened with the known RA drugs based on molecular docking	74	91	ANALYTICAL_METHOD	molecular docking
When considering the intersection of traditionally distinct arenas of medicine, that is, artificial intelligence, healthcare, clinical genomics, and pharmacogenomics-what ties them together is their impact on the development of precision medicine as a field and how they each contribute to patient-specific, rather than symptom-specific patient outcomes	89	112	ANALYTICAL_METHOD	artificial intelligence
Additionally, this study also discusses the advantages as well as the current challenges associated with artificial intelligence, healthcare, clinical genomics, and pharmacogenomics	105	128	ANALYTICAL_METHOD	artificial intelligence
Furthermore, the development of next generation sequencing technology and non-invasive approaches to analyze circulating tumor DNA will make real-time monitoring of the tumor pharmacogenomic markers possible in the clinical routine, rendering precision medicine available to every patient	32	58	TECHNIQUE	next generation sequencing
The potency of EXE and ten of its derivatives was measured with HEK293-overexpressed wild type aromatase (CYP19A1*1) using a rapid novel UPLC tandem mass spectrometry method	142	166	TECHNIQUE	tandem mass spectrometry
Gene Ontology and Reactome Pathways enrichment analyses were conducted, while interactions between differentially expressed genes (DEGs) were determined with the STRING database	0	13	DATABASE	Gene Ontology
Here, we conducted a meta-analysis on the publicly available gene expression cDNA microarray datasets that examine the differential expression observed in response to anti-TNFα therapy with psoriasis (PsO), inflammatory bowel disease (IBD) and rheumatoid arthritis (RA)	82	92	TECHNIQUE	microarray
Drug addiction is a serious relapsing disease that has high costs to society and to the individual addicts	55	65	CHALLENGE	high costs
The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Center is organized around the construction of "Knowledge Engine for Genomics" (KnowEnG), an E-science framework for genomics where biomedical scientists will have access to powerful methods of data mining, network mining, and machine learning to extract knowledge out of genomics data	198	209	ANALYTICAL_METHOD	data mining
The Center is organized around the construction of "Knowledge Engine for Genomics" (KnowEnG), an E-science framework for genomics where biomedical scientists will have access to powerful methods of data mining, network mining, and machine learning to extract knowledge out of genomics data	231	247	ANALYTICAL_METHOD	machine learning
Supervised machine learning models have been favored because they are capable of acquiring both classification patterns and structures from data	11	27	ANALYTICAL_METHOD	machine learning
This article reviews recent advances in applying natural language processing (NLP) to Electronic Health Records (EHRs) for computational phenotyping	49	76	ANALYTICAL_METHOD	natural language processing
After integrating the results of two studies, the genetic variations related to the platinum-based chemotherapy response were further determined by fine-mapping in 838 samples, and their potential functional impact were investigated by eQTL analysis and <i>in vitro</i> cell experiments	236	240	TECHNIQUE	eQTL
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts	242	252	TECHNIQUE	microarray
In contrast, for the previous phenotypes, the Clinical Pharmacogenetics Implementation Consortium (CPIC) voriconazole guideline only recommends a change of treatment	46	97	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Dutch Pharmacogenetics Working Group (DPWG) recommends a 50% dose increase or decrease for cytochrome P450 (CYP) 2C19 ultrarapid (UM) or poor (PM) metabolizers, respectively	4	40	DATABASE	Dutch Pharmacogenetics Working Group
To this end, we used PGxPOP, a PGx allele caller based on the guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), to identify the main phenotypes associated with the PGx alleles most represented in Sardinians	88	139	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We then define a summary score for each gene based on allele frequencies and train linear and logistic regression classifiers to predict drug response phenotypes	94	113	ANALYTICAL_METHOD	logistic regression
Heuristic genotype groupings and principal component analysis demonstrated concordance for Illumina sequencing, fragment analysis, and fluorescent PCR	147	150	TECHNIQUE	PCR
However, Illumina sequencing and fragment analysis returned a range of fragment sizes, likely arising due to PCR "slippage"	109	112	TECHNIQUE	PCR
A total of 200 patients with drug-resistant epilepsy and 200 patients with drug-responsive epilepsy were genotyped for 3 representative the single nucleotide polymorphisms (SNPs) of the voltage-gated sodium channel genes (SCN1A, SCN1B, and SCN2A) by polymerase chain reaction and direct sequencing analysis	250	275	TECHNIQUE	polymerase chain reaction
17<i>β</i>-DHE formation in pooled human liver microsomes subjected to isoform-specific CYP450 inhibition was also monitored using tandem mass spectrometry	131	155	TECHNIQUE	tandem mass spectrometry
To establish a model for predicting clinical efficacy and adverse events, polymorphisms in genes including ABC transporters (<i>ABCB1</i> and <i>ABCG2</i>), <i>UGT1A</i>, and <i>OR2B11</i> were analyzed by whole-exome sequencing, Sanger sequencing, and DNA microarray	257	267	TECHNIQUE	microarray
To establish a model for predicting clinical efficacy and adverse events, polymorphisms in genes including ABC transporters (<i>ABCB1</i> and <i>ABCG2</i>), <i>UGT1A</i>, and <i>OR2B11</i> were analyzed by whole-exome sequencing, Sanger sequencing, and DNA microarray	206	228	TECHNIQUE	whole-exome sequencing
Pharmacogenetics and pharmacogenomics involve the study of the role of inheritance in individual variation in drug response, a phenotype that varies from potentially life-threatening adverse drug reactions to equally serious lack of therapeutic efficacy	245	253	CHALLENGE	efficacy
Recently, two whole-exome sequencing (WES) analysis (including one from our group) were performed to identify variants associated with ONJ	14	36	TECHNIQUE	whole-exome sequencing
Pharmacogenetic differences in MRP3 and OCT1 ontogeny were evaluated by Western blot of hepatic membrane fractions from 50 subjects aged 1 day postnatal to 33 years old	72	84	TECHNIQUE	Western blot
Lack of efficacy or an adverse drug reaction is frequently related to non-genetic factors	8	16	CHALLENGE	efficacy
We searched PubMed, reviewed the Pharmacogenomics Knowledgebase (PharmGKB<sup>®</sup>) website, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, the U	96	147	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We searched PubMed, reviewed the Pharmacogenomics Knowledgebase (PharmGKB<sup>®</sup>) website, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, the U	65	73	DATABASE	PharmGKB
Transcriptomics using DNA microarray has become a practical and popular tool for herbal medicine study because of high throughput, sensitivity, accuracy, specificity, and reproducibility	26	36	TECHNIQUE	microarray
Therefore, this article focuses on the overview of DNA microarray technology and the application of DNA microarray in Chinese herbal medicine study	55	65	TECHNIQUE	microarray
To understand the number and the objectives of articles utilizing DNA microarray for herbal medicine study, we surveyed 297 frequently used Chinese medicinal herbs listed in Pharmacopoeia Commission of People's Republic of China	70	80	TECHNIQUE	microarray
Although thousands of papers applying DNA microarray in Chinese herbal studies have been published since 1998, most of the articles focus on the elucidation of mechanisms of certain biological effects of herbs	42	52	TECHNIQUE	microarray
The All-In-One PGX (All-In-One Pharmacogenetics for Antipsychotics test for CYP2D6, CYP2C19, and CYP2C9) was performed using microarray-based and real-time polymerase chain reaction techniques	156	181	TECHNIQUE	polymerase chain reaction
Specifically, we explored PharmGKB to identify pharmacogenomics related associations as pharmacogenomics profiles for US Food and Drug Administration (FDA) approved breast cancer drugs	26	34	DATABASE	PharmGKB
ITPA haplotyping was performed based on haplotype tagging SNPs (selected from HapMap data) in healthy 130 controls	78	84	DATABASE	HapMap
The difficulty in analyzing the mole of information generated by DMET<sup>TM</sup> platform led to the development and implementation of algorithms and tools for statistical and data mining analysis	178	189	ANALYTICAL_METHOD	data mining
Cox proportional hazards regression with time-varying analysis assessed the association of the eight PK-related SNVs with the risk of bleeding from DOACs in unadjusted and covariate-adjusted models	0	3	ANALYTICAL_METHOD	Cox
This has important pharmacogenetic implications: the Clinical Pharmacogenetics Implementation Consortium recommendations to reduce or consider reduction of thiopurine dose applies to 4	53	104	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Drug-gene interactions (DGIs) preventing potential drug-related deaths have been categorized as "essential" by the Dutch Pharmacogenetics Working Group (DPWG)	115	151	DATABASE	Dutch Pharmacogenetics Working Group
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	116	139	ANALYTICAL_METHOD	artificial intelligence
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	39	55	ANALYTICAL_METHOD	machine learning
<b>Results:</b> Barriers to implementation included lack of knowledge, education, standardized pharmacogenomic reports and national clinical guidelines and financial inaccessibility	132	140	CHALLENGE	clinical
Extracellular and intracellular medium samples were collected and prepared for the LC-MS analysis at predetermined time points (0 min, 15 min, 1 h, 2 h, 4 h, 6 h, 24 h)	83	88	TECHNIQUE	LC-MS
Here, we expand on genome-wide studies of clozapine metabolism, previously focused on common genetic variation, by analysing whole-exome sequencing data from 2062 individuals with schizophrenia taking clozapine in the UK	125	147	TECHNIQUE	whole-exome sequencing
We selected key variants for the array using the clinical annotations of the Pharmacogenomics Knowledgebase (PharmGKB), and we included variants in drug metabolism and transporter genes along with other pharmacogenetically important variants	109	117	DATABASE	PharmGKB
Major barriers to use of medications in this area include lack of clinical guidance and questionable efficacy	101	109	CHALLENGE	efficacy
Major barriers to use of medications in this area include lack of clinical guidance and questionable efficacy	66	74	CHALLENGE	clinical
There are also multiple examples of inherited germline variants for which evidence-based guidelines have been developed by the Clinical Pharmacogenetics Implementation Consortium to guide the selection and dosing of medications in children with cancer	127	178	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In this computational study, protein modeling, shape-based screening, molecular docking, pharmacogenomics, and molecular dynamic simulation approaches have been utilized to retrieve the FDA approved drugs against AD	70	87	ANALYTICAL_METHOD	molecular docking
Single-polymerase chain reaction (PCR) and dual-PCR methods have been proposed to achieve phase-defined determination of the sequence variants	34	37	TECHNIQUE	PCR
Single-polymerase chain reaction (PCR) and dual-PCR methods have been proposed to achieve phase-defined determination of the sequence variants	7	32	TECHNIQUE	polymerase chain reaction
Recently, guidelines for assigning CYP2D6 enzyme activity scores of <i>CYP2D6</i> variant alleles, and subsequent diplotype-to-phenotype translations, were published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group	173	224	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Recently, guidelines for assigning CYP2D6 enzyme activity scores of <i>CYP2D6</i> variant alleles, and subsequent diplotype-to-phenotype translations, were published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group	240	276	DATABASE	Dutch Pharmacogenetics Working Group
This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Tricyclic Antidepressants	39	90	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD	106	114	CHALLENGE	clinical
For that purpose we recruited 544 children of the two ethnicities in three districts of Botswana from primary schools, collected blood samples, extracted DNA and genotyped them through PCR-based restriction fragment length polymorphism analysis	185	188	TECHNIQUE	PCR
However, several studies based on NGS approaches have shown that miRNAs could regulate gene expression during onset and disease progression and could serve as potential diagnostic and pharmacogenomics biomarkers during treatment	34	37	TECHNIQUE	NGS
The carriage of polymorphic markers of the studied genes was determined by the method of polymerase chain reaction in real time	89	114	TECHNIQUE	polymerase chain reaction
<b>Methods:</b> PharmGKB MAFs were gathered from publicly available genetic datasets for Brazil and worldwide	16	24	DATABASE	PharmGKB
Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties	24	40	ANALYTICAL_METHOD	machine learning
The Dutch Pharmacogenetics Working Group (DPWG) indicated a list of actionable genotypes that affect patients' response to more 50 drugs; these drugs which show variable effects based on patients' genetic traits were named as pharmacogenetics (PGX) drugs	4	40	DATABASE	Dutch Pharmacogenetics Working Group
We present Stargazer, a new bioinformatics tool that uses next-generation sequencing (NGS) data to call star alleles for CYP2D6 ( https://stargazer	86	89	TECHNIQUE	NGS
The Pharmacogenomics Knowledge Base and the Clinical Pharmacogenetics Implementation Consortium are among the resources to help clinicians and researchers navigate the many gene-drug associations that have already been discovered	44	95	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We explored the mechanism of STDP against MVA by network pharmacology and molecular docking	74	91	ANALYTICAL_METHOD	molecular docking
For clinical applications, PGx (Pharmacogenomics) and PGt (Pharmacogenetics) fol- lowing NGS (Next Generation Sequencing) are attractive areas for new and future applications	89	92	TECHNIQUE	NGS
Using the HapMap CEU population SNP database, we selected 25 tag Single Nucleotide Polymorphisms (tSNPs) in N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes	10	16	DATABASE	HapMap
The only two rules for the NCBI-assisted hackathons run so far are that 1) data either must be housed in public data repositories or be deposited to such repositories shortly after the hackathon's conclusion, and 2) all software comprising the final pipeline must be open-source or open-use	27	31	DATABASE	NCBI
com/NCBI-Hackathons/ with separate directories or repositories for each team	4	8	DATABASE	NCBI
The Pharmacogenomics Knowledge Base (PharmGKB) [1] is a publicly available central resource for pharmacogenomics data and knowledge, which is being widely employed into clinical practice and thus requires using clinical terminologies	37	45	DATABASE	PharmGKB
Hence, harmonizing PharmGKB drug data with well annotated drug terminologies will facilitate its integration with other related resources and support data representation, interpretation, and exchange within and across heterogeneous sources and applications	19	27	DATABASE	PharmGKB
In this study, we extracted drug and drug class from PharmGKB, and mapped them to National Drug File Reference Terminology (NDF-RT) [2], which is integrated into RxNorm specified by U	53	61	DATABASE	PharmGKB
And the evaluated mapping results will be provided to PharmGKB for further investigation and collaboration	54	62	DATABASE	PharmGKB
The advent of molecular radionuclide theranostics, multidisciplinary tumor board decision making, artificial intelligence and radiomics interpretation of diagnostic imaging, evolution of pharmacogenomics prediction of tumor response, and regulatory requirements for prospective individual dosimetry are just some of the elements which are broadening the essence of physician responsibility	98	121	ANALYTICAL_METHOD	artificial intelligence
Recent expression quantitative trait loci (eQTL) studies have established that the expression of most human genes is regulated by noncoding genetic variations	43	47	TECHNIQUE	eQTL
This chapter describes the development of PCR based custom multiplex SNP mutation analysis assays using Luminex(®) Multi-Analyte Profiling (xMAP(®)) Technology	42	45	TECHNIQUE	PCR
We performed Key Words searches in the public databases PubMed, Medscape, and Rxlisty, Pharm GKB for genetic polymorphisms and the NCBI website for the nomenclature of alleles of CYP450, finding that CYP2D6, CYP2C9, CYP3A4, and CYP2D19 were involved in the metabolism of most antiepileptic drugs, given the allele frequency in the population and the associated variability in the clinical response	131	135	DATABASE	NCBI
We have recently developed a rapid and cost-effective method for single nucleotide polymorphism (SNP) detection, named Smart Amplification Process (SmartAmp), which enables us to detect genetic polymorphisms or mutations in 30 to 45 min under isothermal conditions without the need for DNA isolation and PCR amplification	304	307	TECHNIQUE	PCR
This GeneFocus provides a comprehensive overview and summary of CYP2B6 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	203	254	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This GeneFocus provides a comprehensive overview and summary of CYP2B6 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	185	193	DATABASE	PharmGKB
Among the identified small set of genes associated with reduced breast cancer incidence, laboratory experiments on one of the genes, CDC42, showed that its downregulation by metformin inhibited cancer cell migration and proliferation, thus validating the ability of machine learning approaches to identify biologically relevant candidates for laboratory experiments	266	282	ANALYTICAL_METHOD	machine learning
We also investigated whether the revised Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations for translating genotype to phenotype improve CYP2D6 activity predictions over the current system	41	92	DATABASE	Clinical Pharmacogenetics Implementation Consortium
, individual's symptom profile, concomitant diseases) can be integrated with genetic information through artificial intelligence to provide treatment recommendationsThe creation of pharmacogenetic services within healthcare systems is a challenging and multi-step process, education of health professionals, promotion by institutions and regulatory bodies, economic and ethical barriers are the main issues	105	128	ANALYTICAL_METHOD	artificial intelligence
However, these groups meet a key need in pharmacogenetics research by enabling consistent communication of the scale of variability in global allele frequencies and are now used by Pharmacogenomics Knowledgebase (PharmGKB)	213	221	DATABASE	PharmGKB
Because of under-monitoring of side effects and the lack of alternative treatment choices in schizophrenia, research has focused on identification of various biomarkers and pharmacogenomic targets to focus on the patients at greatest risk of metabolic syndrome, thus aiming to increase the efficacy and minimize the side effects of AAPs	60	71	CHALLENGE	alternative
Because of under-monitoring of side effects and the lack of alternative treatment choices in schizophrenia, research has focused on identification of various biomarkers and pharmacogenomic targets to focus on the patients at greatest risk of metabolic syndrome, thus aiming to increase the efficacy and minimize the side effects of AAPs	290	298	CHALLENGE	efficacy
Following the rise of artificial intelligence (AI) technology such as machine learning and deep learning, an increasing number of GWAS/PheWAS studies have successfully leveraged this technology to overcome the aforementioned challenges	22	45	ANALYTICAL_METHOD	artificial intelligence
Following the rise of artificial intelligence (AI) technology such as machine learning and deep learning, an increasing number of GWAS/PheWAS studies have successfully leveraged this technology to overcome the aforementioned challenges	70	86	ANALYTICAL_METHOD	machine learning
Several case studies under evaluation mainly involve next generation sequencing (NGS) experiments, like deciphering gene expression from total and single cell (scRNA-seq) analysis; for the latter, a description of all recent artificial intelligence (AI) methods for the investigation of cell sub-types, biomarkers and imputation techniques are described	225	248	ANALYTICAL_METHOD	artificial intelligence
In this review, the fundamental basis of machine learning (ML) and data mining (DM) are summarized together with the techniques for distilling knowledge from state-of-the-art omics experiments	67	78	ANALYTICAL_METHOD	data mining
In this review, the fundamental basis of machine learning (ML) and data mining (DM) are summarized together with the techniques for distilling knowledge from state-of-the-art omics experiments	41	57	ANALYTICAL_METHOD	machine learning
Several case studies under evaluation mainly involve next generation sequencing (NGS) experiments, like deciphering gene expression from total and single cell (scRNA-seq) analysis; for the latter, a description of all recent artificial intelligence (AI) methods for the investigation of cell sub-types, biomarkers and imputation techniques are described	53	79	TECHNIQUE	next generation sequencing
Several case studies under evaluation mainly involve next generation sequencing (NGS) experiments, like deciphering gene expression from total and single cell (scRNA-seq) analysis; for the latter, a description of all recent artificial intelligence (AI) methods for the investigation of cell sub-types, biomarkers and imputation techniques are described	81	84	TECHNIQUE	NGS
2) and clinical conditions in relation to severe (III-IV) adverse drug reactions (ADRs), stepwise forward multivariate logistic regression analyses were performed	119	138	ANALYTICAL_METHOD	logistic regression
2% of PGx- (24/215) participants in the I-PICC Study were prescribed Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline-concordant statins (Δ2	69	120	DATABASE	Clinical Pharmacogenetics Implementation Consortium
No statistically significant difference was found between the analysis and NGS	75	78	TECHNIQUE	NGS
In this study, screening, confirmation and validation of mismatch allele-specific (AS) forward (F)-primers are executed to establish a quadruplex amplification analysis (real-time PCR) for discrimination of CYP2D6*10, ADRB1, NPPA and CYP3A5*3 genotypes associated with hypertensive pharmacogenomics	180	183	TECHNIQUE	PCR
Conclusion: Given the lack of evidence of an effective PGx delivery models, this study will provide preliminary evidence regarding a pharmacist-delivered approach	45	54	CHALLENGE	effective
It showed good performance, but failed to attract attention, likely, in relation with lack of clear clinical benefit	94	99	CHALLENGE	clear
It showed good performance, but failed to attract attention, likely, in relation with lack of clear clinical benefit	100	108	CHALLENGE	clinical
In 7,649 unrelated African-ancestry (AFR) and 326,214 unrelated European-ancestry (EUR) participants from the UK Biobank, we associated pharmacogene haplotypes from 50 genes with 265 (EUR) and 17 (AFR) medication use phenotypes using generalized linear models	234	252	ANALYTICAL_METHOD	generalized linear
In this study, we estimated the coefficient of variation (CV) for the intrinsic hepatic clearance of tolbutamide by CYP2C9 for each CYP2C9 genotype using previously reported area under the blood concentration curve (AUC) and oral clearance (CL<sub>oral</sub>) values in a Monte Carlo simulation with a dispersion model	272	283	ANALYTICAL_METHOD	Monte Carlo
Using a DNA microarray, a prominant upregulation of heme oxygenase-1 (HO-1) and heat shock protein (HSP) 72 mRNAs were observed in the basilar artery of a murine vasospasm model	12	22	TECHNIQUE	microarray
It then addresses the need for regulatory oversight of the approval of race-based pharmacogenomic products	31	51	CHALLENGE	regulatory oversight
This study was designed to develop a high-resolution melting (HRM) analysis-based cardiovascular (CV) pharmacogenetics (PGx) genotyping panel for the Canon DNA Genetic Analyzer multiplex genotyping platform and cross-validate its performance with the TaqMan<sup>®</sup>-based OpenArray<sup>®</sup> method	62	65	TECHNIQUE	HRM
Next-generation sequencing (NGS) has been increasingly popular in genomics studies over the last decade, as new sequencing technology has been created and improved	28	31	TECHNIQUE	NGS
Recently, NGS started to be used in clinical oncology to improve cancer therapy through diverse modalities ranging from finding novel and rare cancer mutations, discovering cancer mutation carriers to reaching specific therapeutic approaches known as personalized medicine (PM)	10	13	TECHNIQUE	NGS
Currently, NGS can speed up in the early diagnosis of diseases and discover pharmacogenetic markers that help in personalizing therapies	11	14	TECHNIQUE	NGS
Despite the tremendous growth in our understanding of genetics, NGS holds the added advantage of providing more comprehensive picture of cancer landscape and uncovering cancer development pathways	64	67	TECHNIQUE	NGS
In this review, we provided a complete overview of potential NGS applications in scientific and clinical oncology, with a particular emphasis on pharmacogenomics in the direction of precision medicine treatment options	61	64	TECHNIQUE	NGS
Another key barrier is the lack of incentives for the private sector to invest in the development and licensing of PGx diagnostic tests for improving the safety and efficacy of out-of-patent drugs	165	173	CHALLENGE	efficacy
We focus on evidence-based clinical guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC<sup>®</sup>) to highlight relevant drug-gene pairs, including proton pump inhibitors and selective serotonin reuptake inhibitors and cytochrome P450 (CYP) 2C19, ondansetron and CYP2D6, 6-mercaptopurine and <i>TMPT</i> and Nudix hydrolase 15 (<i>NUDT15</i>), and budesonide and tacrolimus and CYP3A5	64	115	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To account for human complexity, multicomponent biomarker panels encompassing genetic, personal, and environmental factors can guide diagnosis and therapies, increasingly involving artificial intelligence to cope with extreme data complexities	181	204	ANALYTICAL_METHOD	artificial intelligence
009, logistic regression), when comparing "best" and "worst" risk groups	5	24	ANALYTICAL_METHOD	logistic regression
Genetic association studies may improve our understanding of how genetic variation affects skin cancer risk and potentially guide immunosuppressive treatment and skin cancer screening in at risk individuals	0	19	ANALYTICAL_METHOD	Genetic association
Multiple linear regression (MLR) and machine learning techniques in pharmacogenetic algorithm-based warfarin dosing have been reported	37	53	ANALYTICAL_METHOD	machine learning
In this literature-based study, we compared the performances of eight machine learning techniques with those of MLR in a large, racially-diverse cohort	70	86	ANALYTICAL_METHOD	machine learning
However, there is a lack of consensus on the level of evidence required to justify the use of pharmacogenomic testing in clinical practice	121	129	CHALLENGE	clinical
In the cardiovascular field, this lack of agreement has led to somewhat contradicting recommendations by different organizations regarding the clinical utility and use of pharmacogenomic tests or information	143	151	CHALLENGE	clinical
This paper highlights three major challenges facing genomics-enabled learning health care systems, as they pertain to ancestrally diverse populations: inequality in the utility of genomic medicine; lack of access to pharmacogenomics in clinical care; and inadequate incorporation of social and environmental data into the electronic health care record (EHR)	236	244	CHALLENGE	clinical
Despite advances in technology and guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) that focus on how to use pharmacogene test results, hurdles remain that have delayed the widespread application of pharmacogenomics in clinical practice	55	106	DATABASE	Clinical Pharmacogenetics Implementation Consortium
These hurdles include a lack of prospective randomized controlled trials to address the utility of pharmacogenomics on clinical outcomes, what the clinical algorithm for pharmacogenomics should be, and whether pharmacogenomics is cost-effective	119	127	CHALLENGE	clinical
These hurdles include a lack of prospective randomized controlled trials to address the utility of pharmacogenomics on clinical outcomes, what the clinical algorithm for pharmacogenomics should be, and whether pharmacogenomics is cost-effective	235	244	CHALLENGE	effective
The adjusted hazard ratio (HR) in the Cox regression model was calculated	38	41	ANALYTICAL_METHOD	Cox
Genetic analyses of CYP3A4, CYP3A5, and CYP2D6 alleles were carried out by the polymerase chain reaction (PCR)	79	104	TECHNIQUE	polymerase chain reaction
Applying knowledge discovery methods from the area of data mining and machine-learning to this comprehensive set of HCV therapy modulating genes, relating the HCV genes to the world wide knowledge on genes given in the form of the Gene Ontology (GO) knowledge base, found that the relevant genes belong to the GO subcategories of "inflammatory response" and "immune response" and "response to virus"	231	244	DATABASE	Gene Ontology
Applying knowledge discovery methods from the area of data mining and machine-learning to this comprehensive set of HCV therapy modulating genes, relating the HCV genes to the world wide knowledge on genes given in the form of the Gene Ontology (GO) knowledge base, found that the relevant genes belong to the GO subcategories of "inflammatory response" and "immune response" and "response to virus"	246	248	DATABASE	GO
Applying knowledge discovery methods from the area of data mining and machine-learning to this comprehensive set of HCV therapy modulating genes, relating the HCV genes to the world wide knowledge on genes given in the form of the Gene Ontology (GO) knowledge base, found that the relevant genes belong to the GO subcategories of "inflammatory response" and "immune response" and "response to virus"	54	65	ANALYTICAL_METHOD	data mining
<b>Background:</b> Administration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education	71	79	CHALLENGE	clinical
The advancement of next-generation sequencing (NGS) technologies provides opportunities for large-scale Pharmacogenetic (PGx) studies and pre-emptive PGx testing to cover a wide range of genotypes present in diverse populations	47	50	TECHNIQUE	NGS
However, NGS-based PGx testing is limited by the lack of comprehensive computational tools to support genetic data analysis and clinical decisions	9	12	TECHNIQUE	NGS
However, NGS-based PGx testing is limited by the lack of comprehensive computational tools to support genetic data analysis and clinical decisions	128	136	CHALLENGE	clinical
COMPARE and hierarchical cluster analyses of microarray-based transcriptomic mRNA expression data of 59 tumor cell lines revealed a specific gene expression profile predicting sensitivity or resistance towards honokiol	12	32	ANALYTICAL_METHOD	hierarchical cluster
To gain insight into possible modes of collateral sensitivity, we performed in silico molecular docking studies of honokiol to EGFR and EGFR-related downstream signal proteins	86	103	ANALYTICAL_METHOD	molecular docking
COMPARE and hierarchical cluster analyses of microarray-based transcriptomic mRNA expression data of 59 tumor cell lines revealed a specific gene expression profile predicting sensitivity or resistance towards honokiol	45	55	TECHNIQUE	microarray
The final set of key findings and recommendations provided here address issues related to the lack of standardization of complex tests, preclinical issues, establishing clinical validity and utility, pharmacogenomics considerations, and knowledge gaps	139	147	CHALLENGE	clinical
Minor allele frequencies (MAF) for the indicated SNPs for European, South Asian and East Asian populations were obtained from the NCBI website (https://www	130	134	DATABASE	NCBI
However, with the rise of new technologies, as next generation sequencing, allowing to obtain pre-emptive genetic information, one must be aware that the question will no longer be whether to genotype or not but rather whether or not to use the information already there	47	73	TECHNIQUE	next generation sequencing
The main reason is probably the lack of formal proof that clinical outcome really improves after genotype-based dosing	58	66	CHALLENGE	clinical
In this study, using MCF-7 breast cancer cells as a model, we employed quantitative real-time PCR (qRT-PCR), one of the most reliable methods for gene expression analysis in many research fields, to evaluate and to determine the most reliable reference genes for pharmacogenomics and toxicogenomics studies as well as for small RNA expression analysis	94	97	TECHNIQUE	PCR
In our assay DNA extraction and amplification are combined in one single step (direct PCR protocol), which is performed directly on the biological sample without the need of extraction and sequencing passages	86	89	TECHNIQUE	PCR
HLA typing by next-generation sequencing (NGS) has recently been adopted by clinical laboratories for transplantation testing, as it provides unambiguous and cost-effective HLA typing	42	45	TECHNIQUE	NGS
The goal of this study was to evaluate the feasibility of using NGS-based HLA-B and DQ genotyping for clinical HLA disease association testing, and provide direct comparison with the currently used clinical tests, including SSOP genotyping, and real-time PCR with melting curve analysis	64	67	TECHNIQUE	NGS
Our data show that HLA typing by NGS is superior to the existing clinical methods for identifying HLA alleles associated with disease or drug hypersensitivity, and offers a viable approach for high volume clinical diagnostic laboratories	33	36	TECHNIQUE	NGS
The increasing number of HLA alleles discovered generated a list of ambiguities that cannot be resolved with the current clinical assays, which commonly include sequence-specific oligonucleotide probe (SSOP) genotyping, and real-time PCR with melting curve analysis	234	237	TECHNIQUE	PCR
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	161	184	ANALYTICAL_METHOD	artificial intelligence
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	189	205	ANALYTICAL_METHOD	machine learning
These SNPs were determined using polymerase chain reaction/restricted fragment length polymorphism and SNaPshot genotyping	33	58	TECHNIQUE	polymerase chain reaction
EVIDENCE ACQUISITION A literature review was conducted (of original articles, published theses, clinical reports and bibliographic review studies, from 2000 to 2018, in Spanish and English listed in MEDLINE/PubMed, SciELO, LILACS, PharmGKB and Google Scholar) with the following key words: pharmacogenetics, human immunodeficiency virus, anti-retroviral agents, genetic polymorphism, genetic techniques, pharmacogenomic variants	231	239	DATABASE	PharmGKB
In the present study, we used whole exome sequencing data from 50,726 participants, as derived from the DiscovEHR cohort, to identify pharmacogenomic variants of potential clinical relevance, according to their occurrence within the PharmGKB database	233	241	DATABASE	PharmGKB
We used the anti-epileptic drug brivaracetam as a case study and combine a hybrid data/knowledge-driven feature extraction with machine learning to systematically integrate clinical and genetic data from a clinical discovery dataset (n = 235 patients)	128	144	ANALYTICAL_METHOD	machine learning
To our knowledge, our model represents the first retrospectively validated machine learning model linking drug mechanism of action and the genetic, clinical and demographic background in epilepsy patients to clinical drug response	75	91	ANALYTICAL_METHOD	machine learning
Hence, it provides a blueprint for how machine learning-based multimodal data integration can act as a driver in achieving the goals of precision medicine in fields such as neurology	39	55	ANALYTICAL_METHOD	machine learning
To do so, we used the International HapMap project release 27 Data and Pharmacogenomics Knowledge Base (PharmGKB) database	36	42	DATABASE	HapMap
To do so, we used the International HapMap project release 27 Data and Pharmacogenomics Knowledge Base (PharmGKB) database	104	112	DATABASE	PharmGKB
Second, we divided DR genes from PharmGKB into two groups based on the degree of population differentiation as assessed by Fst: genes with a high level of differentiation (HD gene group) and genes with a low level of differentiation (LD gene group)	33	41	DATABASE	PharmGKB
Our analysis suggests that the HD gene group from PharmGKB is associated with cell communication and drug binding	50	58	DATABASE	PharmGKB
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses for target proteins were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) database	41	45	DATABASE	KEGG
The candidate therapeutic targets of ASCVD were screened by Pharmacogenomics Knowledgebase (PharmGKB) and Comparative Toxicogenomics Database (CTD)	92	100	DATABASE	PharmGKB
The following single nucleotide polymorphisms (SNPs) were genotyped; C1236T, C3435T, G2677T/A in MDR1 gene and A6986G in CYP3A5 gene, using PCR-RFLP method and validated by direct gene sequencing	140	143	TECHNIQUE	PCR
This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium	192	243	DATABASE	Clinical Pharmacogenetics Implementation Consortium
To explore the effects of HDAC inhibition on HERV transcription, an unbiased pharmacogenomics approach (total RNA-Seq) was used to evaluate HERV expression following the exposure of primary CD4<sup>+</sup> T cells to a high dose of vorinostat	110	117	TECHNIQUE	RNA-Seq
Four online databases (PubMed, Cochrane CENTRAL, PsycINFO, and PharmGKB) were searched for articles on polymorphisms of SLC6A4 including 5-HTTLPR and STin2 by using a systematic approach	63	71	DATABASE	PharmGKB
Finally, comparing our data with those of three other populations of the HapMap project revealed ethnic specificity of the UGT1 genetic diversity in Chinese	73	79	DATABASE	HapMap
Responses were assessed using multivariable logistic regression	44	63	ANALYTICAL_METHOD	logistic regression
The Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group have proposed a standardized translation scheme based on the activity score system aiming to facilitate more consistent CYP2D6 genotype-phenotype translation	4	55	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group have proposed a standardized translation scheme based on the activity score system aiming to facilitate more consistent CYP2D6 genotype-phenotype translation	60	96	DATABASE	Dutch Pharmacogenetics Working Group
Yet, the use of pharmacogenomics in routine clinical care is minimal, partly due to the lack of efficient and effective use of existing evidence	44	52	CHALLENGE	clinical
Yet, the use of pharmacogenomics in routine clinical care is minimal, partly due to the lack of efficient and effective use of existing evidence	110	119	CHALLENGE	effective
Furthermore, molecular docking analysis of the chemotherapy drug, docetaxel, with CYP1B1 and ABCB1 revealed robust molecular interactions, with binding energies of -20	13	30	ANALYTICAL_METHOD	molecular docking
poor responders, with cDNAs synthesized from isolated RNAs subjected to qPCR analysis	72	76	TECHNIQUE	qPCR
The role of immunomodulatory treatments in SJS/TEN is at present not supported by robust evidence from systematic reviews given the lack of randomized controlled trials	82	88	CHALLENGE	robust
To accommodate various genetic architectures covering different effect directions, signal sparseness and across-trait correlation structures, we further propose an omnibus mtPRS method (mtPRS-O) by combining P values from mtPRS-PCA, mtPRS-ML (mtPRS based on machine learning) and stPRSs using Cauchy Combination Test	258	274	ANALYTICAL_METHOD	machine learning
Genome-wide association (GWA) analyses involving single nucleotide polymorphisms (SNPs), mRNA, and microRNAs microarray data were assessed for association with area under the cytotoxicity dose response curve (AUC) of two mTOR inhibitors in 272 human lymphoblastoid cell lines (LCLs)	109	119	TECHNIQUE	microarray
The identified symbols are supplemented with information from the GenoDB knowledgebase	66	72	DATABASE	GenoDB
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	14	20	DATABASE	GenoDB
GenoDB currently contains information regarding 59,905 gene symbols, 5633 drug-gene relationships, 5981 gene-disease relationships, and 713 pathways	0	6	DATABASE	GenoDB
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	111	120	DATABASE	Hugo Gene
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	82	86	DATABASE	KEGG
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	67	73	DATABASE	Medgen
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	47	51	DATABASE	NCBI
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	88	96	DATABASE	PharmGKB
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	98	105	DATABASE	Uniprot
Specifically, about one in four patients on MTX shows lack of sufficient therapeutic efficacy which may lead to drug discontinuation	85	93	CHALLENGE	efficacy
Recent technological advances in mass spectrometry-based metabolomics and the establishment of omic-scale exposure assessment will enable a broader and systemic investigation of these interactions	33	56	TECHNIQUE	mass spectrometry-based
; Identification of CYP2B6*6 allelic and genotype frequencies in 100 volunteers was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique	100	125	TECHNIQUE	polymerase chain reaction
We found six rSNPs in five genes (<i>CAMP</i>/cathelicidin, <i>S100A7/</i>psoriasin<i>, IL17C, IL1</i>7RA and <i>TNF</i>) and each was confirmed as true rSNP in at least one public eQTL database including GTEx portal and ENCODE (Phase 3)	181	185	TECHNIQUE	eQTL
Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning	93	116	ANALYTICAL_METHOD	artificial intelligence
The present report involves a whole-exome sequencing (WES), in a patient affected by rosuvastatin-induced rhabdomyolysis	30	52	TECHNIQUE	whole-exome sequencing
The whole-exome sequencing and bioinformatics analysis presented here represents an innovative way to identify genomic variants contributing with RIR´s origin and evokes the polygenic nature of adverse drug reactions	4	26	TECHNIQUE	whole-exome sequencing
5-FU clearance (by ultra-HPLC with tandem mass spectrometry) was measured in 3/11 patients	35	59	TECHNIQUE	tandem mass spectrometry
The CPNDS database consisted of 93,974 reports of medication use, including 10,475 reports of ADRs, of which 72	4	9	DATABASE	CPNDS
The CPNDS database is a valuable resource to identify clinical and genomic predictors of ADRs	4	9	DATABASE	CPNDS
Here, we address this issue by analyzing gene and genetic variant annotations from multiple expert-curated knowledge databases, including PharmGKB, CPIC, ClinGen and ClinVar	166	173	DATABASE	ClinVar
Here, we address this issue by analyzing gene and genetic variant annotations from multiple expert-curated knowledge databases, including PharmGKB, CPIC, ClinGen and ClinVar	138	146	DATABASE	PharmGKB
To define the polymorphisms that can be applied, we rely on three fundamental cornerstones: the recommendations of drug regulatory agencies; the implementation guidelines prepared by expert consortia in PGx and information from clinical annotations (the drug/polymorphism relation) according to the scientific level of evidence assigned by PharmGKB experts	340	348	DATABASE	PharmGKB
This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of clopidogrel based on CYP2C19 genotype and includes expanded indications for CYP2C19 genotype-guided antiplatelet therapy, increased strength of recommendation for CYP2C19 intermediate metabolizers, updated CYP2C19 genotype to phenotype translation, and evidence from an expanded literature review (updates at www	40	91	DATABASE	Clinical Pharmacogenetics Implementation Consortium
For the advances of pediatric oncology next generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed	39	65	TECHNIQUE	next generation sequencing
For the advances of pediatric oncology next generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed	67	70	TECHNIQUE	NGS
However, little is known about demographic and clinical characteristics that differentiate families who decline enrollment in pediatric oncology NGS research	145	148	TECHNIQUE	NGS
However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine	50	58	CHALLENGE	clinical
However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine	21	30	CHALLENGE	diversity
Large-scale multidimensional cancer genomic and pharmacological profiles have been created by several large consortium projects, including NCI-60, GDSC and DepMap, providing novel opportunities for data mining and further understanding of intrinsic therapeutic response mechanisms	198	209	ANALYTICAL_METHOD	data mining
The single nucleotide polymorphism genotypes most related to drug metabolism were investigated by polymerase chain reaction and Sanger sequencing	98	123	TECHNIQUE	polymerase chain reaction
The olanzapine pharmacokinetics of 19 healthy volunteers treated with orally disintegrating tablets were determined using high-performance liquid chromatography-tandem mass spectrometry	161	185	TECHNIQUE	tandem mass spectrometry
, the use of artificial intelligence and machine learning is required to be attuned to the development of preventive and personalized medicine	13	36	ANALYTICAL_METHOD	artificial intelligence
, the use of artificial intelligence and machine learning is required to be attuned to the development of preventive and personalized medicine	41	57	ANALYTICAL_METHOD	machine learning
The best example is the application of whole-exome sequencing when identifying aberrant fetuses with healthy karyotypes and chromosomal microarray analysis in complicated pregnancies	136	146	TECHNIQUE	microarray
The best example is the application of whole-exome sequencing when identifying aberrant fetuses with healthy karyotypes and chromosomal microarray analysis in complicated pregnancies	39	61	TECHNIQUE	whole-exome sequencing
Individual analysis consists of a report that is readily comprehensible to patients and practioners who have basic knowledge in pharmacology, a table that summarizes variants and potential affected drug response according to the US Food and Drug Administration pharmacogenomic biomarker labeled drug list and PharmGKB, and visualization of a gene-drug-target network	309	317	DATABASE	PharmGKB
Batch submission facilitates multivariate analysis or data mining of targeted groups	54	65	ANALYTICAL_METHOD	data mining
This work presents a study of Thai <i>HLA</i> alleles on both <i>HLA</i> class I and II genes from 470 unrelated Thai individuals by means of polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) in which oligonucleotide probes along the stretches of <i>HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1</i> genes were genotyped	203	206	TECHNIQUE	PCR
This work presents a study of Thai <i>HLA</i> alleles on both <i>HLA</i> class I and II genes from 470 unrelated Thai individuals by means of polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) in which oligonucleotide probes along the stretches of <i>HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1</i> genes were genotyped	142	167	TECHNIQUE	polymerase chain reaction
The MinION nanopore sequencing device opens the opportunity to cost-effective and point-of-care DNA sequencing	4	30	TECHNIQUE	MinION nanopore sequencing
Through the judicious implementation of DNA pooling on SNP microarrays, it vividly demonstrates that informative genome-wide pharmacogenomic screens can be performed at a fraction of the cost of individual microarray genotyping	59	69	TECHNIQUE	microarray
Pharmacogenomics guidelines have been published by some international scientific consortia such as the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) strongly suggesting a pre-treatment dose adjustment of irinotecan based on UGT1A1*28 genotype and of fluoropyrimidines based on some DPYD genetic variants, to increase treatment safety	170	206	DATABASE	Dutch Pharmacogenetics Working Group
<b>Introduction:</b> Most hepatically cleared drugs are metabolized by cytochromes P450 (CYPs), and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provide curated clinical references for CYPs to apply individual genome data for optimized drug therapy	100	151	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Extensive in vitro cancer drug screening datasets have enabled scientists to identify biomarkers and develop machine learning models for predicting drug sensitivity	109	125	ANALYTICAL_METHOD	machine learning
CREAMMIST provides easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for experiments, and training robust machine learning models	223	239	ANALYTICAL_METHOD	machine learning
The random forest is the most used algorithm; it comprises several decision trees, reduces the training set's overfitting, and makes precise predictions	4	17	ANALYTICAL_METHOD	random forest
Recent pharmacogenomic studies on lithium response have provided promising findings, suggesting that the integration of genome-wide investigations with deep phenotyping, in silico analyses and machine learning could lead us closer to personalized treatments for BD	193	209	ANALYTICAL_METHOD	machine learning
This study aims to develop a machine learning model incorporating genomic data such as Single-Nucleotide Polymorphisms (SNPs) of Human Sulfatase 1 (SULF1) with a CT radiomic model based on pre-treatment CT images, to predict platinum resistance for ovarian cancer (OC) treatment	29	45	ANALYTICAL_METHOD	machine learning
A breakthrough in next generation sequencing (NGS) in the last decade provided an unprecedented opportunity to investigate genetic variations in humans and their roles in health and disease	18	44	TECHNIQUE	next generation sequencing
A breakthrough in next generation sequencing (NGS) in the last decade provided an unprecedented opportunity to investigate genetic variations in humans and their roles in health and disease	46	49	TECHNIQUE	NGS
NGS offers regional genomic sequencing such as whole exome sequencing of coding regions of all genes, as well as whole genome sequencing	0	3	TECHNIQUE	NGS
NGS can also be used to predict the response to or adverse effects of drugs or to calculate appropriate drug dosage	0	3	TECHNIQUE	NGS
Here, we review the basics of NGS technologies and their application in human diseases to foster human healthcare and personalized medicine	30	33	TECHNIQUE	NGS
The justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75	77	128	DATABASE	Clinical Pharmacogenetics Implementation Consortium
There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice	160	168	CHALLENGE	clinical
gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling); 3) expert consensus guidelines for dosing or identifying hypersensitivity risk for these drugs are available from the National Institutes of Health (NIH)-supported Clinical Pharmacogenetics Implementation Consortium (CPIC, www	250	301	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The results were compared with estimates using genome-wide HapMap data for the same individuals	59	65	DATABASE	HapMap
This clinical guideline for caregivers prescribing psychotropic drugs is the product of a broad collaboration of professionals from different disciplines, making use of the information available at the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) so far	254	305	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This clinical guideline for caregivers prescribing psychotropic drugs is the product of a broad collaboration of professionals from different disciplines, making use of the information available at the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) so far	202	238	DATABASE	Dutch Pharmacogenetics Working Group
Next-generation sequencing (NGS) represents a rapid, relatively inexpensive, large-scale DNA sequencing technology with potential relevance as a comprehensive pharmacogenetic genotyping platform to identify genetic variation related to drug therapy	28	31	TECHNIQUE	NGS
However, many obstacles remain before the clinical use of NGS-based test results, including technical challenges, functional interpretation, and strict requirements for diagnostic tests	58	61	TECHNIQUE	NGS
Advanced computational analyses, high-throughput screening methodologies, and generation of shared resources with cell-based and clinical information will facilitate the integration of NGS data into candidate genotyping approaches, likely enhancing future drug phenotype predictions in patients	185	188	TECHNIQUE	NGS
Plasma concentrations of ticagrelor and AR-C124910XX were determined by the high performance liquid chromatography-tandem mass spectrometry method	115	139	TECHNIQUE	tandem mass spectrometry
With machine learning and integrated pharmacogenomics and metabolomics, we demonstrate that KA efficacy is not determined by the status of individual genes, but by the quantitative extent of the WE, leading to a therapeutic window in vivo	5	21	ANALYTICAL_METHOD	machine learning
PBIN also has considerable predictive power, and accounts readily for the large differences in drug uptake between tissues, cells and species, in accounting for the metabolite-likeness of marketed drugs, in pharmacogenomics, and in providing a straightforward explanation for the late-stage appearance of toxicity and of lack of efficacy during drug discovery programmes despite macroscopically adequate pharmacokinetics	329	337	CHALLENGE	efficacy
Moreover, therapeutic choices are limited by the lack of indication for a number of analgesic drugs due to the challenge of conducting clinical trials in children	135	143	CHALLENGE	clinical
We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to detect 86 very important pharmacogene (VIP) variants in Sherpas and compared the genotypic frequencies of these variants with HapMap populations	219	225	DATABASE	HapMap
Overall, 59 of the 60 previously reported variants in the HapMap populations were found in our study	58	64	DATABASE	HapMap
There are occasionally differences in phenotype assignment and medication recommendations between commercial laboratories and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	130	181	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The objectives of the study include the determination of the frequency of genetic variants (CYP2C9*2, CYP2C9*3, and CYP2C19*2) of selected enzymes using allele-specific polymerase chain reaction (ASPCR) and its comparison with Indian as well as global past frequencies	169	194	TECHNIQUE	polymerase chain reaction
We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD)	32	48	ANALYTICAL_METHOD	machine learning
These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers	31	47	ANALYTICAL_METHOD	machine learning
The range of new methods includes modifications of several conventional techniques such as PCR, mass spectrometry, and sequencing as well as more innovative technologies such as fluorescence resonance energy transfer and microarrays	91	94	TECHNIQUE	PCR
Our aim was to estimate the potential impact of genotyping for the HLA risk alleles incorporated in the Dutch Pharmacogenetics Working Group (DPWG) guidelines in The Netherlands	104	140	DATABASE	Dutch Pharmacogenetics Working Group
In conclusion, the advance in this field of modern pharmacology, which allows one to predict the outcome of the treatments and to develop more effective and selective agents able to overcome the lack of effect associated with the existence of some genetic variants, is required to step forward toward a more personalized medicine	143	152	CHALLENGE	effective
90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines	93	144	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants <i>CYP2C9*5</i>, <i>CYP2C9*6</i> and <i>CYP2C9*11</i>, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort	0	51	DATABASE	Clinical Pharmacogenetics Implementation Consortium
US FDA and Dutch Pharmacogenetics Working Group guidelines are based on <i>CYP2C9*2</i> and <i>CYP2C9*3</i> only, hence, unlikely useful in this cohort, where such variants were not detected	11	47	DATABASE	Dutch Pharmacogenetics Working Group
We argue for a new framework for personalised medicine analytics that capitalises on more detailed patient-level data and leverages recent advances in causal inference and machine learning tailored towards decision support applicable to critically ill patients	172	188	ANALYTICAL_METHOD	machine learning
Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA	168	219	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples	20	23	TECHNIQUE	PCR
Slow adoption of PGx testing in routine clinical care is due to implementation barriers, including long test turnaround times, lack of integration in the electronic health record (EHR), and ambiguity in test cost coverage	40	48	CHALLENGE	clinical
<b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively	188	207	ANALYTICAL_METHOD	logistic regression
Herein, the process of personalized medicine is presented together with the options that can be offered in health care systems with limited resources for diseases like rheumatoid arthritis and type 1 diabetes	132	149	CHALLENGE	limited resources
While HLA-B*57:01 testing is usually provided by pharmacogenetics, genetics or blood transfusion services, clinical virology laboratories can be an optimal opportunity for HLA-B*57:01 testing since they receive blood samples for routine HIV monitoring and have the expertise for convenient and less expensive PCR-based point mutation assays	309	312	TECHNIQUE	PCR
DNA from 114 cluster headache patients and 570 non-related controls, representing a general Southeastern European Caucasian (SEC) population, was extracted from buccal swabs and genotyped using real-time PCR	204	207	TECHNIQUE	PCR
Applying polymerase chain reaction and restriction fragment length polymorphism techniques, the prevalence of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms was evaluated in 65 acute lymphoblastic leukemia patients	9	34	TECHNIQUE	polymerase chain reaction
Evidence-based guidelines available for precision pharmacotherapy have been proposed, including guidelines from Clinical Pharmacogenetics Implementation Consortium, the Pharmacogenomics Knowledge Base National Institute of General Medical Sciences of the National Institutes of Health, and the US Food and Drug Administration	112	163	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network (Réseau) of Pharmacogenetics (RNPGx) were selected	53	104	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network (Réseau) of Pharmacogenetics (RNPGx) were selected	4	40	DATABASE	Dutch Pharmacogenetics Working Group
Furthermore, we performed COMPARE and hierarchical cluster analyses of transcriptome-wide mRNA expression profiles of the National Cancer Institute tumor cell line panel	38	58	ANALYTICAL_METHOD	hierarchical cluster
To perform in silico molecular docking studies, we first generated homology models for human P-glycoprotein and ABCB5 based on the crystal structure of murine P-glycoprotein	21	38	ANALYTICAL_METHOD	molecular docking
Molecular docking of apigenin bound to the NDBs of P-glycoprotein and ABCB5 in molecular docking studies	0	17	ANALYTICAL_METHOD	molecular docking
This study genotyped 53 VIP variants of 26 genes in 200 independent Hui individuals based on the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB)	151	159	DATABASE	PharmGKB
Besides, using the PharmGKB database, we identified several VIP variants that may alter the drug metabolism of ibuprofen, rofecoxib (PTGS2), captopril (ACE), citalopram, and escitalopram (CYP2D6)	19	27	DATABASE	PharmGKB
The overprediction observed by the published model may represent overfitting to the initial cohort, possibly limiting generalizability	118	134	CHALLENGE	generalizability
Patients receiving CYP2C19 genotyping after PCI were included and stratified into 2 groups (PGx-optimal vs PGx-suboptimal P2Y<sub>12</sub> inhibitor prescribed) on the basis of CPIC (Clinical Pharmacogenetics Implementation Consortium) recommendations	183	234	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In addition, the participants were divided into dexmedetomidine sensitive or dexmedetomidine tolerant groups based on whether they had a Ramsay score of at least four within 20 min, and <i>CYP2A6</i> rs28399433 was identified to have a significant influence on the dexmedetomidine sedation sensitivity by logistic regression with Plink software [<i>p</i> = 0	305	324	ANALYTICAL_METHOD	logistic regression
Beyond methods involving expression quantitative trait locus analysis and massively parallel reporter assays, we suggest the use of in silico mutagenesis through machine learning methods to understand the roles of variants in transcriptional regulation	162	178	ANALYTICAL_METHOD	machine learning
Since 2017, China, the United States, and the European Union have successively issued national-level artificial intelligence (AI) strategic development plans, and the human history is about to witness the 4th industrial revolution with the theme of "intelligence"	101	124	ANALYTICAL_METHOD	artificial intelligence
GST genotyping was performed by multiplex polymerase chain reaction-based methods	42	67	TECHNIQUE	polymerase chain reaction
Graph structures have received increasing attention owing to their outstanding performance in machine learning	94	110	ANALYTICAL_METHOD	machine learning
With the release of high-precision protein structure prediction artificial intelligence, large-scale high-precision protein structure prediction and docking have become possible	64	87	ANALYTICAL_METHOD	artificial intelligence
Then, QuickVina 2 is used for molecular docking between the proteins and drugs	30	47	ANALYTICAL_METHOD	molecular docking
PGx alert design varied, with some consensus around the use of active, post-test alerts to convey Clinical Pharmacogenetics Implementation Consortium recommendations	98	149	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In recent years, numerous genetic polymorphisms have been linked with reduced platelet inhibition and lack of clinical efficacy of antiplatelet drugs, particularly clopidogrel and aspirin	119	127	CHALLENGE	efficacy
In recent years, numerous genetic polymorphisms have been linked with reduced platelet inhibition and lack of clinical efficacy of antiplatelet drugs, particularly clopidogrel and aspirin	110	118	CHALLENGE	clinical
Genotype-inferred phenotyping of <i>CYP2D6</i> and <i>CYP2C19</i> was carried out as per Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	89	140	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Facilitators included the availability of and adherence to Dutch Pharmacogenetics Working Group guidelines	59	95	DATABASE	Dutch Pharmacogenetics Working Group
While clinical decision support (CDS) is available and valued in our medical center, the lack of availability of CDS may be an important barrier within Dutch healthcare in general	6	14	CHALLENGE	clinical
Currently available biomarkers for clinical practice - for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) - are limited due to invasiveness or lack of specificity	35	43	CHALLENGE	clinical
Variations in CYP2D6 have been implicated in drug response and according to the Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, dosing for CYP2D6 substrates should be based on variants carried by individuals	80	131	DATABASE	Clinical Pharmacogenetics Implementation Consortium
There is largely an absence of validated evidence-based therapies in term- and preterm newborn infants, due to a lack of pharmacological clinical trials	137	145	CHALLENGE	clinical
Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity	0	19	ANALYTICAL_METHOD	Genetic association
Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq™ panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes	55	81	TECHNIQUE	next generation sequencing
After two decades of pharmacogenetic research, variants in genes coding for the cytochromes involved in ADs metabolism (CYP2D6 and CYP2C19) are now considered biomarkers with sufficient scientific support for clinical application, despite the lack of conclusive cost/effectiveness evidence	209	217	CHALLENGE	clinical
After two decades of pharmacogenetic research, variants in genes coding for the cytochromes involved in ADs metabolism (CYP2D6 and CYP2C19) are now considered biomarkers with sufficient scientific support for clinical application, despite the lack of conclusive cost/effectiveness evidence	251	261	CHALLENGE	conclusive
Genotyping was performed by polymerase chain reaction	28	53	TECHNIQUE	polymerase chain reaction
Since the completion of both the Human Genome Project and the International HapMap project, the development of pharmacogenomics has been greatly facilitated	76	82	DATABASE	HapMap
Pharmacogenomics involve the study of the role of genomic variation in individual variations in drug response, a phenotype that varies from potentially life-threatening adverse drug reactions to an equally serious lack of therapeutic efficacy	234	242	CHALLENGE	efficacy
Data integration, data mining, and knowledge discovery (KD) methods would enable the simulation of complex systems and dynamical networks to establish predictive models for achieving predictive, preventive, and personalized medicine	18	29	ANALYTICAL_METHOD	data mining
In the present study, conventional polymerase chain reaction (PCR) based amplification using gene specific primers and Sanger sequencing were performed to identify CDA variants in 50 healthy individuals from Indian sub-population	62	65	TECHNIQUE	PCR
In the present study, conventional polymerase chain reaction (PCR) based amplification using gene specific primers and Sanger sequencing were performed to identify CDA variants in 50 healthy individuals from Indian sub-population	35	60	TECHNIQUE	polymerase chain reaction
Importantly, only 50%-75% of patients have been shown to react adequately to pharmacological interventions, whereas the others experience either a lack of efficacy or suffer from adverse events	155	163	CHALLENGE	efficacy
Here, we introduce a sparse partial least squares (SPLS) framework with or without the network-regularized penalty to identify joint modular patterns demonstrated with a large-scale pairwise gene-expression and drug-response data	28	49	ANALYTICAL_METHOD	partial least squares
SPLS methods could be applied to many biological problems such as the eQTL analysis, which is designed to discover genetic variants that influence downstream gene expression level	70	74	TECHNIQUE	eQTL
COMPARE and hierarchical cluster analyses of transcriptome-wide mRNA expression resulted in a set of 40 genes, which all harbored binding motifs in their promoter sequences for the transcription factor, NF-κB, which is known to be associated with drug resistance	12	32	ANALYTICAL_METHOD	hierarchical cluster
By in silico molecular docking studies, we found that scopoletin bound to NF-κB and its regulator IκB	13	30	ANALYTICAL_METHOD	molecular docking
To translate the pharmacogenetic testing into actionable clinical decisions, the Clinical Pharmacogenetics Implementation Consortium has been developing guidelines for several drug-gene pairs	81	132	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Many machine learning techniques have been demonstrated in this domain	5	21	ANALYTICAL_METHOD	machine learning
The evolution of pharmacogenomics has paralleled the evolution of genotyping technologies, the completion of the human genome sequencing and the HapMap project	145	151	DATABASE	HapMap
At the Pharmacogenomics Knowledgebase (PharmGKB; www	39	47	DATABASE	PharmGKB
For most channelopathies the therapy is mainly empirical and symptomatic, often limited by lack of efficacy and tolerability for a significant number of patients	99	107	CHALLENGE	efficacy
We compared whole exome sequencing (WES, n = 176 patients) and whole genome sequencing (WGS, n = 68) and clinical genotyping (DMET array-based approach) for interrogating 13 genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines	185	236	DATABASE	Clinical Pharmacogenetics Implementation Consortium
The LifeTechnologies OpenArray NT genotyping platform and polymerase chain reaction-based methods were used to analyse 204 single nucleotide polymorphisms and five variable number tandem repeats from 30 candidate genes in 692 available DNA samples from this clinical trial	58	83	TECHNIQUE	polymerase chain reaction
We assessed the allelic heterogeneity of gene expression, population specificity of cis expression quantitative trait loci (eQTLs), and eQTL function in luciferase assays in CEU and Yoruba people of Ibadan, Nigeria (YRI) HapMap lymphoblastoid cell lines in 23 resequenced genes	221	227	DATABASE	HapMap
We assessed the allelic heterogeneity of gene expression, population specificity of cis expression quantitative trait loci (eQTLs), and eQTL function in luciferase assays in CEU and Yoruba people of Ibadan, Nigeria (YRI) HapMap lymphoblastoid cell lines in 23 resequenced genes	124	128	TECHNIQUE	eQTL
Five eQTLs were tested for function in luciferase assays and the effect of two KRAS variants was concordant with the eQTL effect	5	9	TECHNIQUE	eQTL
PDAC is an aggressive disease associated with a poor clinical prognosis, weakly effective therapeutic options, and a lack of early detection methods	53	61	CHALLENGE	clinical
PDAC is an aggressive disease associated with a poor clinical prognosis, weakly effective therapeutic options, and a lack of early detection methods	80	89	CHALLENGE	effective
Drug labels containing PGx information were obtained from Drugs@FDA and guidelines from PharmGKB were used to compare the actionability of PGx information in drug labels across therapeutic areas	88	96	DATABASE	PharmGKB
However, although therapeutic efficiency varies greatly among individuals, there is a lack of pharmacogenomic biomarkers that can be used in clinical settings to identify chemosensitive patients and allow stratification	141	149	CHALLENGE	clinical
A number of genes or variants that play a crucial role in drug responses have been designated Very Important Pharmacogenes (VIP) by the PharmGKB database	136	144	DATABASE	PharmGKB
Furthermore, we demonstrate that the method is robust to technical challenges inherent in long-range sequencing of PCR products, including reference alignment bias and PCR chimerism	115	118	TECHNIQUE	PCR
We also explored potential roles of BATF in a pan-cancer cohort by performing immune infiltration, Gene Ontology (GO) enrichment, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis	99	112	DATABASE	Gene Ontology
We also explored potential roles of BATF in a pan-cancer cohort by performing immune infiltration, Gene Ontology (GO) enrichment, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis	179	183	DATABASE	KEGG
The results of GO, immune infiltration, and KEGG analysis revealed that increased BATF expression in tumors participated in modulating immune cell infiltration <i>via</i> immune-related pathways	44	48	DATABASE	KEGG
We conclude that future studies should focus on modern genome-level tools, such as machine learning, polygenic risk scores and genome-wide association study-transcription meta-analyses, instead of focusing on just single variants	83	99	ANALYTICAL_METHOD	machine learning
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group provide therapeutic recommendations for well-known gene-drug pairs	9	60	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group provide therapeutic recommendations for well-known gene-drug pairs	72	108	DATABASE	Dutch Pharmacogenetics Working Group
This review provides a brief overview in a Danish context of the potential of applying pharmacogenomics (PGx) including companion diagnostics (CDx) in daily clinical practice based on the current knowledge and regulation from the FDA and EMA, Summary of Product Characteristics (SPC), PharmGKB (pharmacogenomics knowledge resource providing clinical dosing guidelines) and partly promedicin	285	293	DATABASE	PharmGKB
Formerly adopted to achieve new disease classifications as it is still done, innovative platforms, such as microarrays, genome-wide association studies (GWAS), and next generation sequencing (NGS), have made the progress in pharmacogenetics faster and cheaper than previously expected	164	190	TECHNIQUE	next generation sequencing
Formerly adopted to achieve new disease classifications as it is still done, innovative platforms, such as microarrays, genome-wide association studies (GWAS), and next generation sequencing (NGS), have made the progress in pharmacogenetics faster and cheaper than previously expected	192	195	TECHNIQUE	NGS
Indeed, GWAS and NGS allow the investigation of the human genome, finding interesting associations with putative or unexpected targets, which in turns may represent new therapeutic possibilities	17	20	TECHNIQUE	NGS
A considerable proportion of children experience therapeutic inefficacy or substantial adverse effects, or both, but a lack of reliable clinical indicators and biomarkers to predict treatment response prevents optimization of existing therapies	136	144	CHALLENGE	clinical
The Next Generation Sequencing (NGS) technology, also known as massively parallel sequencing, symbolizes a high-throughput, fast, sensitive and accurate way to study the molecular landscape of a cancer and this has indeed revolutionized endometrial cancer research	32	35	TECHNIQUE	NGS
Understanding the potential, advantages, and limitations of NGS will be crucial for the healthcare providers and scientists in providing the genome-driven care in this era of precision medicine and pharmacogenomics	60	63	TECHNIQUE	NGS
This mini review aimed to compile and critically summarize the recent findings contributed by NGS technology pertaining to EC	75	78	TECHNIQUE	NGS
Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity	0	19	ANALYTICAL_METHOD	Genetic association
Individual genetic differences could contribute to lack of efficacy	59	67	CHALLENGE	efficacy
Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk	12	31	ANALYTICAL_METHOD	logistic regression
Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype	28	47	ANALYTICAL_METHOD	logistic regression
We assigned star alleles with PharmGKB haplotype set translational table	30	38	DATABASE	PharmGKB
Gene-wise variant burden (GVB) scoring enables us to utilize next-generation sequencing (NGS) data to predict 6-MP intolerance in children with ALL	89	92	TECHNIQUE	NGS
GVB analysis demonstrated that 6-MP intolerance in pediatric ALL can be reliably predicted by aggregating NGS-based common, rare, and novel variants together without hampering the predictive power of the conventional haplotype analysis	106	109	TECHNIQUE	NGS
Whole exome sequencing was performed for 244 pediatric ALL patients under 6-MP treatments	0	22	TECHNIQUE	Whole exome sequencing
One of the reasons for this poor implementation is the current lack of evidence of improved clinical outcome with pharmacogenetic testing	92	100	CHALLENGE	clinical
De-identified data set was used to characterize urgent care utilization and to identify presence of 44 actionable pharmacogenetic variants according to the guidelines of the Clinical Pharmacogenetics Implementation Consortium	174	225	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Lack of equitable representation of global genetic diversity has hampered the implementation of genomic medicine in under-represented populations, including those on the African continent	51	60	CHALLENGE	diversity
This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy	38	89	DATABASE	Clinical Pharmacogenetics Implementation Consortium
, PCR, real-time PCR, DNA micro-array and molecular docking can determine the adverse effects, drug toxicity, bioavailability and therapeutic potential of new drug	42	59	ANALYTICAL_METHOD	molecular docking
, PCR, real-time PCR, DNA micro-array and molecular docking can determine the adverse effects, drug toxicity, bioavailability and therapeutic potential of new drug	2	5	TECHNIQUE	PCR
In this report, we present a case of a patient with a double heterozygote DPYD variant (DPYD activity score: 0,5 according to Clinical Pharmacogenetics Implementation Consortium) who experienced a severe fluoropyrimidine-related toxicity resolved without any consequence	126	177	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We offer detailed descriptions of the necessary components of the pharmacogenomic testing implementation, the development and technical validation of the in-house SNP based multiplex PCR based assay targeting 20 genes and 48 SNPs as well as a separate CYP2D6 copy number assay along with the process of PGx report design, results of the provider and pharmacists usability studies, and the development of the software tool for genotype-phenotype translation and gene-phenotype-drug CPIC-based recommendations	183	186	TECHNIQUE	PCR
The Pharmacogenomics Knowledge Base, PharmGKB, is an interactive tool for researchers investigating how genetic variation affects drug response	37	45	DATABASE	PharmGKB
The PharmGKB Web site, http://www	4	12	DATABASE	PharmGKB
Recent innovations in next-generation sequencing (NGS) technologies have enabled comprehensive genomic profiling of human cancers in the clinical setting	50	53	TECHNIQUE	NGS
In this chapter, we introduce clinical genomic profiling using an NGS-based multiplex gene assay (OncoPrime™) at Kyoto University Hospital	66	69	TECHNIQUE	NGS
lack of alternative treatments with similar or improved cost effectiveness, safety, and efficacy), clinical factors (e	8	19	CHALLENGE	alternative
lack of alternative treatments with similar or improved cost effectiveness, safety, and efficacy), clinical factors (e	88	96	CHALLENGE	efficacy
lack of alternative treatments with similar or improved cost effectiveness, safety, and efficacy), clinical factors (e	99	107	CHALLENGE	clinical
Repeated trough and serial whole blood sirolimus concentrations over a 24-hour dosing interval were collected and assayed using high-performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS)	172	196	TECHNIQUE	tandem mass spectrometry
Medical care in the USA is plagued by high costs, poor quality and fragmented care delivery	38	48	CHALLENGE	high costs
To date, the slow realization of the promise of personalized medicine has been partly attributable to the lack of clear evidence supporting the clinical utility of genetic and genomic tests and the lag in development of clinical guidelines for the use and interpretation of tests	114	119	CHALLENGE	clear
To date, the slow realization of the promise of personalized medicine has been partly attributable to the lack of clear evidence supporting the clinical utility of genetic and genomic tests and the lag in development of clinical guidelines for the use and interpretation of tests	144	152	CHALLENGE	clinical
During the last decade, the interest to apply machine learning algorithms to genomic data has increased in many bioinformatics applications	46	62	ANALYTICAL_METHOD	machine learning
In this study, we propose a general framework to tackle these challenges with different machine learning algorithms and techniques	88	104	ANALYTICAL_METHOD	machine learning
CATCH-KB also contains integrated gene and drug information from open biomedical resources such as PharmGKB<sup>1</sup> and SIDER<sup>2</sup>	99	107	DATABASE	PharmGKB
Western blot experiments clearly revealed dose-dependent downregulation of Akt and STAT3	0	12	TECHNIQUE	Western blot
Each of these elements, and genetic variants within them, are being characterized at an exponential pace by next-generation sequencing (NGS) technologies	136	139	TECHNIQUE	NGS
We also discuss the impact of NGS technologies such as chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq), and the ramifications of new techniques such as high-throughput chromosome capture (Hi-C), chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and massively parallel reporter assays (MPRA)	30	33	TECHNIQUE	NGS
NGS approaches are generating data faster than they can be analyzed, and new methods will be required to prioritize laboratory results before they are ready for the clinic	0	3	TECHNIQUE	NGS
We also discuss the impact of NGS technologies such as chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq), and the ramifications of new techniques such as high-throughput chromosome capture (Hi-C), chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and massively parallel reporter assays (MPRA)	127	134	TECHNIQUE	RNA-Seq
Over the past few years, Genome-Wide Association Studies (GWAS) have revealed novel pharmacogenetic variants related to responses to inhaled corticosteroids and the clinical efficacy of bronchodilators	25	56	TECHNIQUE	Genome-Wide Association Studies
Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation on entire populations is not well understood	68	119	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Although innovative targeted therapies have positively revolutionized psoriasis treatment shifting treatment goals to complete or almost complete skin clearance, primary or secondary lack of efficacy is still possible	191	199	CHALLENGE	efficacy
We validated our results using data from L1000 and Pharmacogenomics Knowledgebase (PharmGKB), and observed high precision and recall	83	91	DATABASE	PharmGKB
Next-generation sequencing (NGS) technologies are emerging as a more comprehensive and time- and cost-effective approach in PGx	28	31	TECHNIQUE	NGS
This review presents the main considerations for applying NGS in guiding drug treatment in clinical practice	58	61	TECHNIQUE	NGS
It discusses both the advantages and the challenges of implementing NGS-based tests in PGx	68	71	TECHNIQUE	NGS
Moreover, the limitations of each NGS platform are revealed, and the solutions for setting up and management of these technologies in clinical practice are addressed	34	37	TECHNIQUE	NGS
To compare the CYP2C9 and VKORC1 allele and genotype frequencies among 260 Ashkenazi (AJ) and 80 Sephardi Jewish (SJ) individuals, we genotyped six CYP2C9 and eight VKORC1 alleles by using the Tag-It Mutation Detection Kit and PCR-RFLP assays	227	230	TECHNIQUE	PCR
Functional characterization of these factors remains challenging, particularly because of the lack of human model systems	102	107	CHALLENGE	human
SNPs were genotyped using real-time PCR in DNA from patients who achieved sustained virological response (SVR) at 12 weeks post-SOF/DCV treatment (i	36	39	TECHNIQUE	PCR
In addition, the impact of next generation sequencing in identifying rare variants will be addressed	27	53	TECHNIQUE	next generation sequencing
Negative binomial regression and logistic regression were used	33	52	ANALYTICAL_METHOD	logistic regression
Negative binomial regression and logistic regression were used	0	28	ANALYTICAL_METHOD	Negative binomial regression
However their efficacy on MS course varies from highly effective to lack of response	14	22	CHALLENGE	efficacy
However their efficacy on MS course varies from highly effective to lack of response	55	64	CHALLENGE	effective
Moreover, a molecular docking study was carried out to check the binding profile of screened flavonoid compounds against DAX1	12	29	ANALYTICAL_METHOD	molecular docking
For specific medication and genotype-phenotype variations, guidance through the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the International Society of Psychiatric Genetics (ISPG) should be reviewed	80	131	DATABASE	Clinical Pharmacogenetics Implementation Consortium
However, there is a lack of established pharmacy-specific acuity factors in the ambulatory hematology/oncology setting	28	39	CHALLENGE	established
Next-generation sequencing (NGS) and long-read sequencing are promising technologies for the field of PGx research	28	31	TECHNIQUE	NGS
Both NGS and long-read sequencing often provide more data and more options with regard to deciphering structural and rare variants compared to SNV panels-in particular, in regard to the number of variants that can be identified, as well as the option for haplotype phasing	5	8	TECHNIQUE	NGS
Application of artificial intelligence technologies such as the Internet of Things, machine learning tools and big data analysis to COVID-19 diagnosis could yield rapid and accurate results	15	38	ANALYTICAL_METHOD	artificial intelligence
In this review, relevant features of artificial intelligence and their potential applications in COVID-19 diagnosis and drug development are highlighted	37	60	ANALYTICAL_METHOD	artificial intelligence
Application of artificial intelligence technologies such as the Internet of Things, machine learning tools and big data analysis to COVID-19 diagnosis could yield rapid and accurate results	84	100	ANALYTICAL_METHOD	machine learning
The neural networks and machine learning tools can also be used to develop potential drug molecules	24	40	ANALYTICAL_METHOD	machine learning
The tests currently used to diagnose COVID-19 are based on real time reverse transcription polymerase chain reaction (RT-PCR), computed tomography medical imaging techniques and immunoassays	121	124	TECHNIQUE	PCR
The tests currently used to diagnose COVID-19 are based on real time reverse transcription polymerase chain reaction (RT-PCR), computed tomography medical imaging techniques and immunoassays	91	116	TECHNIQUE	polymerase chain reaction
The tests currently used to diagnose COVID-19 are based on real time reverse transcription polymerase chain reaction (RT-PCR), computed tomography medical imaging techniques and immunoassays	118	124	TECHNIQUE	RT-PCR
It takes 2 days to obtain results from the RT-PCR test and also shortage of test kits creating a requirement for alternate and rapid methods to accurately diagnose COVID-19	43	49	TECHNIQUE	RT-PCR
5 decision tree, naïve Bayes, and random forests	2	15	ANALYTICAL_METHOD	decision tree
To discover the status of antidepressant treatments, we established an ensemble predictive model with a feature selection algorithm resulting from the analysis of genetic variants and clinical variables of 421 patients who were treated with selective serotonin reuptake inhibitors	104	121	ANALYTICAL_METHOD	feature selection
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	62	79	ANALYTICAL_METHOD	feature selection
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	151	170	ANALYTICAL_METHOD	logistic regression
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	176	195	ANALYTICAL_METHOD	logistic regression
In the wake of recent advances in machine learning research, the study of pharmacogenomics using predictive algorithms serves as a new paradigmatic application	34	50	ANALYTICAL_METHOD	machine learning
In this work, our goal was to explore an ensemble machine learning approach which aims to predict probable antidepressant treatment response and remission in major depressive disorder (MDD)	50	66	ANALYTICAL_METHOD	machine learning
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	30	46	ANALYTICAL_METHOD	machine learning
Our study demonstrates that the ensemble machine learning framework may present a useful technique to create bioinformatics tools for discriminating non-responders from responders prior to antidepressant treatments	41	57	ANALYTICAL_METHOD	machine learning
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	102	132	ANALYTICAL_METHOD	multi-layer feedforward neural
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	172	194	ANALYTICAL_METHOD	support vector machine
Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the <i>SLC22A1</i>, <i>SLC22A2</i>, and <i>SLC22A3</i> genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (<i>p</i> < 0	26	45	ANALYTICAL_METHOD	logistic regression
Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the <i>SLC22A1</i>, <i>SLC22A2</i>, and <i>SLC22A3</i> genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (<i>p</i> < 0	14	45	ANALYTICAL_METHOD	multinomial logistic regression
In 192 Brazilian patients, we assessed plasma levels of tamoxifen and its metabolites at 3, 6, and 12 months of treatment (liquid-chromatography tandem mass spectrometry), adherence behavior (Morisky, Green, and Levine medication adherence scale), and cytochrome P450 2D6 (CYP2D6) and other pharmacogene polymorphisms (matrix-assisted laser-desorption-ionization time of flight) mass spectrometry, real-time polymerase chain reaction)	408	433	TECHNIQUE	polymerase chain reaction
In 192 Brazilian patients, we assessed plasma levels of tamoxifen and its metabolites at 3, 6, and 12 months of treatment (liquid-chromatography tandem mass spectrometry), adherence behavior (Morisky, Green, and Levine medication adherence scale), and cytochrome P450 2D6 (CYP2D6) and other pharmacogene polymorphisms (matrix-assisted laser-desorption-ionization time of flight) mass spectrometry, real-time polymerase chain reaction)	145	169	TECHNIQUE	tandem mass spectrometry
The main objective of this study was to investigate the feasibility of using PharmGKB, a pharmacogenomic database, as a source of training data in combination with text of MEDLINE abstracts for a text mining approach to identification of potential gene targets for pathway-driven pharmacogenomics research	77	85	DATABASE	PharmGKB
We used the manually curated relations between drugs and genes in PharmGKB database to train a support vector machine predictive model and applied this model prospectively to MEDLINE abstracts	66	74	DATABASE	PharmGKB
Our quantitative analysis showed that a support vector machine classifiers trained on MEDLINE abstracts with single words (unigrams) used as features and PharmGKB relations used for supervision, achieve an overall sensitivity of 85% and specificity of 69%	154	162	DATABASE	PharmGKB
We used the manually curated relations between drugs and genes in PharmGKB database to train a support vector machine predictive model and applied this model prospectively to MEDLINE abstracts	95	117	ANALYTICAL_METHOD	support vector machine
Our quantitative analysis showed that a support vector machine classifiers trained on MEDLINE abstracts with single words (unigrams) used as features and PharmGKB relations used for supervision, achieve an overall sensitivity of 85% and specificity of 69%	40	62	ANALYTICAL_METHOD	support vector machine
In silico analysis of the amino-acid change using molecular docking showed that ABCC1 rs45511401 possibly impairs statin efflux	50	67	ANALYTICAL_METHOD	molecular docking
These data, in addition to data on the distribution of indices of drug susceptibility in clinical isolates of pathogens and PK-PD exposure-effect relationships, can be integrated in Monte Carlo simulations, such that antibiotic doses with the highest probability of killing the pathogen and the least probability of causing dose-related toxicity can be predicted	182	193	ANALYTICAL_METHOD	Monte Carlo
Over 25 CYP2D6 alleles were genotyped in Xhosa controls and Xhosa schizophrenia patients using long-range PCR, DNA sequencing and single nucleotide primer extension analysis	106	109	TECHNIQUE	PCR
The variant has also been implicated as an expression quantitative trait locus (eQTL) for several genes	80	84	TECHNIQUE	eQTL
We propose an intrinsic and an extrinsic evaluation scenario which is based on knowledge contained in the PharmGKB knowledge base	106	114	DATABASE	PharmGKB
The Pharmacogenomics Knowledgebase (PharmGKB) is an integrated online knowledge resource for the understanding of how genetic variation contributes to variation in drug response	36	44	DATABASE	PharmGKB
As of April 2021, the annotated content of PharmGKB spans 715 drugs, 1761 genes, 227 diseases, 165 clinical guidelines, and 784 drug labels	43	51	DATABASE	PharmGKB
We have manually curated data from more than 9000 published papers to generate the content of PharmGKB	94	102	DATABASE	PharmGKB
This article contains a basic protocol describing how to navigate the PharmGKB website to retrieve information on how genes and genetic variations affect drug efficacy and toxicity	70	78	DATABASE	PharmGKB
It also includes a protocol on how to use PharmGKB to facilitate interpretation of findings for a pharmacogenomic variant genotype or metabolizer phenotype	42	50	DATABASE	PharmGKB
PharmGKB is freely available at http://www	0	8	DATABASE	PharmGKB
Basic Protocol 1: Navigating the homepage of PharmGKB and searching by drug Basic Protocol 2: Using PharmGKB to facilitate interpretation of pharmacogenomic variant genotypes or metabolizer phenotypes	45	53	DATABASE	PharmGKB
Recently, we have also implemented an automated natural language processing (NLP) tool to broaden our coverage of the pharmacogenomic literature	48	75	ANALYTICAL_METHOD	natural language processing
The major challenge in applying pharmacogenomics to everyday clinical practice in heart failure (HF) is based on (1) a lack of robust clinical evidence for the differential utilization of neurohormonal antagonists in the management of HF in different subgroups, (2) inconsistent results regarding appropriate subgroups that may potentially benefit from an alternative strategy based on pharmacogenomic analyses, and (3) a lack of clinical trials that focused on testing gene-guided treatment in HF	356	367	CHALLENGE	alternative
The major challenge in applying pharmacogenomics to everyday clinical practice in heart failure (HF) is based on (1) a lack of robust clinical evidence for the differential utilization of neurohormonal antagonists in the management of HF in different subgroups, (2) inconsistent results regarding appropriate subgroups that may potentially benefit from an alternative strategy based on pharmacogenomic analyses, and (3) a lack of clinical trials that focused on testing gene-guided treatment in HF	127	133	CHALLENGE	robust
The major challenge in applying pharmacogenomics to everyday clinical practice in heart failure (HF) is based on (1) a lack of robust clinical evidence for the differential utilization of neurohormonal antagonists in the management of HF in different subgroups, (2) inconsistent results regarding appropriate subgroups that may potentially benefit from an alternative strategy based on pharmacogenomic analyses, and (3) a lack of clinical trials that focused on testing gene-guided treatment in HF	61	69	CHALLENGE	clinical
In the present study, we genotyped 85 very important pharmacogenetic (VIP) variants (selected from the PharmGKB database) in the Kyrgyz population and compared our data with other four major human populations including Han Chinese in Beijing, China (CHB), the Japanese in Tokyo, Japan (JPT), a northern and western Europe population (CEU), and the Yoruba in Ibadan, Nigeria (YRI)	103	111	DATABASE	PharmGKB
Acquired resistance and clonal heterogeneity are critical challenges in cancer treatment, and the lack of effective computational tools hampers the discovery of new treatments to overcome resistance	106	115	CHALLENGE	effective
Next generation DNA sequencing (NGS) techniques have been used increasingly in clinical laboratories to scan the whole or part of the human genome in order to facilitate diagnosis and/or prognostics of genetic disease	32	35	TECHNIQUE	NGS
Areas covered: This review focuses on lessons learned through early attempts of clinically implementing PGx testing; the challenges and opportunities that PGx testing brings to precision medicine in the era of NGS	170	173	TECHNIQUE	NGS
Expert commentary: Replacing targeted analysis approach with NGS for PGx testing is neither technically feasible nor necessary currently due to several technical limitations and uncertainty involved in interpreting variants of uncertain significance for PGx variants	61	64	TECHNIQUE	NGS
Because most signals from GWAS are in the non-coding region, other machine learning and omics approaches have been developed to identify the potential causative single-nucleotide polymorphisms and genes that explain these phenotypes	67	83	ANALYTICAL_METHOD	machine learning
Furthermore, the lack of diversity in studies has stymied the advance of precision medicine for many historically excluded populations	25	34	CHALLENGE	diversity
Novel algorithms to interpret CYP2D6 function from sequencing data that consider structural variants, and machine learning approaches to characterise the functional impact of novel variants, are being developed	106	122	ANALYTICAL_METHOD	machine learning
However, there is lack of conclusive evidence regarding the overall influence of CYP2D6 polymorphisms on codeine efficacy and toxicity	113	121	CHALLENGE	efficacy
Lack of sufficient resources, provider knowledge, and ethical, legal, and social issues are several limitations and challenges to implementing pharmacogenomic testing in clinical practice	170	178	CHALLENGE	clinical
However, there is lack of conclusive evidence regarding the overall influence of CYP2D6 polymorphisms on codeine efficacy and toxicity	26	36	CHALLENGE	conclusive
Information on the genetic effects is limited owing to the lack of large-scale studies	67	78	CHALLENGE	large-scale
To allocate exposure, we genotyped eleven SNPs with TaqMan probes on RT-PCR and regressed them to tumor response using linear modeling	69	75	TECHNIQUE	RT-PCR
At baseline, we collected a blood sample (for genotyping), fine needle aspirates (for Western blot), and tumor measurements by imaging	86	98	TECHNIQUE	Western blot
The binding interaction patterns and conformational behaviors of screened drugs within the active region of Ewing sarcoma protein (EWS) were confirmed through molecular docking profiles	159	176	ANALYTICAL_METHOD	molecular docking
cyminum</i> and its association with the biosynthesis of secondary metabolites were determined using NGS technology	101	104	TECHNIQUE	NGS
The current version also supports summary analysis on differentially expressed genes between the HapMap samples of European and African ancestry, as well as queries for summary information of correlations between gene expression and pharmacological phenotypes	97	103	DATABASE	HapMap
PACdb will be linked into PharmGKB to benefit the next wave of pharmacogenetic and pharmacogenomic discovery	26	34	DATABASE	PharmGKB
This involved the utilisation of next-generation sequencing (NGS) at the intersection of research and service delivery for development of a comprehensive genetic testing platform in South Africa	61	64	TECHNIQUE	NGS
Here we demonstrate the value of this approach using NGS to 1) determine the variant spectrum applicable to targeted therapy and implementation of prevention strategies using the 15-gene Oncomine™ BRCA Expanded Panel, and 2) searched for novel and known pathogenic variants in uninformative cases using whole exome sequencing (WES)	53	56	TECHNIQUE	NGS
Targeted NGS performed as a routine clinical service in 414 South African breast and/or ovarian cancer patients resulted in the detection of 48 actionable variants among 319 (15%) cases	9	12	TECHNIQUE	NGS
Experimental WES using a virtually constructed multi-cancer NGS panel in 16 genetically unresolved cases (and four controls) revealed novel protein truncating variants in the basal cell carcinoma gene <i>PTCH1</i> (c	60	63	TECHNIQUE	NGS
Lack of international consensus regarding risk categorization of established cancer susceptibility genes and the level of evidence required for prediction of drug response supported the development of a central database to facilitate clinical interpretation	65	76	CHALLENGE	established
Lack of international consensus regarding risk categorization of established cancer susceptibility genes and the level of evidence required for prediction of drug response supported the development of a central database to facilitate clinical interpretation	234	242	CHALLENGE	clinical
Six modern PGx assays were compared with the Pharmacogenomics Knowledge Base (PharmGKB) to determine the proportion of the currently known PGx genotypes that are assessed by these assays	78	86	DATABASE	PharmGKB
The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system	80	104	TECHNIQUE	tandem mass spectrometry
The plasma concentration of aripiprazole was measured by liquid chromatography-tandem mass spectrometry	79	103	TECHNIQUE	tandem mass spectrometry
541C>T (rs36027551) in a Canadian cohort of 248 patients who were wild type for Clinical Pharmacogenetics Implementation Consortium recommended DPYD variants and had received a standard dose of fluoropyrimidine chemotherapy	80	131	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This discipline has a greater impact in those medical specialties that treat complex diseases in which the therapeutic response is insufficient and/or have high costs such as psychiatry	156	166	CHALLENGE	high costs
Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or safety issues, more often after conspicuous research and economic efforts	65	73	CHALLENGE	efficacy
Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or safety issues, more often after conspicuous research and economic efforts	29	37	CHALLENGE	clinical
We have recently developed a rapid and cost-effective method, named Smart Amplification Process 2 (SmartAmp2), which enables us to detect genetic polymorphisms or mutations in target genes within 30 to 45 min under isothermal conditions without DNA isolation and PCR amplification	263	266	TECHNIQUE	PCR
Variants of CYP2D6 were genotyped by polymerase chain reaction for CYP2D6 *4, *10, *41 and long polymerase chain reaction for CYP2D6 *5	37	62	TECHNIQUE	polymerase chain reaction
We present a novel method termed 'Slowdown PCR', which allows the successful PCR-amplification of extremely GC-rich (>83%) DNA targets	43	46	TECHNIQUE	PCR
The polymerase chain reaction (PCR) technique has become an indispensable method in molecular research	4	29	TECHNIQUE	polymerase chain reaction
Luciferase-based reporter cell line experiments and molecular docking studies yielded supportive results emphasizing the inhibitory activity of CSA and its derivatives on MYC	52	69	ANALYTICAL_METHOD	molecular docking
Promoter motif analysis of the deregulated genes further supported the microarray gene expression analysis results emphasizing the relevance of transcription factors regulating cell cycle and proliferation, with MYC as being the most pronounced one	71	81	TECHNIQUE	microarray
Next-generation sequencing (NGS) is a cost-effective technology for genotyping several pharmacogenomic loci at once, thereby increasing publicly available data	28	31	TECHNIQUE	NGS
A panel of 100 pharmacogenes among Southeast Asian (SEA) populations was resequenced using the NGS platform under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm)	95	98	TECHNIQUE	NGS
An annotation method was proposed to summarize prescribing recommendations and classify drugs into avoid use, use with caution, and routine use, following the recommendations of the Clinical Pharmacogenetics Implementation Consortium (CPIC), etc	182	233	DATABASE	Clinical Pharmacogenetics Implementation Consortium
It further predicts phenotypes of specific drugs in terms of toxicity, dosage, efficacy, and metabolism by integrating the high-confidence clinical annotations in the Pharmacogenomics Knowledgebase (PharmGKB)	199	207	DATABASE	PharmGKB
<b>Introduction:</b> Next-generation sequencing (NGS) technologies have been widely used in clinical genomic testing for drug response phenotypes	49	52	TECHNIQUE	NGS
<b>Methods:</b> An automated Pharmacogenomics Annotation tool (PAnno) was implemented, which reports prescribing recommendations and phenotypes by parsing the germline variant call format (VCF) file from NGS and the population to which the individual belongs	204	207	TECHNIQUE	NGS
One challenge of implementing PGx is extracting genomic variants and assigning haplotypes in order to apply prescribing recommendations and information from the Clinical Pharmacogenetics Implementation Consortium (CPIC), the US Food and Drug Administration (FDA), the Pharmacogenomics Knowledgebase (PharmGKB), etc	161	212	DATABASE	Clinical Pharmacogenetics Implementation Consortium
One challenge of implementing PGx is extracting genomic variants and assigning haplotypes in order to apply prescribing recommendations and information from the Clinical Pharmacogenetics Implementation Consortium (CPIC), the US Food and Drug Administration (FDA), the Pharmacogenomics Knowledgebase (PharmGKB), etc	300	308	DATABASE	PharmGKB
This study assesses the value of potentially functional single nucleotide polymorphisms (pfSNPs) and employs six machine learning algorithms to identify the combination of SNPs that best predict myalgia	113	129	ANALYTICAL_METHOD	machine learning
Variants that were highly associated with myalgia from this and previous studies were extracted, assessed for potential functionality (pfSNPs) and incorporated into six machine learning models	169	185	ANALYTICAL_METHOD	machine learning
The minimum combination of SNPs to achieve maximum sensitivity and specificity as determined by AUC, that predict atorvastatin-induced myalgia in most, if not all the six machine learning models was determined	171	187	ANALYTICAL_METHOD	machine learning
Although none of the individual SNPs achieved genome wide significance in univariate analyses, machine learning models identified a combination of 15 SNPs that predict myalgia with good predictive performance (AUC >0	95	111	ANALYTICAL_METHOD	machine learning
pfSNPs were found to be more robust in predicting myalgia, outperforming non-pf SNPs in the majority of machine learning models tested	104	120	ANALYTICAL_METHOD	machine learning
<b>Conclusion:</b> Combinations of pfSNPs that were consistently identified by different machine learning models to have high predictive performance have good potential to be clinically useful for predicting atorvastatin-induced myalgia once validated against an independent cohort of patients	89	105	ANALYTICAL_METHOD	machine learning
1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)	86	105	ANALYTICAL_METHOD	logistic regression
Bromocriptine strongly bound to NF-κB pathway proteins as shown by molecular docking and interacted more strongly with DNA-bound NF-κB than free NF-κB, indicating that bromocriptine may inhibit NF-κB binding to DNA	67	84	ANALYTICAL_METHOD	molecular docking
COMPARE analysis of microarray-based mRNA expression in these cell lines revealed that genes from various functional groups such as ribosomal proteins, transcription, translation, DNA repair, DNA damage, protein folding, mitochondrial respiratory chain, and chemokines correlated with cellular response to bromocriptine	20	30	TECHNIQUE	microarray
PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www	0	8	DATABASE	PharmGKB
The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research	13	21	DATABASE	PharmGKB
PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries	0	8	DATABASE	PharmGKB
Recently, PharmGKB has embraced a new role--broker of pharmacogenomic data for data sharing consortia	10	18	DATABASE	PharmGKB
PharmGKB has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia	0	8	DATABASE	PharmGKB
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	69	95	TECHNIQUE	next generation sequencing
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	40	43	TECHNIQUE	PCR
Advances in biotechnology and bioinformatics have enabled genomic research to evolve from the evaluation of alterations at the single-gene level to studies on the whole-genome scale using large-scale genotyping and next generation sequencing techniques	215	241	TECHNIQUE	next generation sequencing
<b>Methods:</b> 54 very important pharmacogene variants were selected from PharmGKB and genotyped in 199 Lisu individuals	75	83	DATABASE	PharmGKB
LASSO computational approach was adopted for generating a DNA damage repair-relevant gene signature	0	5	ANALYTICAL_METHOD	LASSO
In this research we evaluate whether relational machine learning (ML) using inductive logic programming (ILP) can contribute to addressing these issues as a viable approach for EHR-based phenotyping	48	64	ANALYTICAL_METHOD	machine learning
Following DNA extraction all samples underwent PCR amplification and were scrutinized for small fractions of EGFR mutation using deep sequencing with the Ion torrent PGM technology	47	50	TECHNIQUE	PCR
